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Background
Clostridium difficile is an anaerobic spore-forming bacillus that can be found in a 
wide range of habitats, from soil and water to intestines of animals, including humans. 
The bacterium was identified as the most important infectious cause of antibiotic- 
associated diarrhea in the 1970s [1]. C. difficile infection (CDI) is transmitted via the 
fecal-oral route. It has been associated mainly with hospitals, where it occurs both 
endemically and epidemically. However, since the beginning of the new millennium, 
the epidemiology of CDI appears to be changing. Higher incidence rates of CDI were 
recorded and large outbreaks with relatively high morbidity and mortality were 
noticed, first in Canada, followed by the US, the UK and the European mainland [2]. 
These outbreaks were found to be caused by a specific strain of C. difficile, typed as 
North American pulse field gel electrophoresis type I and PCR ribotype 027 [3]. This 
change in epidemiology renewed scientific interest in CDI, which led to more 
advanced understanding of the disease.
Pathogenesis
Much has been learnt about how C. difficile causes disease. This has been helped 
by molecular techniques, such as the construction of C. difficile mutants, and the 
availability of improved animal models. C. difficile spores, which are resistant to 
various physical and chemical attacks, may survive for years. Once they have been 
ingested and have passed the stomach, they germinate in the intestinal lumen under 
the influence of the binding of the primary bile acids cholic acid and cheodeoxycholic 
acid [4] to the receptor CspC [5]. The vegetative forms of the bacterium have to 
colonize the mucosa, a process that is greatly facilitated by disruption of the resident 
microbiome, usually as a result of antibiotics. The microbiome of CDI patients has 
less diversity than that of individuals without CDI. The proportion of lactate-producing 
bacteria is increased and that of butyrate-producing bacteria is decreased with 
great proportional losses of firmicutes and bacteriodetes [6]. A healthy microbiome 
may protect against colonization by C. difficile by metabolizing primary bile acids, 
competing for nutrients and mucosal surface, producing bacteriocins and influencing 
host defense [7]. The so-called surface layer proteins, especially SlpA, play an 
important role in adherence to the mucosal surface [8]. Pathogenic C. difficile strains 
produce the toxin TcdB and usually also TcdA. These large clostridial toxins probably 
leave the bacterial cell through a holin, coded by TcdE [9]. These toxins bind to 
unknown and probably different surface receptors on epithelial cells, and, after loss 
of epithelial barrier function, to underlying stromal cells. After binding, the toxins enter 
the cell through clathrin-mediated endocytosis [10]. Under the influence of decreasing 
pH in the endosome, TcdB undergoes a conformational change, resulting in its 
autocatalytic cleavage and release of the N-terminal catalytic domain in the cytoplasm 
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homes, where the most susceptible population of elderly, chronically ill individuals 
exposed to antibiotics is concentrated. This population might serve as a reservoir, in 
which C. difficile can multiply. The highly resilient spores are easily transmitted 
between patients, via the hands of hospital personnel, fomites [31] and even the air, 
which may contain spores in the vicinity of diarrheic patients [32, 33]. However, 
doubts have risen as to whether this model is entirely true. A large proportion of 
endemic hospital CDI cases cannot be linked to other cases in the same hospital [34] 
and community-onset cases with no apparent link to healthcare facilities have been 
described [35, 36]. Therefore, it seems likely that colonization with C. difficile often 
occurs outside of healthcare facilities and the disease only becomes symptomatic 
when other factors, such as the use of antibiotics, occur during a subsequent stay in 
a healthcare facility. If C. difficile colonization is acquired outside of healthcare 
facilities, what could be the reservoir? The meat industry has been implicated, since 
C. difficile has been cultured from meat products, albeit not consistently, and 
C. difficile is known to colonize and cause disease in farm animals, especially pigs [37]. 
Typing studies that found similarities between strains colonizing humans and animals 
have lent support to the hypothesis that animals can be a reservoir from which 
humans are colonized [38]. On the other hand, outbreaks with links to a food source 
or farm have not been described, and the link between humans and animals may 
also be explained by transmission from human to animal. 
 Various typing methods have been used for C. difficile, of which PCR ribotyping 
has gained greatest popularity. This method is based on the amplification of the 
 variable-length spacer region between the two genes coding for the 16S and 23S 
ribosomal subunits [39]. Notable PCR ribotypes are the above-mentioned type 027, 
and type 078, which has been associated with farm animals [40]. Both of these PCR 
ribotypes are characterized by a deletion in TcdC, a putative negative regulator of 
toxin expression (although this function is debated [41, 42]), and production of CDT.
Clinical manifestations
The clinical manifestations of CDI vary. After ingestion of spores and successful 
colonization of the gut, asymptomatic carriage may follow, but in an estimated 15 to 
30% colonized individuals [25, 43], symptomatic disease develops. This disease 
ranges from mild self-limiting diarrhea to fulminant colitis with a severe systemic 
inflammatory response, leukemoid reaction and ileus. The latter manifestation, which 
fortunately is rare, may lead to complications such as septic shock and perforation. 
This severe complicated form of CDI may be refractory to antimicrobial therapy. 
Usually though, CDI responds to antimicrobial therapy. In this case, the symptoms 
gradually improve over days to weeks. However, in some cases diarrhea relapses. 
The proportion of patients who suffer recurrences varies in studies from 6% to 77% 
depending on the number of previous CDI episodes [44-46], age [47-50], comorbidity 
[11]. The autocatalytic activity of the toxins is partly countered by S-nitrosylation in the 
intoxicated cell [12]. In the cytoplasm, the toxins glycosylate Rho and Ras family 
GTPases [13, 14]. Glycosylation of RhoA, Rac1 and Cdc42 leads to loss of organization 
of the cytoskeleton, microscopically visible in vitro by characteristic rounding of 
intoxicated cells [15]. Although they have 48% homology, the toxins probably have 
different functions. TcdA appears to play a more important role in loss of epithelial 
cell polarity and epithelial integrity [16] and TcdB is more potent. TcdB-induced 
activation of Rac1 leads to assembly of the NADPH oxidase complex on endosomes, 
resulting in the formation of reactive oxygen species and eventually cell necrosis [17]. 
Both toxins appear to be capable of causing disease on their own [18]. The resulting 
pathologic effect is cell necrosis, fluid secretion and a massive influx of neutrophils, 
leading to the formation of cryptabscesses, which coalesce into macroscopically 
visible pseudomembranes (figure 1) [19]. Pathologic changes occur mainly in the 
colon, although ileitis has also been described, especially after colectomy [20]. Some 
strains also produce a third toxin, the binary toxin or C. difficile transferase (CDT), 
coded by the genes CdtA and CdtB. These genes are not part of the so-called 
Pathogenicity Locus, which contains genes for the large clostridial toxins. The lipolysis- 
stimulated lipoprotein receptor (LSR) has been identified as the receptor for CDT [21]. 
CDT modifies actin by binding ADP-ribose to it. Thus, it increases the cell surface 
available for bacterial adherence by induction of the formation of protrusions on 
the intoxicated cell [22]. Although this toxin is produced by the epidemic strain PCR 
ribotype 027, it is unclear how important this toxin is for its virulence. Certainly, 
C. difficile strains can cause severe disease without it.
Epidemiology
Admission to healthcare facilities and the use of antibiotics [23], which increase the 
risk of CDI for at least three months [24], are considered the most important risk 
factors for CDI. In addition, risk factors that have repeatedly been associated with the 
acquisition of CDI include advanced age [25], serious comorbidity [26], use of proton 
pump inhibitors [25, 27, 28], and failure to mount an antibody response against TcdA 
and TcdB [29, 30]. It is hard to pinpoint specific comorbidity predisposing to CDI and 
the severity of the comorbid illness seems more important than the exact nature. 
Proton pump inhibitor use is extremely difficult to separate from severe comorbidity, 
even after correction for confounding. Furthermore, a plausible biological mechanism 
by which proton pump inhibitors might predispose to CDI is lacking, since C. difficile 
spores, by which transmission mainly occurs, are acid-resistant. CDI has been 
regarded as a hospital-acquired infection, because patients admitted for other 
diseases develop CDI during their hospital stay and outbreaks have only been 
described in healthcare facilities. The hypothesis was that, even though C. difficile is 
a ubiquitous bacterium, it found a niche in hospitals and – to a lesser extent – nursing 
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73], rifaximin [74] and tigecyclin [75]. Several new compounds have been investigated 
for the treatment of CDI, of which the non-absorbable oxazolidinone cadazolid [76] 
and macrocyclic thiopeptide LFF571 [77] have been studied in published phase 
I clinical trials. The toxin-binding resin tolevamer was shown not to be effective [78]. 
Other treatment modalities may be divided in immunotherapy and microbial therapy. 
Immunotherapy concerns the administration of non-specific intravenous immuno-
globulins or oral [79] or intravenous polyclonal or monoclonal antibodies directed 
against C. difficile and the large clostridial toxins, in order to supply additional 
antibodies when the patient fails to mount a sufficient humoral immune response. 
The intravenous administration of two monoclonal antibodies after antibiotic treatment 
for CDI resulted in a lower percentage of recurrences as compared to placebo [80]. 
However, selection bias may have been accountable for this result, because during 
the study, its endpoint was changed from reduction of symptoms in patients with 
diarrhea to reduction of recurrences in only those patients who became diarrhea-free. 
Microbial therapy concerns the administration of probiotics, donor feces or non- 
toxigenic C. difficile strains, in order to restore the microbiome and thus the 
colonization barrier against C. difficile. Of these, ‘transplantation’ of feces from 
healthy donors is currently the only therapy supported by a randomized trial [81]. 
There is no high-grade evidence on how to treat CDI when oral therapy is not possible, 
e.g., because of ileus. In severe cases of CDI with (imminent) toxic megacolon, 
surgery is the only remaining effective treatment. This consists of subtotal colectomy 
with end-ileostomy or, more recently, of the creation of a diverting loop ileostomy, 
followed by colonic lavage and flushing with vancomycin [82].
Prevention and control
Prevention and outbreak control measures are limited to prudent use of antibiotics 
(if necessary within the context of an antimicrobial stewardship program), adequate 
hand hygiene (with water and soap) and glove use, and disinfection of medical 
devices and surfaces of healthcare facilities with chlorine-containing solutions [83]. 
Isolation and cohorting of CDI patients seems a logical control measure, although 
there is no high-grade evidence for this. The role of asymptomatic carriers in the 
spread of C. difficile is unclear as yet. There is no convincing evidence that probiotics 
prevent CDI [84]. 
[50, 51], the need to continue antimicrobials for other infections than CDI [49, 50], 
humoral immune response [52-56], virulence of the C. difficile strain [57], treatment 
for CDI [58, 59] and, again arguably, the use of proton pump inhibitors [49, 60]. The 
majority of these recurrences are relapses, although some are reinfections [61, 62]. 
Without typing methods, which are not part of routine practice in most laboratories, 
this distinction is obviously difficult to make. An additional problem with this distinction 
is the fact that in some patients, more than one strain may be found at the same time 
[63]. The meaning of this is unclear as yet, although it seems most plausible that one 
of these strains represents the causative agent of the disease, whereas the others 
represent colonization. In order to distinguish between healthcare-associated and 
community-associated cases, and relapses and reinfections, arbitrary epidemiological 
criteria have been developed [64], although the biological ground for these criteria 
may be debated. 
Diagnosis
The diagnosis of CDI is hampered by the fact that the distinction between colonization 
and disease is not always clear. Diagnostics can be based on the demonstration of 
free toxin (by cytotoxicity assay, based on demonstration of the above-mentioned 
characteristic cell rounding after exposure to patient feces in vitro, or by ELISA) or the 
bacterium in feces (by nucleic acid amplification test or culture) [65]. Demonstration 
of free toxin is thought to correlate better with disease as opposed to carriage [66], 
although toxin ELISAs are less sensitive than cytotoxicity assays. Diagnostic methods 
that demonstrate the bacterium instead of toxin may be better at distinguishing 
colonization from disease if they are quantitative [67]. 
Treatment
Mild CDI that develops during the use of antibiotics may be cured by stopping the 
antibiotic without directed treatment [68], but more-severe cases must be treated. 
As mentioned above, CDI usually responds to antibacterial therapy. Antibiotics that 
have traditionally been used are oral metronidazole and oral vancomycin (or related 
teicoplanin). The glycopeptides are generally considered slightly more effective than 
metronidazole on the basis of clinical studies and pharmacokinetics [69]. These 
antibiotics have the disadvantage that they cause collateral damage by harming 
the intestinal microbiome, thus predisposing to recurrences of CDI. Fidaxomicin, an 
antibiotic that came to market in 2011 for the treatment of CDI, has a narrower 
spectrum, and appears associated with fewer recurrences [58, 59]. Nevertheless, 
recurrences still do occur and remain the biggest challenge in treating CDI. Therefore, 
new antibiotics and other treatment modalities are still being searched for. 
Antimicrobials that are already available for treatment of other infections have been 
studied for the treatment of CDI. These include fusidic acid [70, 71], nitazoxanide [72, 
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Outline of this thesis
The research described in this thesis focuses on three issues united by a link to 
the major clinical challenge of CDI, the risk of a complicated or recurrent course: 
the distribution of C. difficile strains among various populations and recognition of 
strains associated with complications and/ or recurrences, predicting a complicated 
or recurrent course of CDI, and choosing therapy in order to minimize the risk of 
complications and recurrences. 
Chapter 1 reviews what is known on community-acquired CDI, illustrated by two 
case reports of community-onset CDI.
In chapter 2, a study is reported that investigates community-onset cases of CDI in 
The Netherlands, focusing on risk factors and the distribution of C. difficile strains.
Chapter 3 reports a study into C. difficile carriage among patients with cystic fibrosis, 
a population in whom CDI is rare, despite the fact that they should be at high risk due 
to frequent contact with hospitals and high exposure to antibiotics.
Chapter 4 describes a study into the distribution of C. difficile strains among CDI 
cases across European hospitals and their clinical course.
In chapter 5, a case-control study is reported that investigated the value of one 
clinical marker and two biomarkers in predicting primary therapy failure and 
recurrence after initially successful therapy for CDI.
Chapter 6 describes a study into the association of antibody responses against large 
clostridial toxins and other C. difficile antigens with recurrence of CDI.
Chapter 7 describes a prospective interventional cohort study, in which participants 
received an experimental product made from whey of cows immunized with killed 
C. difficile and toxoid in addition to antimicrobial therapy for CDI, in order to reduce 
the risk of a recurrence.
Chapter 8 and 9 are the first version and an update of the guidance document issued 
by the European Society for Clinical Microbiology and Infectious Diseases for the 
treatment of CDI.
In the summary and general discussion, the conclusions of each chapter are 
summarized and suggestions for clinical practice and further research are made.
It is still unclear what the source of emerging  
C. difficile strains is and how they spread
The emergence of PCR ribotype 027 has been attributed to its acquisition of fluor-
oquinolone resistance and positive selection pressure from widespread use of these 
antimicrobials, and to increased virulence [85]. However, where the strain came from 
is unclear. In general, it is unclear what controls the dynamics of C. difficile strains. 
Where do new strains come from? How do they spread? What drives their spread? 
In particular, what is the role of the community and what is the role of asymptomatic 
carriers?
Better predictors of recurrence are needed to  
guide treatment of CDI 
Many episodes of CDI will respond to stopping the inciting antibiotic or a first course 
of directed antimicrobial therapy. Some patients, however, will suffer one or multiple 
recurrences of CDI with associated protein-losing enteropathy, malnutrition, 
hypovolemia and even death. Identifying these patients may influence the choice of 
treatment. In such patients, an oral glycopeptide may be preferred over metronidazole, 
in spite of higher cost and (debatable) positive selection pressure for vancomycin- 
resistant enterococci [86]. In case of a really high risk of recurrence, it may be 
advantageous to choose costly fidaxomicin up front. A lower risk of recurrences as 
compared to vancomycin has been shown in patients with a first episode or first 
recurrence of CDI. Fidaxomicin has not been investigated in randomized trials in 
patients with multiple recurrences. Although it could be argued that treatment with a 
small-spectrum agent like fidaxomicin to prevent further loss of diversity of the 
microbiome in these patients is effective, it could also be argued that the advantage 
of the microbiome-sparing effect of fidaxomicin is lost in this patient category who 
have already lost most of the diversity of their microbiome. If the latter were true, it 
would be even more important to identify patients with a high risk of recurrence 
during their first episode. Predicting a high risk of recurrence might also lead to the 
decision to start adjunctive immunotherapy for CDI, or to administer donor feces. 
Unfortunately, predicting recurrence remains a major challenge, in spite of attempts 
to construct prediction scores [47].
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Summary
The emergence of hypervirulent strains of Clostridium difficile causing outbreaks in 
hospitals and nursing homes may result in a greater than before spread of the 
bacterium in the community. By consequence the incidence of community-onset 
cases of Clostridium difficile–associated diarrhoea (CDAD) may increase outside 
known risk groups that are presently characterized by prior hospitalization, prior 
antibiotic usage, older age and significant co-morbidity. Herein, we describe two 
case histories of community-onset CDAD. The first concerns a previously healthy 
young female with community-acquired CDAD without recent hospitalization or 
antibiotic usage. The second patient developed diarrhoea in the community after 
discharge from a hospital where –in retrospect– an outbreak of CDAD occurred. The 
cases illustrate that CDAD should be included in the differential diagnosis of patients 
seeking care for community-onset diarrhoea, even in those without characteristic risk 
factors for CDAD.
Introduction
Recently, outbreaks of diarrhoea due to Clostridium difficile PCR-ribotype 027 have 
been reported in Canada, the United States and Europe, including The Netherlands.1-5 
Typically, outbreaks occur in a hospital or nursing home and primarily affect elderly 
individuals who suffer significant underlying conditions that make them susceptible 
to acquiring C. difficile-associated diarrhoea (CDAD).6 Among predisposing conditions, 
the exposure to antibiotics during an extended period of hospitalization is regarded 
as most significant7. The severity of CDAD can range from transient, mild diarrhoea 
to fulminant colitis. A recently circulating strain of C. difficile characterized as 
toxinotype III, North American pulsed field type 1, restriction endonuclease analysis 
group BI and PCR ribotype 027 has been associated with enhanced virulence, 
apparently due to the production of higher amounts of toxins.1,4,8
 As can be expected from the known risk factors of CDAD (i.e., hospitalization, old 
age, antibiotic usage, underlying medical conditions, gastro-intestinal surgery, 
nasogastric tubes, etc), most of the outbreak reports have dealt with nosocomial 
CDAD. There is an overall lack of information on community-onset CDAD. Herein, we 
describe two of such cases: a case of truly community-acquired CDAD without any 
known risk factors and a case of community-onset CDAD caused by an epidemic 
strain likely acquired during a recent stay in a hospital. The two cases illustrate various 
aspects of community-onset CDAD and indicate that physicians should be aware of 
the possibility of CDAD cases in the community, also in those who do not have known 
risk factors for CDAD. Moreover, such cases suggest that the epidemiology of CDAD 
may be changing, with a greater than before circulation of the bacterium in the 
community due to increased introduction of the bacterium from hospitals and 
institutions with outbreaks. 
Case Report
A 28-year old female presented to the emergency department because of syncope 
and severe diarrhoea. Her prior medical history was unremarkable with the exception 
of two caesarean sections, performed years before the present admission. On 
presentation, she complained of cramping abdominal pain, nausea and vomiting of 
one day duration, and passing of profuse watery stools mixed with blood. Soon after 
her symptoms began she noticed light-headedness and briefly lost consciousness 
during passage of stools. Because of the peracute nature and severity of her symptoms, 
her general practitioner referred her to the emergency room of the nearby hospital. 
 The patient did not take any medication, nor had she recently used any. On 
physical examination, she did not appear severely ill. A blood pressure of 80/40 
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inflammation with infiltration of eosinophils. Microbiological examination of stools 
including multiple tests for C. difficile toxin and extensive parasitological examination 
was negative. On the basis of these findings and especially the fact that repeatedly, 
no infectious agent could be demonstrated, a differential-diagnosis of eosinophilic 
colitis or cholesterol embolism was made. Symptomatic treatment with loperamide 
and haemodialysis was started. Upon readmission the patient had a fever up to 39.1 
ºC. His medication consisted of loperamide, aspirin, clopidogrel, atorvastatin, 
perindopril, metoprolol, temazepam, levodopa/carbidopa, alfacalcidol, epoetin beta 
iv during haemodialysis and ipratropium albuterol inhalations; he had not received 
antibiotics recently. The patient lived in a nursing home. Physical examination, 
including the abdomen, did not reveal abnormalities except for mild tachycardia of 
110 beats per minute and increased bowel sounds. Laboratory investigation showed 
a leukocytosis of 15.6 · 109/l and an ESR of 48 mm/h. The eosinophilia had decreased. 
His C-reactive protein level was 322 mg/l. A rapid immunoassay for C. difficile toxin A 
(ELFA, BioMérieux) was positive. C. difficile was cultured from the stool as well; the 
strain was typed as ribotype 027. This case later on proved to be part of an epidemic 
due to ribotype 027 in this hospital. Treatment was started with oral vancomycin 250 
mg qid for 14 days. After the antimicrobial regimen, the patient participated in the 
experimental protocol as well and received a bovine immune milk preparation 
(‘Anti-CD WPC’) for two weeks. His condition improved and he was discharged from 
the hospital; rapid stool tests for C. difficile toxins were repeatedly negative. 
Discussion
The present cases concern community-onset CDAD. The first case illustrates that 
CDAD can be acquired in the community in the absence of any of the known risk 
factors for this disease. The second case illustrates how exposure to C. difficile in a 
hospital in which CDAD is endemic, can cause CDAD to spread into the community. 
It underlines once more that prior use of antibiotics is not a necessary factor for 
CDAD to develop.
 Three factors are thought to explain the classical risk profile for CDAD. First, the 
patient must be exposed to the pathogen. Although the bacterium is ubiquitous and 
can be isolated from many sources both inside and outside hospitals, CDAD is most 
frequently acquired in hospitals and care institutions, where the bacterial load likely is 
high because host factors predispose the population admitted to these institutions to 
develop clinical disease.6 Second, prior administration of antibiotics and consequent 
disruption of the resident bowel flora has always been considered important, if not 
necessary, for colonization by C. difficile. In particular clindamycin, cephalosporins, 
fluoroquinolones (especially of the later generations) and less so macrolides and 
mmHg and a pulse of 60 beats per minute were noted. Examination of heart and 
lungs was unremarkable, her abdomen was tender. Rectal examination revealed pink 
stools with some mucus. 
 Laboratory investigation revealed a leukocytosis of 12.9 · 109/l, with a neutrophil 
count of 11.2 · 109/l. The haemoglobin level was 8.5 mmol/l and the ESR was 5 mm/h. 
Urea, creatinin, glucose, electrolyte and liver enzyme levels were within normal limits. 
 A diagnosis of vasovagal syncope due to a severe bout of gastro-enteritis and 
mild dehydration was made. The patient was admitted for fluid resuscitation (3 l in the 
first 24 h). Stool cultures were negative for Salmonella, Shigella, Yersinia and 
Campylobacter and stool examination did not reveal parasites like Gardia lamblia. An 
enzyme-linked immunosorbent assay (ELFA, Biomerieux) for C. difficile toxin A on 
stool was positive. Stool was not cultured for C. difficile. Treatment with oral 
metronidazole 500 mg tid for 10 days was initiated, a regimen to which she responded 
favourably. After 3 days she was discharged and completed her 10 day course of 
antibiotics at home. After completion of the antimicrobial regimen, she participated in 
an experimental protocol aimed at reducing the occurrence of relapses of CDAD and 
received a bovine immune milk preparation (‘Anti-CD WPC’) for two weeks. During a 
follow-up up to 60 days after start of the immune milk, the patient remained 
asymptomatic, and contact over one year later indicated that CDAD had not recurred. 
 Regarding the possible source of her C. difficile infection, an extensive history 
was taken.  This revealed that three months ago the patient’s two infant sons had 
been admitted to another hospital for two days because of a respiratory tract infection. 
The patient had spent one night in the hospital with her children during their admission. 
There had been no C. difficile outbreak in this hospital. Of note, neither the sons nor 
other family members had experienced diarrhoea. Moreover, after the diagnosis of 
CDAD had been made in the patient, stool cultures of her husband and two sons 
were taken but were negative for C. difficile. In conclusion, no plausible source of 
exposure could be established. It seems highly unlikely that the patient’s episode of 
CDAD is related to her one day stay in hospital three months earlier.
The second case concerns a 71-year old male who was admitted with progressive 
diarrhoea. He had suffered a stroke in the past and had vascular dementia with 
secondary parkinsonism, chronic obstructive pulmonary disease, hypertension and 
chronic renal failure due to nephrosclerosis. One week before admission, he had 
been discharged from hospital where he was being examined for chronic watery 
stools with concomitant loss of an already compromised kidney function. Diarrhoea 
had been present for half a year. At that admission, there was peripheral eosinophilia 
(0.7 · 109/l). A CT-scan of the abdomen showed extensive arterial wall abnormalities 
compatible with atherosclerosis and thickening of the sigmoid wall. Colonoscopy 
had not revealed abnormalities, whereas biopsies of the sigmoid showed mild 
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intravenous β-lactams with β-lactamase inhibitors have been associated with 
CDAD.2,7,9-19, Lastly, a host factor appears to determine, at least in part, whether or not 
colonization is followed by clinical manifestations of CDAD. Older age cohorts 
admitted for extended periods because of severe underlying disease are at highest 
risk for CDAD.7,19-22 Presumably, in these individuals a lack of effective anti-toxin 
humoral immunity is a decisive factor in developing CDAD, since long duration of 
disease and relapse has been associated with lower concentrations of circulating 
and faecal antibodies against C. difficile toxins A and B. A. 23-25
 Since early 2003, an increase in the incidence of CDAD has been reported in 
Canada and subsequently in the upper part of the United States of America and 
Europe. The CDAD cases in this outbreak were remarkable because they ran a more 
severe course.19,26-28  The greater morbidity was associated with the emergence of 
PCR ribotype 027.1,4,8 In just a few years, outbreaks of CDAD due to PCR ribotype 027 
occurred in The Netherlands as well 3,4,29-31 Of note, the outbreaks concerned 
hospitalized or institutionalized patients. One report already noted an increase of 
community-acquired cases of CDAD in a population not considered at risk but 
unfortunately only a few strains of C. difficile were available for typing and type 027 
was not found.32
 The rate of community-acquired(CA-) CDAD, formerly a very rare entity, appears 
to be increasing.19,33-35 Table 1 summarizes findings in the studies that have been 
published on this subject. Some of these cases may actually be hospital-acquired, 
since definitions of CA-CDAD vary. However, some clearly do not fit the classical risk 
profile.19,32,36  A systematic surveillance of CA-CDAD has not been performed until 
recently. Stool samples of 703 patients with diarrhoea submitted by general 
practitioners in an area of 3.6 million inhabitants in Germany were investigated for 
pathogens including C. difficile by culture and enzyme immunoassay for C. difficile 
toxin A/B. The C. difficile-Toxin A/B assay was positive in 66 (9.3%) of the stool 
samples. Thirty-one (47%) of 66 patients had healthcare-associated diarrhoea (i.e., 
defined as an onset of symptoms within 4 weeks after hospital discharge) whereas 
35 (53%) were truly community-acquired. Recent usage of antibiotics was reported 
by 34/66 (52%) patients, most frequently cephalosporins (33%) and fluoroquinolones 
(33%).37  
If the incidence CA-CDAD is indeed increasing, what could be the cause? The 
emergence of CDAD in hospitals outbreaks undoubtedly leads to the spread of the 
pathogen among admitted patients, not all of whom will develop symptoms of CDAD 
during hospitalization. As illustrated by the second case, some cases of CDAD can 
be expected to occur in the weeks or even months following discharge. In addition, 
the increased circulation of C. difficile within hospitals will increase the rate of 
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chronic community-onset diarrhoea, even when the patient has not recently taken 
antibiotics, is young and has no co-morbidity. It also underscores that strict hygienic 
measures should be taken in all patients with diarrhoea to prevent spread of the 
pathogen.
excretion of the pathogen by discharged patients and or health care workers. Contact 
with such cases in the end will lead to some cases of community-acquired CDAD. 
Furthermore, it has been suggested that an animal reservoir may play a role in the 
emergence of community-acquired CDAD.38 C. difficile-associated disease and 
carriage have been reported in pets and farm animals. In 1993, the role of pets as a 
reservoir was investigated comparing restriction endonuclease analysis  types of C. 
difficile isolates from pets, veterinary clinics, humans and hospitals.39 In that study, 
there was no correlation between isolates from pets and humans and therefore it was 
concluded that animals do not form an important reservoir for strains that cause 
human disease. However, C. difficile seems to become more important as an animal 
pathogen40 and a number of recent studies have found overlap between animal and 
human ribotypes, suggesting that there is interchange of strains between animals 
and humans.41,42 Of note, C. difficile could be cultured from 20% of retail meat samples 
in a Canadian study, with a majority of the toxigenic isolates being C. difficile type 
027.43 Incidentally, neither of the patients we describe had had contact with any 
possible animal source.
The first patient recovered quickly after treatment with metronidazole. In the recent 
outbreaks, however, the relapse rate of CDAD has increased from about 20% to as 
high as 47% in cases caused by PCR ribotype 027. Unfortunately, besides increasing 
the dose or extending the course of antibiotics, switching metronidazole into oral 
vancomycin and using alternating or pulsed regimens, there is little one can do to 
prevent cycles of relapses and even the measures mentioned are not proven 
efficacious. Also, the efficacy of strategies including probiotics, bacteriotherapy, 
 toxin-absorbent resins and intravenous immunoglobulins is  presently uncertain and 
not supported by  evidence from clinical trials.44-45 Previously, we reported on the 
use of passive immunotherapy with anti-C. difficile whey protein concentrate (40%; 
Anti-CD-WPC)  made of milk from cows immunized with inactivated C. difficile toxins 
and killed bacterial cells. Anti-CD-WPC neutralizes the action of toxins in vitro and 
protects against CDAD in an animal model.46 As a milk product, it was found safe for 
use in humans with CDAD47 and in a first, uncontrolled trial an about 50 percent 
reduction in relapse rate was observed.48 However, the efficacy of this treatment 
modality still has to be submitted to a dose finding and placebo-controlled randomized 
trial. 
In conclusion, the emergence of new strains of C. difficile that cause outbreaks in 
hospitals and nursing homes in the last years may also forward the circulation of such 
strains in the general population, and increase the incidence of community-acquired 
cases of CDAD outside the well known risk groups. The present case histories 
illustrate that CDAD should be included in the differential diagnosis of both acute and 
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Abstract
To elucidate the prevalence, characteristics and risk factors of community-onset 
Clostridium difficile infection (CO-CDI), an uncontrolled prospective study was 
performed. For 3 months in 2007–2008, three laboratories in The Netherlands tested 
all unformed stool samples submitted by general practitioners (GPs) for C. difficile by 
enzyme immunoassay for toxins A and B, irrespective of whether GPs specifically 
requested this. Patients with positive results were asked to complete a questionnaire. 
Positive stool samples were cultured for C. difficile, and isolates were characterized. 
In all, 2443 stool samples from 2423 patients were tested, and 37 patients (1.5%) with 
positive toxin test results were identified. Mixed infections were not found. Age varied 
from 1 to 92 years, and 18% were under the age of 20 years. Diarrhoea was typically 
frequent and watery, sometimes with admixture of blood or fever. Eight of 28 patients 
(29%) suffered recurrences. Among 31 patients with toxin-positive stool samples for 
whom information was available, 20 (65%) had not been admitted to a healthcare 
institution in the year before, 13 (42%) had not used antibiotics during the 6 months 
before, and eight (26%) had neither risk factor. A separate analysis for patients whose 
samples were both toxin-positive and culture-positive produced similar results. 
Cultured C. difficile isolates belonged to 13 different PCR ribotypes, and 24% of the 
isolates were non-typeable (rare or new) PCR ribotypes. In conclusion, CO-CDI can 
affect all age groups, and many patients do not have known risk factors. Several PCR 
ribotypes not encountered in hospital-associated outbreaks were found, suggesting 
the absence of a direct link between outbreaks and community-onset cases.
Introduction
Previously identified risk factors for Clostridium difficile infection (CDI) include admission 
to  hospital  or  nursing  home, old age, chronic comorbidity, longer hospital stay, 
antibiotic usage and prior chemotherapy [1], use of gastric acid sup- pressants, and 
nasogastric tubes. Since early 2003, both the incidence and the severity of cdi 
appear to have increased. This has been ascribed at least partly to the emergence of 
the new strain, PCR ribotype 027. In 2007, PCR ribotype 027 was found in stool 
samples of 25% of patients with nosocomial CDI in The Netherlands [2].
 The incidence of cdi occurring outside healthcare facilities, usually termed 
 community-onset  CDI (CO-CDI),  may be rising as well [3–10]. Some of the reported 
cases of CO-CDI may be truly community-acquired, but many cases may actually be 
linked to healthcare  institutions.  CO-CDI has never been investigated with detailed 
characterization of C. difficile isolates. In the present study, we aimed to investigate 
both the clinical characteristics and the source of CO-CDI in three areas in The 
Netherlands where outbreaks of nosocomial CDI due to PCR ribotype 027 had 
recently occurred. We screened all stool samples submitted by general practitioners 
(GPs) for C. difficile, characterized the cultured C. difficile isolates, and obtained 
patient information using a standardized questionnaire.
Materials and methods
Three medical microbiological laboratories in The Netherlands participated, namely 
SALTRO Artsenlaboratorium in Utrecht (providing services for 900 GPs), Public Health 
Laboratory Kennemerland in Haarlem (400 GPs) and the Laboratory for Medical 
Microbiology and Infectious Diseases in Zwolle (195 GPs). All unformed stool samples 
submitted by GPs during a period of three months were tested for C. difficile, using a 
commercially available rapid enzyme immunoassay (EIA) for C. difficile toxins A and 
B (ICTAB, Meridian). Samples were assayed irrespective of the diagnostic tests 
requested by the GP. If a stool sample tested positive and the corresponding patient 
had no earlier positive stool sample, this patient was included in our study.
Microbiological tests
If a stool sample gave positive results, the sample was cultured in the regional 
laboratory and isolates were sent to the reference laboratory at the Leiden University 
Medical Center. All isolates were genetically identified as C. difficile by an in-house 
PCR for the presence of the gluD gene specific for C. difficile [7]. C. difficile isolates 
were characterized by PCR ribotyping [11]. The presence of tcdA, tcdB, and binary 
toxin genes was investigated as described previously [2]. Antimicrobial susceptibility 
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Co-infection and characterization of the isolates   
Co-infection of CDI with other enteropathogens was not found. Thirteen different 
PCR-ribotypes were found and seven strains could not be characterized by 
PCR-ribotyping (table 1). No C. difficile could be cultured from stool samples of five 
patients (14%) and the stools of three patients (8%) were not cultured due to logistical 
errors. As these eight patients may have had false positive stool toxin tests, we 
performed the analysis for all patients and for patients who had a positive culture. In 
spite of the fact that outbreaks due to the strain PCR-ribotype 027 had occurred in all 
regions, this PCR-ribotype was not found in the community.
 Different PCR-ribotypes were not clearly linked to an age group or region, except 
for PCR-ribotype 078, which was found four times in the region of Zwolle and not in both 
other regions. The numbers of patients in each specific PCR-ribotype group were very 
small, limiting the possibility of finding associations with clinical characteristics.
was determined by E-test for erythromycin, clindamycin, moxifloxacin and ciprofloxacin, 
using the breakpoints recently described [12].
Clinical and epidemiological information
The laboratories collected demographic data from all patients whose stool samples 
were submitted by GPs. If a stool sample gave positive results, the GP who had 
submitted the sample was asked to give the patient an envelope containing 
information on the background and aim of our study, together with a request to 
complete a web-based or printed questionnaire.
 The patients were asked for information concerning their symptoms, treatment 
and possible risk factors. The question about stool consistency on the day of maximal 
illness was illustrated by drawings from the Bristol Stool Scale [13]. We chose to 
enquire after antibiotic use during six months prior to diarrhoea instead of three 
months, because we wanted to rule out damage to the colonization barrier persisting 
longer than three months after the use of antibiotics. It is unclear how long this 
damage may persist, but, in animal models, persisting susceptibility to C. difficile 
colitis 74 days after one dose of clindamycin has been described [14]. If the patient 
could not or did not respond, we asked the GPs for the most essential patient 
information.
 In June 2008, we asked the GPs of all included patients for information on 
persistent diarrhoea attributed to CDI, recurrences and deaths. The diagnosis of a 
recurrence was left to the judgment of the GPs.
Statistical analysis
Data were analysed with SPSS 14.0 for Windows (SPSS, Inc., Chicago, IL, USA). 
Descriptive statistics and Maentel-Haenszel-adjusted odds ratios were used to 
examine possible correlations. Non-normally distributed continuous variables were 
compared with the Mann-Whitney U-test.
Results
In total, 2443 stool samples from 2423 patients were submitted in by GPs. Thirty-seven 
(1.5%) patients with positive samples were identified. Of all 419 samples from patients 
aged 65 or older, 19 (4.5%) were toxin-positive. The laboratories in Utrecht and Zwolle 
registered whether GPs explicitly requested testing for C. difficile. This was the case 
in 12 of 32 positive stool samples.
 Twenty-one patients completed a questionnaire. Information on ten of the 
remaining 16 patients was obtained from their GPs. We obtained follow-up information 
on 25 patients from their GPs in June, 2008.
Table 1   PCR-ribotypes found at various regional laboratories, followed by number 
(percentage) of isolates that contained binary toxin genes and number 
(percentage) that were resistant to various antibiotics.
PCR-ribotype










002 1 0 0 1 (100) 1 (100) 0
014 3 0 0 3 (100) 1 (33) 1 (33)
015 2 0 0 2 (100) 0 0
023 1 1 (100) 0 1 (100) 0 0
025 1 0 0 1 (100) 1 (100) 0
043 1 0 0 1 (100) 0 0
044 1 0 0 1 (100) 1 (100) 0
067 1 0 0 1 (100) 0 0
078 4 3* (75) 0 4 (100) 2 (50) 1 (25)
081 1 0 1 (100) 1 (100) 0 0
110 1 0 0 1 (100) 1 (100) 0
117 2 0 1 (50) 2 (100) 0 0
172 3 0 0 3 (100) 0 0
unknown ribotype 7 0§† 0 6 (100) † 1 (17) † 0
no C. difficile  
was cultured
5
no culture  
was performed
3
* Two isolates contained only the gene for CdtA, not CdtB.
§  One isolate did not contain genes for TcdA or TcdB.
† One isolate was not available for binary toxin and susceptibility testing.
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 Five out of seven unknown PCR-ribotypes belonged to patients who had not 
been admitted to a hospital or nursing home and who were not employed in health 
care. A sixth patient had both been admitted to a hospital and a nursing home and 
for the seventh patient this information was not available.
 The isolates were tested for antimicrobial susceptibility and production of binary 
toxin (table 1). Genes for binary toxin production were found in four isolates, which 
either belonged to PCR-ribotype 023 or 078, both of which have been associated 
with binary toxin production.
Clinical characteristics and follow-up information
Clinical patient characteristics are listed in table 2. Median ages of the patients with 
positive and with negative toxin stool tests were significantly different (54 years (range 
1 – 92) and 37 (range 0 – 97), respectively; p<0.001). Symptoms were serious, with 
watery consistency, high stool frequency and often fever (27%) and admixture of 
blood (36%) and patients were usually treated (86%). The recurrence rate was high 
with eight (29%) of patients suffering recurrences and 1 patient (4%) still suffering 
from diarrhoea on follow-up. Of those eight patients who suffered a recurrence, six 
patients suffered one recurrence, one patient two recurrences and one four 
recurrences. Four out of 32 patients had died. Three deaths were deemed by the GPs 
not to be attributable to CDI and of one death this information was not available.
Risk factors
Risk factors we investigated are listed in table 3. Only 35% of patients had been 
admitted to health care facilities and only 58% had used antibiotics during the six 
months before diarrhoea developed. This percentage was similar among those who 
had been admitted (55%) and those who had not (60%). The antibiotics mentioned 
most often were amoxicillin/clavulanic acid (nine patients) and amoxicillin (4 other 
patients).
 Most patients had comorbidity, as judged by the fact that 21 out of 31 (68%) used 
medication and 13 out of 21 (62%) reported being monitored by a medical specialist. 
When two patients who used only a selective serotonin reuptake inhibitor for a mood 
disorder and one patient who used only acetaminophen for pain because of 
osteoporosis were excluded, the percentage of patients who used medication fell to 
58. Use of medication was associated with older age groups, but not restricted to 
these groups (lowest age quartile: none of six patients; both middle quartiles: two of 
nine patients; highest quartile: seven of seven patients). Gastric acid suppressants 
were used by 26% of patients. No patient was found to have a profession involving 
contact with farm animals. 
Table 2   Clinical characteristics of CDI (sums of percentages may amount to more 
than 100 due to rounding)
Toxin-positive Toxin and 
culture-positive
Characteristic (continuous variables) Median (range)
Age (years) 54 (1 – 92) 69 (1 – 92)
Interval between start of diarrhoea and stool test 
(days)*
10 (5 – 65) 12 (7 – 65)
Characteristic (categorical variables) Proportion (percentage)
Age category:
0 – 4 2/ 37 (5) 1/ 29 (3)
5 – 9 1/ 37 (3) 1/ 29 (3)
10 – 14 2/ 37 (5) 2/ 29 (7)
15 – 19 2/ 37 (5) 2/ 29 (7)
20 – 39 4/ 37 (11) 2/ 29 (7)
40 – 59 7/ 37 (19) 4/ 29 (14)
60  - 79 8/ 37 (22) 8/ 29 (28)
≥ 80 10/ 37 (27) 9/ 29 (31)
Female sex 20/ 37 (54) 16/ 29 (55)
Stool consistency on the day of maximal illness:
formed 1/ 21 (5) 1/ 16 (6)
mushy 1/ 21 (5) 1/ 16 (6)
watery 19/ 21 (90) 14/ 16 (88)
Stool frequency on the day of maximal illness  
(times per day):
1 – 3 2/ 21 (10) 1/ 16 (6)
4 – 6 7/ 21 (33) 5/ 16 (31)
7 – 10 5/ 21 (24) 4/ 16 (25)
> 10 7/ 21 (33) 6/ 16 (38)
Admixture of blood with stools on any day 7/ 21 (33) 4/ 16 (25)
Abdominal pain on any day 14/ 21 (67) 9/ 16 (56)
Temperature over 38 ºC on any day 5/ 21 (24) 3/ 16 (19)
Treatment:
metronidazole 16/ 21 (76) 13/ 16 (81)
metronidazole, followed by vancomycin 2/ 21 (10) 2/ 16 (13)
no treatment 3/ 21 (14) 1/ 16 (6)
Course of diarrhoea:
recovery from diarrhoea without antibiotics 9/ 28 (32) 7/ 22 (32)
recovery from diarrhoea after one treatment 10/ 28 (36) 8/ 22 (36)
recovery from treatment after ≥ 1 recurrences 8/ 28 (29) 7/ 22 (32)
persistent diarrhoea 1/28 (4) 0/ 22 (0)
Mortality:
died 4/ 32 (13) 4/ 25 (16)
death partially attributable to CDI 0/ 31 (0) 0/ 24 (0)
* of the 21 patients who filled in the questionnaire
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Discussion
In this study of clinical and microbiological characteristics of CO-CDI, the prevalence 
of CDI among patients with community-onset diarrhoea for which microbiological 
diagnostics were requested amounted to 1.5%. In most cases, there was no specific 
request to test for C. difficile, which would have caused six out of ten cases to be 
missed. The clinical picture of the disease was severe with a high recurrence rate. We 
found no link to health care facilities in the majority of cases. Moreover, of the patients 
who were not admitted to healthcare institutions, 40% had not used antibiotics during 
the six months prior to the development of diarrhoea. Furthermore, 42% of all patients 
did not use medication compatible with relevant comorbidity and 18% were under 20 
years of age. Finally, most of the PCR-ribotypes found were not associated with 
outbreaks in health care institutions. In particular, PCR-ribotype 027 was not found, in 
spite of the fact that in all of these areas outbreaks with this PCR-ribotype had recently 
occurred.
 Methodological issues might have affected the results of this study. First, our 
study population was based on stool samples that were submitted by GPs, which 
may have led to referral bias. In The Netherlands, GPs are encouraged by their 
guidelines to culture stools when there is serious illness [15]. Therefore, it is possible 
that CO-CDI can run a much milder self-limiting course, in which no diagnostic tests 
are performed. Second, we screened for cases with an EIA for toxins A and B, and 
test characteristics will have influenced the population identified.  EIAs may be 
relatively insensitive in comparison with stool culture and cytotoxicity assays [16]. We 
used an immunochromatography assay (ICTAB, Meridian), which has been shown to 
have a sensitivity of 91%, a specificity of 97%, a positive predictive value of 70% and 
a negative predictive value of 99% in comparison with the cytotoxicity assay used as 
the reference standard [17]. However, the characteristics of this assay were 
determined in a population of hospitalized patients and it is unknown if these charac-
teristics may be extrapolated to a community setting. The design of the study was not 
optimized for a high recovery rate of C. difficile cultures, as each centre was allowed 
to apply its own culture protocol. This may have resulted in 14% toxin-positive and 
culture-negative stool samples. Alternatively, EIAs of these samples may have been 
falsely positive. Therefore, we analysed results from toxin-positive and culture-posi-
tive samples in a separate analysis. Third, bias may have been introduced by the 
manner in which clinical data were gathered. Part of the  information came from 
questionnaires, which were completed by 21 of 37 patients. Possibly, the severity of 
diarrhoea or comorbidity of patients who completed the questionnaire differed from 
those who did not.
 In spite of this possible bias, we feel that the strength of the study is the detail of 
the information that we did obtain. Most previous studies lack this detail,  and  no 






hospital admission in the year prior to diarrhoea and/or 9/ 31 (29) 8/ 25 (32)
admission to a nursing home in the year prior to diarrhoea 6/ 31 (19) 6/ 25 (24)
no admission to health care institutions in the year  
prior to diarrhoea
20/ 31 (65) 15/ 25 (60)
employment in health care 1/ 31 (3) 0/ 25 (0)
no admission to health care institutions in the year  
prior to diarrhoea or employment in health care
19/ 31 (61) 15/ 25 (60)
family members employed in health care 4/ 21 (19) 3/ 16 (19)
hospital admission of family members in the year  
prior to diarrhoea
2/ 21 (10) 2/ 16 (13)
visit to a nursing home in the year prior to diarrhoea 4/ 21 (19) 3/ 16 (19)
no link to healthcare institutions  
(as assessed by the above variables)
9/ 21 (43) 6/ 16 (38)
antibiotics during six months prior to diarrhoea 18/ 31 (58) 16/ 25 (64)
antibiotics during six months prior to diarrhoea of  
those not admitted to health care institutions in the year  
prior to diarrhoea
12/ 20 (60) 11/ 15 (73)
no admission to health care institutions in the year  
prior to diarrhoea or employment in health care or  
antibiotics during six months prior to diarrhoea
7/ 31 (23) 4/ 25 (16)
family members who experienced diarrhoea  
during the month prior to diarrhoea
5/ 19 (26) 4/ 14 (29)
use of medication 21/ 31 (68) 15/ 25 (60)
use of medication compatible with relevant comorbidity 18/ 31 (58) 14/ 25 (56)
use of corticosteroids 0/ 31 (0) 0/ 25 (0)
use of antiperistaltic agents 1/ 31 (3) 0/ 25 (0)
use of gastric acid suppressants 8/ 31 (26) 7/ 25 (28)
monitoring by a medical specialist  
(including nursing home physician)
13/ 21 (62) 12/ 16 (75)
pet ownership 6/ 21 (29) 4/ 16 (25)
professional contact with farm animals 0/ 31 (0) 0/ 25 (0)
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the results of surveillance studies of gastro- enteritis in Dutch general practices 
[23,24],  which  did  not test for C. difficile.
 Interestingly, our data suggest that CO-CDI does not directly result from the 
effects of healthcare-associated out- breaks. We did not find support for the 
hypothesis that an animal reservoir plays a major role in CO-CDI. However, in the 
region of Zwolle, PCR ribotype 078 was the most frequently encountered strain. This 
strain has frequently been found in recent surveillance studies of nosocomial CDI in 
The Netherlands. It has also been found in farm animals and meat products, and 
transmission from animals to humans seems possible. It was isolated from stools of 
diarrhoeal piglets in The Netherlands [25]. The city of Zwolle is situated in a rural part 
of The Netherlands, and one could speculate that a link between humans and animal 
cases exists in this area.
 In conclusion, the prevalence of C. difficile in stools of patients with communi-
ty-onset diarrhoea in The Netherlands for which diagnostics are requested by their 
GPs is 1.5%. All age groups can be affected, and many patients have not been 
admitted to healthcare institutions or used antibiotics. Many PCR ribotypes of C. 
difficile that are not encountered in hospital-associated outbreaks are found. 
Physicians, including GPs, should be aware of  the  possibility  of  CDI  outside  of the 
known risk factors.
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other  study has investigated the follow-up of patients with CO-CDI. Moreover, we 
characterized C. difficile isolates by ribotyping, which serves as an extra tool with 
which to investigate epidemiological  associations.
 Most studies on CO-CDI lack a clear definition of what is to be considered com-
munity-acquired. Often, CDI is designated as community-acquired when stool 
samples were collected in the community without knowledge  of  the patient’s prior 
healthcare contacts. The European Centre for Disease Prevention and Control and 
the CDC have arbitrarily divided CO-CDI (and nosocomial CDI during the first 48 h of 
the admission) into community-onset healthcare facility-associated (CO-CDI 
occurring within 4 weeks after dis- charge from a healthcare facility) and communi-
ty-acquired (occurring after 12 weeks after discharge) [18,19], leaving an intermediate 
period. Using these definitions, Kutty et al. [20] found many CO-CDI cases to be 
community-onset  health- care facility-associated, suggesting that they were not 
actually acquired in the community, but in healthcare facilities. Only 17% of CO-CDI 
cases in a Dutch hospital-based surveillance study were community-acquired when 
the definitions of the European Centre  for Disease  Prevention  and Control were 
applied [7]. The detail of the clinical information that we obtained allows for a clear 
distinction between CDI that is truly community-acquired and CDI that may have 
been acquired in healthcare facilities.
 Furthermore, studies investigating CO-CDI seldom use molecular characterization 
of C. difficile isolates as an additional epidemiological tool. A Canadian study [21] 
characterized 17% of C. difficile strains from community sources as PCR ribotype 
027, but no clinical data were available to verify that the patients had not been recently 
admitted to healthcare institutions.
 A recent surveillance study by the CDC [10] found results very similar to ours. 
However, in this investigation,  unlike ours, patients were not systematically surveyed 
and PCR ribotyping was not performed.
 Finally, a recent case–control study in the UK [22] investigated the prevalence 
and clinical characteristics of patients with cytotoxin-positive stools submitted  by 
GPs. The proportion of positive samples (2.1%) was consistent with that in our study. 
The proportions of patients who used antibiotics in the previous 4 weeks and who 
were hospitalized in the last 6 months were 52% and 45%, respectively. Unfortunately, 
no information was provided on comorbidity, animal contacts, follow-up and clinical 
characteristics of the diarrhoeal illness other than stool frequency. Also, the authors 
mentioned the frequent occurrence of PCR ribotype 001, but did not provide 
information on other PCR ribotypes found and whether these are associated with 
hospital outbreaks.
 The incidence rate of CO-CDI cannot be estimated from our data, as it is unclear 
how many cases have been missed because patients did not visit their GPs or GPs 
did not perform diagnostic tests. Therefore, it is difficult to compare our findings with 
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Abstract
Thirty-year-old observations report frequent asymptomatic Clostridium difficile 
carriage among cystic fibrosis (CF) patients. In this case-control study, we found 
more carriers among CF patients than controls (47% versus 11%), but most strains 
carried by CF patients were non-toxigenic (77% versus 17%). Among CF patients, 
carriers were younger with more-severe pulmonary disease than non-carriers. Strains 
belonged to multiple PCR-ribotypes, suggesting that these CF patients did not 
acquire strains from each other.
Clostridium difficile infection (CDI) is an important cause of diarrhea and colitis. The 
most important risk factors  are exposure to healthcare institutions and the use of 
antibiotics. Other associated factors are advanced age, severe comorbidity, 
decreased humoral immunity against C. difficile toxins and the use of proton pump 
inhibitors. Intestinal colonization with C. difficile may lead to disease, but also to 
asymptomatic carriage. The role of asymptomatic carriers in the spread of CDI is 
unclear as yet [1], as is the reason why some become carriers and others develop 
disease.
 Several studies have suggested that patients with cystic fibrosis (CF) are often 
asymptomatic carriers of C. difficile [2-4], not surprising given their frequent use of 
antibiotics and exposure to hospitals. However, these observations were made in the 
1980s, when the incidence of CDI was lower than now and epidemic strains such as 
PCR ribotype 027 had not yet emerged. Furthermore, the strains CF patients carry 
have not been characterized with molecular methods and predictors of C. difficile 
carriage among CF patients have not been investigated. Lastly, why CF patients 
apparently seldom develop disease remains unclear. Filling in these knowledge gaps 
may provide insight in CDI epidemiology and pathogenesis and have implications for 
infection prevention. In this case-control study, we sought to confirm earlier 
observations of frequent C. difficile carriage in CF patients, to characterize their C. 
difficile strains using molecular methods, to compare the aforementioned risk factors 
for CDI in this group with a control group and to identify predictors of C. difficile 
carriage in CF patients.
 From June 2012 through November 2012, all adult CF patients monitored at 
Erasmus Medical Center, Rotterdam, a national CF center, were asked to participate 
in the study.  The only exclusion criterion was failure to give informed consent. 
Inpatients submitted a stool sample on the ward, which was transported to Leiden 
University Medical Center the same day. Outpatients sent a stool sample by mail, 
which usually arrived the next day. Stool samples were cultured for C. difficile using 
selective media and the alcohol shock method [5]. Strains were characterized by 
PCR-ribotyping [6] and PCRs for toxin genes (TcdA, TcdB and binary toxin genes 
CdtA and CdtB) [5, 7, 8]. Patients described their bowel movements in a diary [9]. 
Clinical and epidemiological information was collected from patient charts. 
As controls, we asked all patients present on 10 separate days between March 1st 
2011 and September 30th 2011 on the internal medicine ward of Bronovo Hospital, 
The Hague, a general hospital with 815 beds, to participate in the study.
 The distributions of continuous variables were compared using a Mann-Whitney 
U test.  Pulmonary function test results were log-normalized for comparison and 
compared by t test. For associations between categorical variables, odds ratios 
(ORs) with 95% confidence intervals (95% CI) were calculated. IBM SPSS Statistics 
20.0 software was used for the calculations.
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colonic mucus or microbiome [14], non-toxigenic strains can colonize CF patients 
more efficiently than non-CF patients. The questions remain how non-toxigenic C. 
difficile strains can establish durable colonization in CF patients, and whether other 
factors than colonization by non-toxigenic strains protect CF patients from CDI.
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Fifty-five CF patients and 108 controls submitted a stool sample. Twenty-six (47%) of 
CF patients were carriers versus 12 (11%) of controls (OR: 7.17; 95% CI: 3.22 – 16). 
Only 6 (23%) strains from CF patients were toxigenic, contrary to 10 (83%) strains 
from controls. Strains in both groups belonged to various PCR ribotypes (CF patients: 
009, 010 (7 patients), 012 (2), 035, 039 (5), 046, 078, 097, 140, 151, 169, 207, unknown 
(3); controls: 018, 026, 043, 054, 076 (2), 081, 140, 142, unknown (2), 1 strain was not 
available). In only two strains, belonging to PCR ribotype 078 and an unknown 
ribotype, both from CF patients, genes for binary toxin were present.
 None of 36 carriers had diarrhea (a mean of three watery bowel movements 
during three consecutive days), as opposed to five of 115 non-carriers; information 
was incomplete in 12 patients. 
 Among controls, the only statistically significant association was heart failure as 
defined in the Charlson comorbidity index [10] (Table 1). 
 CF patients had received more antibiotics than controls. Among CF patients, 
surprisingly, carriers were younger than non-carriers (Table 2). Also, carriers had 
worse pulmonary function parameters. Carriage was associated with severe (class I) 
mutations in the CFTR gene. Continuous variables were dichotomized using the 
median of the whole population as a cut-off. Because of an inverse relationship 
between age and pulmonary function, the odds ratios for pulmonary function 
parameters were adjusted for age by logistic regression analysis to correct for 
confounding. Age under 31 and FEV1 under 65% of predicted were significantly 
associated with carriage.
 Strengths of this study were the detailed data, including daily defined antibiotic doses, 
pulmonary function tests and CFTR mutations, and the molecular characterization of 
C. difficile strains. A weakness of this study is the small number of patients. Furthermore, 
a comparison of CF patients with any other patient group is necessarily flawed 
because of differences in age and comorbidities. We tried to compensate for this by 
detailed documentation of risk factors for C. difficile carriage. 
 In the three studies from the 1980s, carriage rate among CF patients receiving 
antibiotics ranged from 22% to 50% versus 0% among those not receiving antibiotics 
[2-4]. Most of the colonized patients did not have diarrhea. Our finding of a high 
asymptomatic carriage rate is compatible with these studies, but only one study 
found a similarly low proportion of toxigenic strains. The association between carriage 
and more-severe pulmonary disease can probably be explained by higher antibiotic 
consumption. The association with younger age might tentatively be explained by a 
higher exposure to (non-toxigenic) strains circulating in the community.
 Colonization with non-toxigenic C. difficile may protect against colonization with 
toxigenic strains [11] and may partially explain why CF patients seldom develop 
disease. Non-toxigenic strains might be less efficient at establishing long-term 
carriage than toxigenic C. difficile [12, 13]. We hypothesize that, due to differences in 












































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































62 | Chapter 3 Carriage of C. difficile in cystic fibrosis | 63
Reference List
1. Walker AS, Eyre DW, Wyllie DH, et al. Characterisation of Clostridium difficile hospital ward-based 
transmission using extensive epidemiological data and molecular typing. PLoS Med 2012; 9:e1001172.
2. Wu TC, McCarthy VP, Gill VJ. Isolation rate and toxigenic potential of Clostridium difficile isolates from 
patients with cystic fibrosis. J Infect Dis 1983; 148:176.
3. Peach SL, Borriello SP, Gaya H, Barclay FE, Welch AR. Asymptomatic carriage of Clostridium difficile 
in patients with cystic fibrosis. J Clin Pathol 1986; 39:1013-1018.
4. Welkon CJ, Long SS, Thompson CM, Jr., Gilligan PH. Clostridium difficile in patients with cystic fibrosis. 
Am J Dis Child 1985; 139:805-808.
5. Paltansing S, van den Berg RJ, Guseinova RA, Visser CE, van d, V, Kuijper EJ. Characteristics and 
incidence of Clostridium difficile-associated disease in The Netherlands, 2005. Clin Microbiol Infect 
2007; 13:1058-1064.
6. Bidet P, Lalande V, Salauze B, et al. Comparison of PCR-ribotyping, arbitrarily primed PCR, and 
pulsed-field gel electrophoresis for typing Clostridium difficile. J Clin Microbiol 2000; 38:2484-2487.
7. Kato H, Kato N, Watanabe K, et al. Identification of toxin A-negative, toxin B-positive Clostridium 
difficile by PCR. J Clin Microbiol 1998; 36:2178-2182.
8. Stubbs S, Rupnik M, Gibert M, Brazier J, Duerden B, Popoff M. Production of actin-specific ADP-ribo-
syltransferase (binary toxin) by strains of Clostridium difficile. FEMS Microbiol Lett 2000 May; 
186:307-312.
9. O’Donnell LJ, Virjee J, Heaton KW. Detection of pseudodiarrhoea by simple clinical assessment of 
intestinal transit rate. BMJ 1990 Feb; 300:439-440.
10. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM 
administrative databases. J Clin Epidemiol 1992; 45:613-619.
11. Wilson KH, Sheagren JN. Antagonism of toxigenic Clostridium difficile by nontoxigenic C. difficile. J 
Infect Dis 1983; 147:733-736.
12. Natarajan M, Walk ST, Young VB, Aronoff DM. A clinical and epidemiological review of non-toxigenic 
Clostridium difficile. Anaerobe 2013;22:1-5.
13. Villano SA, Seiberling M, Tatarowicz W, Monnot-Chase E, Gerding DN. Evaluation of an oral suspension 
of VP20621, spores of nontoxigenic Clostridium difficile strain M3, in healthy subjects. Antimicrob 
Agents Chemother 2012; 56:5224-5229.
14. Lynch SV, Goldfarb KC, Wild YK, Kong W, De Lisle RC, Brodie EL. Cystic fibrosis transmembrane 
conductance regulator knockout mice exhibit aberrant gastrointestinal microbiota. Gut Microbes 2013; 
4:41-47.
Chapter 4
Clostridium difficile infection in Europe:  
a hospital-based survey
Martijn P. Bauer,1,2 Daan W. Notermans,1 Birgit H.B. van Benthem,1 
Jon S. Brazier3, Mark H. Wilcox,4 Maja Rupnik,5 Dominique L. Monnet,6 
Jaap T. van Dissel2 and Ed J. Kuijper,2 for the ECDIS Study Group.†
Lancet 2011;377(9759):63-73
1Centre for Infectious Disease Control Netherlands (CIb), National Institute for Public Health  
and the Environment (RIVM), Bilthoven, The Netherlands
2 Centre for Infectious Diseases, Leiden University Medical Center, Leiden, The Netherlands
3 Anaerobe Reference Laboratory, National Public Health Service for Wales, Microbiology Cardiff 
University Hospital of Wales, Cardiff, United Kingdom
4 Department of Microbiology, Old Medical School, Leeds General Infirmary & University of Leeds,  
Leeds, United Kingdom
5 Institute of Public Health Maribor, Centre for Microbiology, Maribor, Slovenia
6 Scientific Advice Unit, European Centre for Disease Prevention and Control, Stockholm, Sweden
† ECDIS Study Group: see list of members after acknowledgements
66 | Chapter 4 CDI in Europe | 67
Summary
Background 
Little is known about the extent of Clostridium difficile infection in Europe. Our aim 
was to obtain a more complete overview of C. difficile infection in Europe and build 
capacity for diagnosis and surveillance.
Methods 
We set up a network of 106 laboratories in 34 European countries. In November, 
2008, one to six hospitals per country, relative to population size, tested stool samples 
of patients with suspected C. difficile infection or diarrhoea that developed 3 or more 
days after hospital admission. A case was defined when, subsequently, toxins were 
identified in stool samples. Detailed clinical data and stool isolates were collected for 
the first ten cases per hospital. After 3 months, clinical data were followed up.
Findings 
The incidence of C. difficile infection varied across hospitals (weighted mean 4.1 per 
10,000 patient-days per hospital, range 0.0-36.3). Detailed information was obtained 
for 509 patients. For 389 of these patients, isolates were available for characterisa-
tion. 65 different PCR ribotypes were identified, of which 014/020 (61 patients [16%]), 
001 (37 [9%]), and 078 (31 [8%]) were the most prevalent. The prevalence of 
PCR-ribotype 027 was 5%. Most patients had a previously identified risk profile of old 
age, comorbidity, and recent antibiotic use. At follow up, 101 (22%) of 455 patients 
had died, and C. difficile infection played a part in 40 (40%) of deaths. After adjustment 
for potential confounders, an age of 65 years or older (adjusted odds ratio 3.26, 95% 
CI 1.08-9.78; p=0.026), and infection by PCR-ribotypes 018 (6.19, 1.28-29.81; 
p=0.023) and 056 (13.01; 1.14-148.26; p=0.039) were significantly associated with 
complicated disease outcome.
Interpretation 
PCR ribotypes other than 027 are prevalent in European hospitals. The data 
emphasise the importance of multicountry surveillance to detect and control C. 
difficile infection in Europe.
Funding 
European Centre for Disease Prevention and Control.
Introduction
Clostridium difficile infection is prevalent in health-care facilities throughout the 
developed world, but also presents as large outbreaks. Less often, it is acquired in 
the community from an unknown source. It characteristically occurs in elderly patients 
with comorbidity in whom the intestinal flora has been disrupted by previous use of 
antibiotics.1,2 Since early 2003, increasing rates of C. difficile infection have been 
reported in Canada and the USA, with a larger proportion of severe and recurrent 
cases occurring in these countries than previously reported. The raised incidence 
and virulence of such infection have partly been explained by the spread of fluoro-
quinolone-resistant strains belonging to the PCR-ribotype 027.3-5 In addition to the 
usual toxins A and B, these fluoroquinolone-resistant strains produce a binary toxin, 
with a hitherto uncertain pathogenic significance.1-6 In Europe, PCR-ribotype 027 was 
first reported in 2005 in England and shortly thereafter in the Netherlands.7,8 
Subsequently, epidemics of C. difficile infection caused by PCR-ribotype 027 have 
been recognised in hospitals in many European countries.9 
 The attention given to this infection, diagnostic procedures in hospitals, presence 
and methodology of national surveillance, and availability of typing vary widely 
across Europe, which hampers comparisons between countries.9,10 We did this study 
to obtain a more complete overview of the situation in Europe and build capacity for 
diagnosis and surveillance of C. difficile infection both nationally and Europe-wide.
Methods
Study design and patients
With support from the European Centre for Disease Prevention and Control, we 
appointed national coordinators for 34 European countries (including 27 member 
states, three candidate states, and four European-Free-Trade-Association countries) 
who selected hospitals in each country, relative to the country’s population size. No 
randomisation was used for this selection. The aim was to include one hospital for 
countries with fewer than two million inhabitants, three for those with between two 
and 20 million inhabitants, and five for those with more than 20 million inhabitants, 
with a balance between academic and non-academic institutions. A study protocol 
noting all procedures was distributed to national coordinators and coordinators in all 
hospitals. Hospitals and laboratories completed a web-based questionnaire 
(Appendix) with epidemiological data, including numbers of patient-days, admissions, 
and stool samples tested for C. difficile infection in November, 2008, and technical 
data such as assays and culture methods used.
68 | Chapter 4 CDI in Europe | 69
We adhered to the epidemiological recommendations as defined by the ad hoc C. 
difficile surveillance working group.1,18 Briefly, C. difficile infection is divided into 
health-care-associated cases (i.e., occurring in a hospital or nursing home after 48 h 
of admission or within 4 weeks after discharge from such a facility), community-asso-
ciated cases (i.e., occurring in the community, provided that the patient had not been 
admitted to a health-care facility in the previous 12 weeks), and an indeterminate 
group for infections occurring between 4 and 12 weeks after discharge from a 
health-care facility. Furthermore, complicated disease was defined as C. difficile 
infection that contributed to or caused ICU admission or death, or led to colectomy. 
Severe comorbidity was defined as having a chronic-health points score over 0, as 
defined by the Acute Physiology, Age, Chronic Health Evaluation (APACHE) II score.19 
Quinolones were classified as old quinolones (nalidixic acid, norfloxacin, ofloxacin, 
ciprofloxacin) and new quinolones (levofloxacin, moxifloxacin, gatifloxacin).
Statistical analysis
For all hospitals, incidence rates of health-care-associated C. difficile infection were 
obtained by dividing the number of health-care-associated occurrences in November, 
2008, (extrapolated by multiplication of the proportion of healthcare-associated 
infection in the questionnaires with all cases recorded in November, 2008) by the 
number of patient-days in November, 2008. Health-care-associated C. difficile 
infection incidence rates were also calculated with the total number of admissions as 
the denominator. Weighted mean incidence rates per hospital were calculated for 
each country from the incidence rates of all hospitals in that country, using the 
number of patient-days and the number of admissions per hospital as a weighting 
factor.
 The associations of patient and pathogen characteristics with two outcome 
measures (complicated infections or recurrence within the 3-month follow up) were 
investigated. Since patients were nested within hospitals and might be exposed to 
common characteristics of their hospitals that could be important determinants of 
outcome, we could not assume independence of observations. Therefore, we chose 
a two-level multilevel-regression method, which takes into account within-group 
(hospital) and between-group relations, and allows for integration of hospital and 
patient variables. Since the outcome (complicated infection or recurrence) was 
binary, we used the logistic form of the multilevel-regression model. An odds ratio 
with a 95% CI was calculated for all associations between a patient or pathogen 
characteristic and an outcome—i.e., complicated infection or recurrence. Cases in 
which non-toxigenic strains were cultured were classified as culture negative, since 
these strains were not thought to be the cause of symptoms. Many of the associations 
reported in the analysis could be subject to confounding. For example, an association 
between the acquisition of C. difficile infection in a health-care facility (as opposed to 
Procedures
Hospitals were asked to test for C. difficile infection in outpatients and inpatients 
suspected of having the infection by their treating physician and all inpatients who 
developed diarrhoea 3 days or more after admission. Clinical grounds on which to 
suspect recurrence were left to the attending physicians’ judgment, who could use 
the definition of C. difficile infection according to the European Society of Clinical 
Microbiology and Infectious Diseases (ESCMID) treatment guidance for C. difficile 
infection.11 Only patients aged 2 years or older were included in the study. Patients 
with suspected C. difficile infection and diarrhoea, whose stool samples were positive 
for toxin A, B, or both (EIA, cytotoxicity test, or PCR) or revealed the presence of tox-
in-producing C. difficile were defined as having C. difficile infection.
 A web-based questionnaire (Appendix) was used to gather additional information 
about demography, clinical data, and risk factors associated with the infection in the 
first patients to be diagnosed, with a maximum of ten patients included per 
participating hospital. If patients had episodes of C. difficile infection in the previous8 
weeks, they were reported as having recurrent disease at inclusion. Stool samples 
from the first ten patients were cultured for C. difficile according to local protocols, 
and the isolates were sent to a central laboratory (Leiden University Medical Centre, 
Leiden, Netherlands) for further characterisation.
 3 months after diagnosis, follow-up clinical data were obtained as part of the 
web-based questionnaire, including overall mortality, mortality attributable to C. 
difficile infection, colectomy, intensive-care-unit (ICU) admission, and recurrences 
during follow-up. Clinical grounds on which to suspect recurrence were left to the 
attending physicians’ judgment, who could use the definition of recurrence according 
to the ESCMID treatment guidance for C. difficile infection.11 All patients suspected of 
recurrence, who had toxin-positive-stool samples, were reported as having 
recurrence. No attempt was made to differentiate between relapses and reinfections.
Identification of C. difficile was confirmed by an in-house PCR test for the glutamate 
dehydrogenase gene specific to C. difficile.12 Isolates were further characterised by 
PCR ribotyping.13 Since PCR-ribotypes 014 and 020 are nearly identical and differ 
only by one band on a specific agarose-gel electrophoresis, the types were reported 
together as ribotype 014/020. The presence of toxin A, toxin B, and binary toxin genes 
were investigated with standardised PCRs.14,15 Isolates that were difficult to type were 
sent to the Anaerobe Reference Laboratory in Cardiff, UK, for further characterisation 
by the Cardiff PCR-ribotyping library, which currently consists of more than 300 
ribotypes.16 These isolates, and isolates of PCR ribotypes for which the toxinotype 
was unknown, were sent to the Institute of Public Health in Maribor, Slovenia, for 
toxinotyping.17 No attempt was made to identify more than one causative ribotype, 
because infection by C. difficile resulting from more than one ribotype is thought to 
be rare.
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countries); PCR ribotype 027 ranked sixth (in six countries; table 2). Some commonly 
encountered PCR ribotypes were identified in a few countries and their distribution 
suggested regional spread (figure). Among these were PCR ribotype 106, which was 
reported in the UK (13 isolates), Ireland (five), and Spain (two), and PCR ribotype 018, 
which was recorded in Italy (19), Spain (two), Austria (one), and Slovenia (one). 12 
different toxinotypes were identified. Of these, toxinotype 0 was most prevalent, 
representing 248 (65%) of 383 isolates; toxinotype III was identified predominantly in 
PCR-ribotype 027 strains (19 isolates) and only in five isolates belonging to rare PCR 
ribotypes (075, 099, 176, and 208); toxinotype IV predominantly in PCR-ribotype 023; 
and toxinotype V in PCR ribotypes 078 (30 isolates) and 126 (12); toxinotype XII fully 
correlated with PCR-ribotype 056. 13 (3%) isolates were C. difficile-toxin-A negative 
and C. difficile- toxin-B positive. 11 of these isolates belonged to PCR ribotype 017 
and one each to the newly identified PCR ribotypes 232 and 234. Six (2%) isolates 
were non-toxigenic and were not included in further analyses.
the community) and a complicated outcome might be confounded by age. To adjust 
the odds ratios for such potential confounders, we did a multivariate analysis for a 
selection of variables, again using a two-level logistic-regression model. As potential 
confounders, we selected variables for which a role as a confounder was biologically 
plausible and that were correlated to outcome with an alpha level less than 0.2, since 
significance-selection strategies to select for possible confounders do best at this 
level.20 We tested whether confounders were highly collinear (variance inflation factor 
>10), in which case only one of them would be introduced as a covariate in multivariate 
analysis. Generally, statistical significance was declared for p values less than 0.05. 
Data were analysed with Stata 10.1.
Role of funding source
The study was funded by the European Centre for Disease Prevention and Control 
(ECDC) through a specific service contract (ECD.894) to the Centre for Infectious 
Disease Control Netherlands, National Institute for Public Health and the Environment, 
Bilthoven, Netherlands. The decision to submit for publication was taken by the study 
coordinator in the Netherlands. ECDC provided support on the study design, 
suggested national coordinators, and provided comments on the analysis and the 
final report.
Results
In total, 97 hospitals provided patients or epidemiological data, or both. Because 
some hospitals were unable to supply denominator data, we could not calculate 
incidences for all hospitals (table 1). Most hospitals were large, as judged by the 
number of patient-days and admissions (median number of admissions per month 
2,645; IQR 1,808-4,257); 62 hospitals (67%) were academic hospitals. The estimated 
incidence of health-care-associated infection varied widely between hospitals. We 
calculated the proportion of health-care-associated C. difficile infection by the sum of 
health-care-associated and community-associated infections (table 1).
 We tested associations between high-incidence hospitals (>10 per 10,000 
patient-days) and antibiotics used by the patients in the month preceding inclusion. 
Use of aminopenicillins (odds ratio [OR] 2.70, 95% CI 1.17-6.22), first-generation 
cephalosporins (6.98, 1.83-26.62), or second-generation cephalosporins (2.40, 
1.28-4.50) was significantly associated with high-incidence hospitals.
 395 isolates from 73 hospitals in 26 countries were available for detailed 
 characterisation. 65 different PCR ribotypes were identified (figure), including six new 
PCR ribotypes: 228, 229, 230, 231, 232, and 234. The most common PCR ribotypes 
were 014 and 020 (found in 19 countries), 001 (in 13 countries), and 078 (in 18 
Figure   Geographical distribution of Clostridium difficile PCR ribotypes in European 
countries with more than five typable isolates, November 2008.
Pie charts show proportion of most frequent PCR-ribotypes per country. The number in the centre of pie 
charts is the number of typed isolates in the country.
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associated C. difficile infection 
incidence rate per hospital 
(minimum to maximum range) †
Percentage of health-care-
associated C. difficile infection 
cases in health-care-associated 
and community-associated
C. difficile infections
Number  of 
complicated cases/
number of  cases with 
available data (%)
Toxin tests used  
(number of hospitals)




Austria 53/ 330 (16%) 52 3 7.5 (4.3 - 10.9) 36 (20 - 46) 92% 4/ 26 (15%) A+B (2); A+B and Cu (1)
Belgium 16/ 283 (6%) 55 3 2.8 (0.0 - 6.2) 19 (0 - 39) 91% 0/ 11 (0%) A+B (1); Cy and A+B (1); A (1)
Bulgaria 2/ 9 (22%) 3 3 0.6 (0.0 - 2.1) 3 (0 - 10) 100% 1/ 1 (100%) A+B (3)
Croatia 22/ 197 (11%) 41 3 (2) 0.7 (0.5 - 2.1) 6 (4 - 20) 18% 1/ 14 (7%) A+B (2)
Cyprus 1/ 28 (4%) 34 1 1.2 5 100% 0/ 1 (0%) A+B (1)
Czech Republic 10/ 152 (7%) 17 3 1.1 (0.0 -1.3) 7 (0 - 9) 100% 2/ 7 (29%) A+B (3)
Denmark 28/ 330 (8%) 74 3 5.5 (4.4 - 9.6) 18 (10 - 25) 88% 1/ 19 (5%) A+B (1); Cu (2)
Finland 52/ 351 (15%) 141 3 19.1 (8.7 - 28.5) 80 (30 - 132) 91% 2/ 22 (9%) A+B and Cu (1); Cu (1); A&B (1)
France 37/ 626 (6%) 42 5 (4) 2.1 (1.0 - 3.1) 15 (6 - 27) 84% 4/ 34 (12%) A+B (2); Cu (1); Cy (1)
Germany 93/ 602 (15%) 72 6 (5) 7.4 (2.9 - 16.4) 60 (25 - 276) 91% 2/ 24 (8%) A+B (3); Cu (1); Cy (1)
Greece 21/ 288 (9%) 60 3 3.7 (1.3 - 4.9) 29 (9 - 44) 84% 0/ 17 (0%) A+B (3)
Hungary 22/ 333 (7%) 38 3 2.0 (0.4 - 3.9) 9 (1 - 23) 68% 1/ 25 (4%) A+B (3)
Iceland 6/0 ·· 1 ·· ·· 100% 0/ 6 (0%) ··
Ireland 38/ 493 (8%) 94 3 7.3 (6.5 - 7.9) 63 (39 - 92) 100% 5/ 21 (24%) A+B (3)
Italy 57/ 533 (11%) 39 5 3.6 (0.4 - 5.8) 22 (2 - 61) 85% 5/ 18 (28%) A+B (2), GluD and A+B (1); Cy (1)
Latvia 13/ 64 (20%) 10 3 1.9 (0.0 - 2.8) 13 (0 - 20) 91% 0/ 13 (0%) A (2); A+B (1)
Luxembourg 0/ 28 (0%) 49 1 0.0 0 NA 0 A+B
Netherlands 18/ 309 (6%) 69 3 4.0 (2.3 - 8.5) 23 (13 - 43) 100% 1/ 15 (9%) A+B (2); Cy (1)
Norway 37/ 241 (15%) 50 3 7.6 (0.4 - 16.5) 56 (3 - 229) 100% 1/ 16 (6%) A+B (3)
Poland 102/ 263 (39%) 45 3 12.5 (3.8 - 36.3) 76 (29 - 189) 79% 1/ 11 (9%) A+B (2); Cu (1)
Portugal 14/ 158 (9%) 45 3 (2) 2.6 (1.9 - 8.2) 13 (13 - 14) 86% 0/ 10 (0%) A+B (3)
Romania 1/ 11 (9%) 3 5 (1) 0.3 2 100% 0/ 1 (0%) A+B (2)
Slovakia 10/ 91 (11%) 16 3 (2) 1.4 (0.0 - 2.1) 11 (0 - 15) 71% 0/ 5 (0%) A (1); Cu (1)
Slovenia 24/ 123 (20%) 17 3 (2) 2.8 (1.5 - 3.2) 19 (10 - 23) 67% 1/ 10 (10%) A+B (2)
Spain 46/ 485 (9%) 45 5 4.3 (0.0 - 16.7) 30 (0 - 47) 100% 5/ 28 (18%) A+B (2); Cu (1); A+B and Cy and Cu (1); 
A+B and Cu (1)
Sweden 69/ 430 (16%) 74 3 9.8 (6.3 - 15.7) 50 (28 - 71) 86% 2/ 30 (7%) A+B (2); Cy (1)
Switzerland 16/ 150 (11%) 45 3 4.8 (0.0 - 7.5) 50 (0 - 84) 100% 0/ 12 (0%) A+B (2); Cu (1)
Turkey 4/ 105 (4%) 4 5 0.0 (0.0 - 0.6) 0 (0 - 4) 20% 0/ 4 (0%) A+B (3); A (1)
United Kingdom 164/ 1,695 (10%) 115 6 10.6 (6.7 - 30.3) 50 (44 - 135) 92% 5/ 40 (13%) A+B (3); Cy (3)
Total NA NA 97 (87) 4.1 (0.0 - 36.3) 23 (0 - 276) NA 44/ 442 (10%) NA
A+B=enzyme immunoassay for C. difficile toxin A and B. A=enzyme immunoassay for C. difficile toxin A only. 
Cu=toxigenic culture. Cy=cytotoxicity test. GluD=enzyme immunoassay for C. difficile-specific glutamate 
dehydrogenase. NA=not applicable. ··=data not available. *Number of hospitals on which incidence data are 
based is shown in parentheses. The remaining hospitals did not provide denominator data. †Weight factor for 
weighted-mean incidence per 10,000 patient-days=number of patient-days; weight factor for weighted-mean 
incidence per 10,000 admissions=number of admissions. The UK and Germany were each granted one extra 
hospital. In Poland, three hospitals rather than five were recruited. No hospitals were recruited in Lithuania, and 
one was recruited in Malta. From Estonia, Liechtenstein, and the Former Yugoslav Republic of Macedonia no 
data or isolates were received.
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Female 287/ 509 (56%)
Age ≥65 years* 319/ 509 (63%)
Epidemiological association
Health-care associated 408/ 506 (80%)
Community associated 70/ 506 (14%)
Indeterminate association 28/ 506 (6%)
Explicit request to test for infection 441/ 507 (87%)
Use of an antibiotic not directed at C. difficile infection
Any antibiotic not directed at C. difficile infection 366/ 463 (79%)
Aminopenicillin 28/ 463 (6%)
Aminopenicillin - β-lactamase inhibitor combination 86/ 463 (19%)
Antipseudomonal penicillin - β-lactamase inhibitor combination 38/ 463 (8%)
Second-generation cephalosporin 60/ 463 (13%)
Ceftazidime 78/ 463 (17%)
Any cephalosporin 155/ 463 (34%)
Carbapenem 41/ 463 (9%)
Aminoglycoside 27/ 463 (6%)
Old quinolone 80/ 463 (17%)
New quinolone 29/ 463 (6%)
Any quinolone 104/ 463 (23%)
Intravenous glycopeptide 33/ 463 (7%)
Lincosamide 28/ 463 (6%)
Macrolide 27/ 463 (6%)
Co-trimoxazole 25/ 463 (5%)




Severe comorbidity (APACHE II CHP >0) 204/ 468 (44%)
Liver cirrhosis (APACHE II) 21/ 488 (4%)
Heart disease (APACHE II) 47/ 484 (10%)
Pulmonary disease (APACHE II) 54/ 480 (11%)
Chronic dialysis (APACHE II) 30/ 496 (6%)
Immunocompromised status (APACHE II) 106/ 488 (22%)
Treatment for inflammatory bowel disease 21/ 492 (4%)
Episodes of infection in previous 8 weeks 68/ 431 (16%)
Disease characteristics
Outpatient 56/ 509 (11%)
Duration of diarrhoea
<1 week 334/ 461 (73%)
1 to 3 weeks 92/ 461 (20%)
>3 weeks 35/ 461 (8%)
Table 2   Continued.
n/ N (%)
Disease characteristics
Diarrhoea mixed with blood at any moment in previous week 48/ 416 (12%)
Fever (temperature >38.5ºC) 167/ 446 (37%)
Ileus at any moment in previous week 20/ 509 (4%)
Last leukocyte count in previous week ≥15 × 109/L† 122/ 428 (29%)




Pseudomembranes 7/ 29 (24%)
Ulceration 13/ 29 (45%)
Imaging‡
Colonic wall thickening on CT 26/ 63 (41%)
Pericolonic fat stranding on CT 7/ 63 (11%)
Bowel distension on plain abdominal radiograph or CT 27/ 117 (23%)
Microbiological characteristics
Most frequent PCR ribotypes among toxigenic isolates
014/020 61/ 389 (16%)
001 37/ 389 (10%)
078 31/ 389 (8%)
018 23/ 389 (6%)
106 20/ 389 (5%)
027 19/ 389 (5%)
002 18/ 389 (5%)
012 17/ 389 (4%)
017 14/ 389 (4%)
015 13/ 389 (3%)
126 12/ 389 (3%)
023 10/ 389 (3%)
046 8/ 389 (2%)
003 7/ 389 (2%)
011 6/ 389 (2%)
053 6/ 389 (2%)
056 6/ 389 (2%)
Presence of either or both binary toxin genes in toxigenic isolates 90/ 389 (23%)
Toxin A negative, toxin B positive strains in toxigenic isolates 13/ 389 (3%)
All time periods mentioned are related to the time of collection of the stool sample. Only antibiotics that 
were administered to more than 5% of patients are given. APACHE II=acute physiology, age, chronic 
health evaluation version two. CHP=chronic health points. N=total number of patients for whom 
information was available.
*Median 71 (IQR 56 - 81). †Leucocyte count distribution ´10⁹ per L (11; 11 - 15). ‡Data apply to current 
episode of C.. difficile infection. If several procedures were done during an episode, only the first was 
considered. §Two patients were treated for inflammatory bowel disease.
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were more likely to be outpatients at the time of presentation (OR 1.97, 95% CI 0.98 - 
3.97), to have community-associated infection (2.59, 1.39 - 4.84), and be infected by 
PCR ribotype 018 (3.24, 1.20 - 8.73) or PCR ribotype 106 (3.96, 1.44 - 10.95); they 
were less likely to be aged 65 years or older (0.61, CI 0.36 - 1.02) and to have severe 
comorbidity (0.56, 0.31 - 1.01), especially pulmonary disease (0.26, 0.06 - 1.10). A 
separate analysis in which non-complicated C. difficile infection was assumed for 
patients with missing information resulted in closely similar values for the association 
of PCR-ribotype 018 with complicated infection (5.65; 1.63 - 19.57).
 Because death or colectomy could have precluded a patient from having a 
recurrence, a separate analysis was done for risk factors for recurrence in only those 
patients who did not die or undergo a colectomy. Results of the univariate analysis 
mirrored the analysis for the whole group, except that previous use of intravenous 
glycopeptides and chronic dialysis were significantly associated with recurrence 
(3.28, 1.12 - 13.78 and 2.87, 1.02 - 8.14, respectively).
 Different cutoff values for the continuous variables age and leukocyte count, as 
assessed by receiver operator characteristics, did not lead to improved performance 
in the prediction of complicated C. difficile infection.
 Most cases were health-care associated or community associated, leaving 6% 
of indeterminate association (table 2). Most patients fitted the previously established 
risk profile, with almost two-thirds aged 65 years or more, about two-fifths having 
severe comorbidity, and almost all having received antibiotics during the 3 months 
before their infection, most commonly cephalosporins, quinolones, and amino-
penicillin - β-lactamase-inhibitor combinations (table 2). 68 (16%) of 431 patients had 
recurrent C. difficile at inclusion.
 Data after 3-months’ follow-up were obtained for about 90% of patients (table 3). 
An exact number cannot be provided, since follow-up was incomplete for some 
patients and therefore the number of patients with follow-up data differs for each 
variable. Of the 101 patients who had died, 40 (40%) of 101 deaths were judged to be 
related to C. difficile infection.
 All seven patients who died from C. difficile infection as a main cause were aged 
75 years or older and their infection was health-care associated. Six of them had 
severe comorbidity (four had pulmonary disease, three were immunocompromised, 
and two had heart disease). Two of these patients had a recurrent episode of infection 
at presentation. Two had leukocyte counts of 30 ´ 109 per L or greater and two of 4 ´ 
109 per L or less. The strains causing these infections belonged to PCR-ribotypes 
015, 018, 027 (two patients), and 056. No isolate could be obtained for two patients. 
An age of 65 years or older, severe pulmonary comorbidity, previous use of a new 
quinolone, and infection by PCR-ribotypes 027, 015, and 018 were significant risk 
factors for complicated infections in univariate analysis (table 4). Patients with this 
comorbidity were distributed evenly among all hospitals. No disease characteristic—
such as duration of diarrhoea, presence of fever, or leukocyte count—was significantly 
associated with complicated infection nor was the presence of binary toxin. After 
correction for potential confounders, an age of 65 years or older and infection by 
PCR-ribotypes 018 and 056 were significantly associated with complicated infection. 
These PCR ribotypes were binary-toxin negative and belonged to toxinotype 0 (type 
018) and XII (type 056). The seven complicated cases caused by PCR-ribotype 018 
occurred in four different hospitals in two countries, and the two complicated cases 
caused by PCR-ribotype 056 occurred in two hospitals in two countries.
 An age of 65 years or older, previous use of ceftazidime, and recent episodes of 
C. difficile infection were significantly associated with recurrences during follow-up in 
univariate analysis (table 5). After correction for potential confounders, previous use 
of ceftazidime and recent episodes of infection were significantly associated with 
recurrence.
 Since differences between patients with follow-up information and those without 
were possible, the characteristics of patients with available follow-up information 
about C. difficile infection complications (n=442) were compared with patients for 
whom this information was not available (n=67). Patients without this information 
Table 3   Treatment and outcome (3-month follow up) characteristics of patients 
with Clostridium difficile infection.
n/ N (%)
Initial episode treated with
     Oral metronidazole 341/ 477 (71%)
     Intravenous metronidazole 50/ 472 (11%)
     Oral vancomycin 89/ 483 (18%)
     Intracolonic vancomycin 1/ 473 (0.2%)
ICU admissions 31/ 459 (7%)
     CDI contributive 6/ 459 (1%)
     CDI primary cause 1/ 459 (0.2%)
Colectomy for CDI 3/ 460 (0.7%)
Death 101/ 455 (22%)
     CDI contributive 33/ 455 (7%)
     CDI primary cause 7/ 455 (2%)
Complicated CDI 44/ 442 (10%)
Recurrent CDI* 86/ 484 (18%)
Both complicated and recurrent CDI 10/ 440 (2%)
Of 491 (96%) of 509 patients, complete or partial follow-up information was available. n=characteristics 
of patients with Clostridium difficile for whom questionnaires were completed. N=total number studied. 
ICU=intensive care unit. CDI=C. difficile infection. *Number of recurrences during follow-up in those 
patients who had recurrences: median 1; 1 - 3.
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014 were the most prevalent, followed by 027 and 020. Epidemic PCR-ribotype 027 
was less prevalent in our study. By contrast, the prevalence of PCR-ribotypes 078 
and 018 was increased. The high prevalence of PCR-ribotype 018 in our study is 
accounted for by its high prevalence in three Italian hospitals. Barbut and colleagues21 
reported that PCR-ribotype 078 was dominant only in Greece, whereas in our study 
it was the third most prevalent PCR ribotype. This increase of PCR ribotype-078 in 
Europe accords with findings for the Netherlands26 and reports of PCR ribotype-078 
in piglets with diarrhoea in the Netherlands and Spain.27,28 Interestingly, human and 
animal isolates of PCR-ribotype 078 are genetically highly related, supporting the 
hypothesis that no interspecies barrier exists for C. difficile infection due to 
PCR-ribotype 078.26 Research suggests that food products might play a part in 
interspecies transmission.29,30 In one study, patients infected with PCR-ribotype 078 
were younger than those infected with PCR-ribotype 027, but had a similar attributable 
mortality.27 We could not show an association between PCR-ribotype 078 and 
complicated infection; however, patients with infection as a result of this ribotype 
(n=31) were more likely to have a rise in serum creatinine than were patients with 
other ribotypes (n=362, OR 3.20, 95% CI 1.08 - 9.49), and had a slightly higher mean 
leukocyte count.
 Although we emphasise that C. difficile infection incidence rates of participating 
hospitals were not representative of national incidence rates, many hospitals with 
high rates of C. difficile infection were from countries in northern and central Europe. 
Most of these countries are thought to have low antibiotic consumption per head, 
even during the winter-respiratory-infection season.31 Heightened awareness of C. 
difficile infection, as shown by the number of patients tested per 10,000 patient-days, 
might partly account for these differences in infection-incidence rates. Differences in 
the severity of illness of patients in hospital or those prescribed antibiotics might be 
other explanations. Patients admitted to high-incidence hospitals were more likely to 
have received aminopenicillins and first-generation and second-generation 
cephalosporins than were patients admitted to low-incidence hospitals.
 Most risk factors for complicated or recurrent infection were consistent with those 
reported in previous studies. Old age,32-34 previous hospital or nursing-home 
admission,33 ileus,33,34 and infection by PCR-ribotype 02735 have been associated 
with complicated C. difficile infection. The use of certain antibiotics, especially fluor-
oquinolones, has been associated with infection by PCR-ribotype 027, and through 
this association with complicated or recurrent disease.35,36 We did not find an 
association between the use of fluoroquinolones and complicated or recurrent 
disease, possibly because of the small number of infections resulting from 
PCR-ribotype 027 in our study. Alternatively, some confounding effects in earlier 
studies—notably data for antimicrobial prescribing in outbreak settings that might 
overestimate C. difficile infection risk associated with specific antibiotics—were not 
Discussion
We have shown that the incidence of C. difficile infection and the distribution of 
causative PCR ribotypes differed greatly between hospitals in Europe; overall and 
attributable mortality were strikingly high. The strengths of this pan-European study 
are the large number of participating countries and hospitals, and a study design with 
a fixed 3-month follow-up. The high follow-up rate and the fact that patients with 
missing follow-up were younger, were more likely to be outpatients, and had less 
comorbidity than patients with follow-up, minimised the risk that cases of complicated 
infection were missed. If all patients with missing follow-up information had had an 
uncomplicated course, this factor would not have affected predictors for complicated 
infection.
 This study has some limitations. First, selection of the hospitals in each country 
was left to the national coordinators, and the number of hospitals per country was 
small. Therefore, results derived from this sample of hospitals might not be 
representative of each country. Furthermore, some hospitals might have been 
selected because of outbreaks of C. difficile infection, thus introducing bias. Second, 
there might have been differences in physician awareness of infection between 
hospitals and countries. We note that the frequency of testing for infection varied up 
to 47 times between countries (as expressed by number of patients tested per 10,000 
patient-days; table 1). Additionally, because there is no consensus on optimum 
testing for C. difficile infection, diagnostic (and culture) methods were not uniform. 
Third, detailed information for cases of infection was obtained only for the first 
ten patients enrolled in each hospital, which might have introduced bias if risk 
factors varied across hospitals. Furthermore, this low number might have led to 
under- representation of PCR ribotypes that caused outbreaks of infection in some 
hospitals.
 Results from endoscopy or CT might be biased since these examinations tend to 
be triggered by a more severe course of disease. The proportion of patients with 
severe comorbidity might be overestimated because one of five items was sufficient 
to declare severe comorbidity, whereas if one item was scored missing, absence of 
severe comorbidity could not be declared.
 Barbut and colleagues21 reported a mean incidence of nosocomial C. difficile 
infection in 23 European hospitals of 2.45 per 10,000 patient-days (minimum to 
maximum range; 0.1-7.1), which is lower than the overall figure of 4.1 per 10,000 
patient-days in our study. However, that study differed from ours in methodology. 
Reports from Denmark, Finland, Germany, Spain, and the UK22–25 support the 
impression of an increase in incidence of C. difficile infection in Europe. PCR ribotypes 
identified by Barbut and colleagues21 differed strikingly from those we identified. In 
their study, among isolates from 38 hospitals in 14 countries, PCR-ribotypes 001 and 
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as likely in our study. An association of PCR-ribotypes 018 and 056 with complicated 
infection has not been reported before. However, the number of complicated 
infections for which these associations were based was small. Old age32,37 and a long 
cumulative duration of previous episodes of C. difficile infection38 have been identified 
as predictors of recurrent infection. We could not confirm leucocytosis33,34,37,39 as a 
strong predictor of complicated infection, possibly because we included leukocyte 
counts only from the week before the patients’ inclusion, whereas in most studies the 
maximum leukocyte count during the course of the illness was examined. These 
findings underscore the importance of local surveillance to detect and control 
endemic and epidemic C. difficile infection.
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Abstract
Nonsevere and severe Clostridium difficile infection (CDI), which carries a higher risk 
than nonsevere CDI for treatment failure and recurrence, are difficult to distinguish at 
the time of diagnosis. To investigate the prognostic value of 3 markers of severe CDI 
suggested by recent guidelines (fever, leukocytosis, and renal failure), we used the 
database of a randomized controlled trial, which contained information for 1105 
patients with CDI. Leukocytosis (risk ratio [RR], 2.29; 95% confidence interval [CI], 
1.63–3.21) and renal failure (RR, 2.52; 95% CI, 1.82–3.50) were associated with 
treatment failure. Fever, although associated with treatment failure (RR, 2.45; 95% CI, 
1.07–5.61), was rare. Renal failure was the only significant predictor of recurrence 
(RR, 1.45; 95% CI, 1.05–2.02). Different timing of measurements of leukocyte count 
and serum creatinine around the CDI diagnosis led to a different severity classification 
in many cases. In conclusion, both leukocytosis and renal failure are useful predictors, 
although timing of measurement is important.
Introduction
Clostridium difficile infection (CDI) has become an increasing problem in many 
hospitals in the Western world during the past decade. C. difficile causes diarrhea 
and colitis with a tendency to recur after initially successful antimicrobial therapy. 
Furthermore, gut inflammation may be so severe that antimicrobial therapy is not 
effective; in such cases, complications such as hypotension, perforation, and toxic 
megacolon may develop. Several risk factors for CDI have been identified, of which 
the use of antibiotics is the most important. Predicting which patients are at risk for 
developing complications or recurrences can guide the choice and duration of 
therapy. In 2009, a prediction rule for recurrences, incorporating age, comorbid 
conditions, and the necessity to continue inciting antibiotic therapy, was published 
[1]. This rule was derived from and validated in 2 cohorts of 44 and 64 patients, 
respectively. The relatively small sample sizes challenge the credibility of this rule. 
Several risk factors for complications of CDI and prediction rules based upon these 
factors have been described, but unfortunately, none of these prediction rules have 
been validated [2–6]. 
 The choice of an appropriate endpoint for a prediction rule for complicated and/
or recurrent CDI has been problematic. The clinical judgment of whether to attribute 
endpoints such as CDI-related mortality and intensive care unit admission may be 
highly subjective, especially in elderly patients who are often admitted with severe 
illness and usually have significant comorbid conditions. Endpoints concerning the 
resolution and recurrence of diarrhea need a precise definition of diarrhea and 
quantitative measurement of stool volume and frequency, which may be difficult to 
obtain. Furthermore, the parameters included in a prediction rule should be objective, 
routinely measured in clinical practice, and be available at the moment the rule is 
applied (ie, when CDI is diagnosed). 
 A recent guideline by the Society for Healthcare Epidemiology of America 
(SHEA) and the Infectious Diseases Society of America (IDSA) recommends that 
age, peak leukocyte count, and peak serum creatinine level be taken into account as 
potential indicators of a complicated course of CDI when treatment is started [7]. The 
European Society for Clinical Microbiology and Infectious Diseases (ESCMID) has 
issued a guidance document for the treatment of CDI that also lists qualitative and 
quantitative symptoms, signs, laboratory parameters, and radiological findings that 
may reflect more severe disease with associated higher risk for complications and 
recurrences [8]. Three quantitative parameters for diagnosing severe colitis were 
included: body temperature >38.5°C, leukocyte count >15 × 109/L, and serum 
creatinine level >50% above baseline; however, these cutoff values have not been 
confirmed prospectively. 
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 In both analyses, we defined fever as core body temperature >38.5°C and 
leukocytosis as leukocyte count >15 × 109/L. Because the pre-CDI serum creatinine 
level was not known for each patient, we substituted the 50% creatinine level increase 
with a fixed value of the creatinine level >133 μmol/L (>1.5 mg/dL). This served as a 
proxy for renal failure. 
Analyses
The intention-to-treat population that received at least 1 dose of study medication 
was used for the analysis. Distributions of the continuous variables of temperature, 
leukocyte count, and creatinine level were compared for patients with and without 
clinical treatment failure and recurrence. Non-normally distributed variables were 
compared with a Mann-Whitney U test. Proportions were compared with β2 test. Risk 
ratios (RRs) and 95% confidence intervals (CIs) were calculated for the associations 
of fever, leukocytosis, and renal failure with the outcome parameters. Kaplan-Meier 
survival curves were constructed to investigate the association of fever, leukocytosis, 
and renal failure with time to resolution of diarrhea (expressed in hours from the first 
dose of fidaxomicin or vancomycin). The log-rank test was used to test the difference 
between the survival curves. Cox regression was used to calculate hazard ratios 
(HRs) with 95% CIs. Receiver operating characteristic curves were constructed to 
assess the validity of the cutoff values used to define categorical variables. Variability 
of leukocyte counts and serum creatinine levels were compared within patients and 
expressed in absolute differences. All analyses were carried out in SPSS for Windows 
software, version 17.0 (SPSS Inc, Chicago, Illinois, USA).
Results
There were 1105 patients with CDI in the clinical trial database. Patients treated with 
vancomycin (566) or fidaxomicin (539) had similar median values for temperature, 
leukocyte count, and serum creatinine level and were evenly distributed across the 
groups based on dichotomized continuous variables (data not shown). Fever was 
rare; only 1.2% of patients (13 out of 1102) had a temperature >38.5°C. Median 
treatment duration was 11 days for the fidaxomicin and vancomycin treatment groups. 
Overall, 143 patients (13%) experienced clinical treatment failure at the end of 
treatment. Of the 962 patients who were cured after treatment, 194 patients (20%) 
experienced recurrence within the following 28 (±2) days. 
 Median leukocyte count and creatinine level were significantly higher in patients 
with clinical treatment failure; temperature distributions in patients with and without 
treatment failure were almost identical. In addition, dichotomous categories of fever, 
leukocytosis, and renal failure all showed significant correlation with treatment failure 
 In the present study, we sought to investigate the value of 3 quantitative severity 
criteria in predicting the failure of antimicrobial therapy and recurrence after initially 
successful treatment. Furthermore, we aimed to investigate whether leukocyte count 
and serum creatinine level fluctuate early in the course of a CDI episode and therefore 
whether the timing of their measurements can influence whether severity criteria are 
met. For our analyses, we used the database from 2 large randomized clinical trials 
that employed a strict objective definition of diarrhea and the database of a 
prospective single-center cohort study that recorded sequential leukocyte counts 
and serum creatinine levels around the date of CDI diagnosis.
Methods
Databases
The database from 2 randomized controlled phase 3 trials comparing vancomycin 
with fidaxomicin for the treatment of CDI was used to assess the predictive value of 
fever, leukocyte count, and serum creatinine level [9, 10]. Patients were recruited in 
the United States, Canada, and Europe (Study NCT00314951, April 2006–July 2008, 
United States, Canada; Study NCT00468728, April 2007–November 2009, United 
States, Belgium, Canada, France, Germany, Italy, Spain, Sweden, United Kingdom; 
www.clinicaltrials.gov). Patients with CDI, defined as diarrhea (>3 unformed bowel 
movements [UBMs] per day) with a positive stool toxin test result for C. difficile, were 
randomly assigned to receive vancomycin, 125 mg, 4 times daily or fidaxomicin, 200 
mg, twice daily for 10 days. The number and times of UBMs were recorded during 
treatment and for 2 days after an end-of-therapy visit. For patients with rectal collection 
devices, volume was converted to number of UBMs by dividing the volume by 60 mL 
and rounding up to the nearest whole number. At the end-of-therapy visit, an 
investigator assessed the success of therapy. Clinical failure was defined as the 
persistence of diarrhea, need for additional therapy for CDI, or both, in the opinion of 
the investigator [10]. Recurrence of CDI (determined by use of the same criteria as for 
enrollment [ie, >3 UBMs per 24 hours and positive stool toxin test result]) was 
assessed during the 28 (±2) days of follow-up after completion of therapy. At 
enrollment, temperature, leukocyte count, and serum creatinine level were collected. 
 To assess whether the timing of laboratory measurements could influence their 
prognostic value, we used the database of a prospective cohort study performed at Leeds 
Teaching Hospital in 2007. In this database, 104 consecutive adult in-patients with CDI 
(unformed stool and positive C. difficile toxin test result) were included. On days −3 to +3 
relative to day 0 (the day the diarrheal sample was collected), leukocyte count and serum 
creatinine level were recorded. A minimum of 2 leukocyte counts and creatinine levels 
on different days were required for patients to be included in the analyses. 
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 Clinical treatment failure rates were similar in the fidaxomicin and vancomycin 
treatment groups regardless of clinical status using the 3 severity factors. Recurrence 
was significantly more frequent following vancomycin treatment compared with 
fidaxomicin. In patients without renal failure, 93 of 402 (23.1%) patients cured by 
vancomycin therapy had a recurrence, whereas only 56 of 403 (13.9%) experienced 
a recurrence after successful fidaxomicin treatment (P < .001). In patients with renal 
failure at baseline, fidaxomicin therapy was associated with a 60% reduction in 
frequency of recurrences (8/54 [14.8%]) relative to vancomycin (24/65 [36.9%]; 
P = .007). Likewise, in patients categorized as having leukocytosis or severe CDI, the 
incidence of recurrence was more than double for patients cured with vancomycin 
compared with those treated successfully with fidaxomicin (P < .01 for each comparison).
Because leukocytosis and renal failure at the time of diagnosis were shown to be the 
strongest predictors, we investigated the stability of these parameters during a 6-day 
interval around diagnosis. In the population from the database of Leeds Teaching 
(Table 1). Median creatinine level was significantly higher in patients with recurrence, 
and this parameter was the only significant predictor of recurrence (Table 2). Different 
cut-off values for the continuous variables of temperature, leukocyte count, and 
creatinine level, assessed by receiver operating characteristics, did not lead to higher 
relative risks and therefore better performance in the prediction of clinical treatment 
failure or recurrent CDI. 
The probability of resolution of diarrhea within 10 days of treatment was slightly lower 
in patients with renal failure compared with patients without renal failure (HR, 0.83; 
95% CI, .68–1.02; Figure 1). Neither fever (HR, 1.08; 95% CI, 0.61–1.91) nor 
leukocytosis (HR, 1.02; 95% CI, 0.84–1.24) was associated with a lower probability of 
resolution of diarrhea. Although creatinine level distributions were similar between 
patients treated with fidaxomicin and vancomycin, we repeated the analysis of renal 
failure as a predictor of resolution of diarrhea stratified according to treatment group 
and found similar results (vancomycin: HR, 0.80 [95% CI, 0.61–1.05]; fidaxomicin: 
HR, 0.88 [95% CI, 0.66–1.19]). Because recurrences occurred less often in patients 
treated with fidaxomicin, the CI is widest in that group.
Table 1   Determinants of Clinical Treatment Failure
Continuous variables
Variable Outcome Median IQR Pa




Failure 10.5 6.8–17.4 .002
Cure 8.9 6.5–12.1
Creatinine (μmol/L) Failure 80 62–150 .005
Cure 71 62–97
Categorical variables
Variable Category Failure (n/N) RRb 95% CI
Fever Temperature >38.5°C 4/13 2.45 1.07–5.61
 ≤ 38.5°C 137/1089
Leukocytosis Leukocytes  >15 × 109/L 38/153 2.29 1.63–3.21
 ≤ 15 × 109/L 90/829
Renal failure Creatinine  ≥ 133 μmol/L 41/160 2.52 1.82–3.50
 <133 μmol/L 91/896 
CI, confidence interval; IQR, interquartile range; RR, risk ratio.
aP value for the comparison between patients with clinical treatment failure with those with clinical cure.
bRR for the association of the variable with failure.
Table 2   Determinants of Recurrence
Continuous variables
Variable Outcome Median IQR Pa













Variable Category Recurrence (n/N) RRb 95% CI
Fever Temperature >38.5°C 1/9 0.55 0.09–3.51
 ≤ 38.5°C 192/952
Leukocytosis Leukocytes >15 × 109/L 22/115 1.00 0.67–1.50
 ≤ 15 × 109/L 141/739
Renal failure Creatinine  ≥ 133 μmol/L 32/119 1.45 1.05–2.02
 <133 μmol/L 149/805
CI, confidence interval; IQR, interquartile range; RR, risk ratio.
aP value for the comparison between patients with recurrence with those without recurrence.
bRR for the association of the variable with recurrence.
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Discussion
Leukocytosis and renal failure were significant predictors of failure of CDI treatment. 
Only renal failure showed a trend toward longer duration of diarrhea during treatment 
and was correlated significantly with recurrence after successful treatment. Both 
leukocyte count and serum creatinine level were highly variable around diagnosis. 
Fever was found to be too infrequent in our study to be a useful predictor, but its 
associated relative risk was significant.
 In previous studies, leukocytosis and renal failure were also associated with 
complications and recurrence of CDI [3,11–13]. Therefore, both parameters could be 
suitable for evaluation in a prediction model. However, due to the variable nature of 
these values around the time of CDI diagnosis, a strict definition is needed before 
incorporating these parameters in a prediction rule. Early or late diagnosis could 
influence leukocyte count and serum creatinine level. Fever appeared not to be a 
useful predictor of failure of CDI treatment. This was also shown by a small study in 
2007 [14].
 Both fever and leukocytosis are thought to reflect more severe inflammation of 
the bowel wall. However, fever was too rare in our patient population to be of use as 
a predictor. Renal failure may reflect loss of effective circulating volume due to either 
dehydration because of diarrhea or shock in the context of a systemic inflammatory 
response. Unfortunately, the predictive value of these parameters may decrease 
because of underlying illnesses and comorbid conditions. Renal failure was present 
in 14% of clinical patients and was the only significant predictor of recurrence and the 
only parameter associated, albeit non-significantly, with a longer time to resolution of 
diarrhea. Thus, creatinine level may be good predictor, also because of its relatively 
greater stability around the time of CDI diagnosis in comparison to leukocytosis.
 Strengths of this study are the large number of patients with CDI in the database 
with a well-described definition of diarrhea and a consistent measure of UBMs. 
Limitations include that other potential predictors of severe CDI, such as age, serum 
albumin level, or use of concomitant antibiotics, were not included in this analysis. 
Therefore, we were not able to develop a complete risk score. Another limitation is 
the absence of a baseline creatinine level for each patient, precluding us from 
distinguishing between chronic and acute renal failure.
The results of our study suggest that both leukocytosis and renal failure predict 
clinical treatment failure, whereas only renal failure is a predictor of recurrence after 
therapy. However, these predictors are highly dependent on the timing of their 
determination, hampering their use in clinical practice. We need better and more 
closely defined predictors to construct a reliable prediction score for complicated 
and recurrent CDI that is applicable in clinical practice.
Hospital, the highest mean leukocyte count was found on the day of CDI diagnosis 
(13.4 × 109/L). Within the interval from 3 days before to 3 days after the diagnosis of 
CDI, the mean difference between the highest and lowest leukocyte count values 
recorded was 6.4 × 109/L. Twenty of 86 (23.3%) patients had a minimum to maximum 
leukocyte count range >10 × 109/L and 33 (38.4%) patients had a minimum to 
maximum leukocyte count range that included the cutoff of 15 × 109/L; therefore, a 
difference in timing of a single blood sample around diagnosis could have led to a 
different severity classification. Mean serum creatinine concentration was 147 μmol/L 
on the day of diagnosis. Mean minimum to maximum range in serum creatinine 
values was 38.7 μmol/L. Nineteen of 93 (20.4%) patients had a minimum to maximum 
creatinine range that included the cutoff of 133 μmol/L, which could have led to a 
different classification in the case of different timing.
Figure 1  Kaplan-Meier analysis of time to resolution of diarrhea for patients with  


































P (log rank) = 0.065
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Abstract
Low serum concentrations of antibodies directed against large clostridial toxins 
(TcdA and TcdB) have been associated with a higher risk of recurrence of Clostridium 
difficile infection (CDI) after successful antibiotic treatment. However, there are 
conflicting reports. Herein, we compared serum levels of antibodies of patients with 
a single episode of CDI with those of patients who subsequently suffered a recurrence. 
We used a serum bank from patients who received an experimental whey protein 
product following successful antibiotic treatment for CDI. We determined levels of IgA 
and IgG directed against TcdA, TcdB and non-toxin cell surface antigens in serum 
collected directly and three weeks after completing a 10 days course of antibiotic 
treatment for CDI. We also developed an objective flow cytometry-based assay to 
determine the proportion of cells exhibiting cytopathic effect after exposure to TcdB. 
Using this method, we measured sera’s TcdB-neutralizing capacity. We compared 
the results for patients without a subsequent recurrence with those of patients who 
suffered a recurrence within 60 days after completing the antibiotic treatment. 
Advanced age, comorbidity other than immunocompromised state and low serum 
levels of anti-TcdA and TcdB antibodies were associated with recurrence, whereas 
serum levels of antibodies directed against cell surface antigens were not. Serum 
TcdB-neutralizing capacity, which correlated only weakly with serum IgG anti-TcdB, 
was not significantly associated with recurrence. 
Key words: Clostridium difficile, toxins, antibodies, recurrence, IgA, IgG
Introduction
Clostridium difficile infection (CDI) is an important problem in healthcare facilities. 
Spores of this bacterium are ingested and bacteria may colonize the gut after 
germination. Colonization of the gut may lead to carriage or disease, which ranges 
from mild self-limiting diarrhea to fulminant life-threatening colitis. Mild disease may 
subside after withdrawal of antibiotics. Moderate and severe disease usually respond 
to oral metronidazole, glycopeptides, or fidaxomicin, but often recur. Factors 
associated with the outcomes of exposure to spores, colonization of the gut and 
disease include recent exposure to antibiotics, virulence of the C. difficile strain, 
advanced age, severe comorbidity, the use of proton pump inhibitors and the 
presence of antibodies directed against the large clostridial toxins TcdA and TcdB 
and/or other antigens [1]. 
 However, the role of humoral immunity in CDI is unclear due to conflicting reports 
on the association between the humoral immune response and disease outcome 
[2-11]. Important issues include the type of antibodies (secretory IgA or IgG) involved, 
whether serum antibodies reflect mucosal immunity in the gut, whether TcdA or TcdB 
must be neutralized, which toxin epitope is the most important one, and whether 
antibodies directed against antigens other than toxin matter. 
 To investigate the possible relationship between the humoral immune response 
and the outcome of CDI, we compared serum levels of IgA and IgG directed against 
TcdA, TcdB and non-toxin cell surface antigens of patients with a single episode to 
those of patients with a subsequent CDI recurrence. 
Methods
Serum samples
Serum samples were taken during a prospective cohort study [12] into the safety and 
preliminary efficacy of a whey protein concentrate made from milk of cows immunized 
against C. difficile to prevent recurrences after successful antibiotic treatment of CDI 
[13].  CDI was suspected clinically and confirmed by a positive fecal toxin assay and 
culture. Patient data registered on enrollment included age, sex, disease severity and 
chronic comorbidity according to the Acute Physiology, Age and Chronic Health 
Evaluation (APACHE) II prognostic system [14], previous episodes of CDI, and 
antibiotic treatment before starting the whey protein concentrate. After completion of 
10 days of standard antibiotic therapy and reaching clinical remission of CDI, 
participating patients received this whey protein concentrate orally for two weeks with 
a follow-up period of 60 days. Outcome measures were CDI recurrences. Recurrence 
was declared if the patient reported looser stools according to a three-grade visual 
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(mechanically sheared and purified on a cesium chloride gradient) as described by 
Hancock and Poxton [17]. ELISAs for IgG levels to these antigens were performed as 
described by Sanchez-Hurtado et al [16].
Flow cytometric assay to determine the capacity of serum to 
neutralize TcdB
We developed an objective method to determine the level of TcdB-neutralizing 
antibodies in sera. Briefly, 3T3 cells, a spontaneously immortalised cell line derived 
from embryonic mouse fibroblasts, were cultured in a 96-wells tissue culture plate 
until a semi-confluent monolayer was formed. Serial dilutions of TcdB in culture 
medium were preincubated 1:1 with fourfold diluted heat-inactivated patient serum 
for one hour at room temperature on a microplate shaker. Next, we incubated these 
mixtures of toxin and serum (100 μL per well) with the cells at 37 °C for one hour. 
Heat-inactivated pooled human serum (Lonza, Basel, Switzerland) was used as a 
standard. Toxin diluted in culture medium to a concentration of 50 ng/mL was used 
as a positive control and culture medium only as a negative control. After washings, 
the cells were cultured overnight and the degree of CPE was assessed microscopi-
cally. Next, we removed the cells from the wells by mechanically detaching them and 
then examined approximately 10,000 cells per sample on a FCSCalibur (Becton and 
Dickinson, La Jolla, CA).  Results are expressed as the mean fluorescence intensity 
(MFI) in arbitrary units. The MFI of the cell population was used as a measure of the 
proportion of cells showing CPE. The MFI’s for the positive control well and the 
negative control well were considered to characterize a cell population with maximum 
CPE and an unaffected cell population, respectively. For practical purposes, the 
mean of these MFI values was considered to represent 50% CPE. The MFI for the 
toxin dilution pre-incubated with patient serum that resulted in 50% CPE was divided 
by the value for the toxin dilution pre-incubated with standard serum resulting in 50% 
CPE to yield a standardized measure of the toxin-neutralizing capacity (Table 1).
Statistical analysis
The distributions of continuous variables were compared with a Mann-Whitney U test 
and proportions with the β2 test. The strength of the relationship between two 
continuous variables was estimated by Kendall’s tau-b. Continuous variables were 
dichotomized using the median for the entire population as a cut-off. For the 
association between dichotomized variables and recurrence, odds ratios (ORs) with 
95% confidence intervals were calculated. To examine the presence of confounding, 
categorical variables with a strong and clear association (OR > 2 and P < 0.2) with 
recurrence were introduced into a multivariate logistic regression model. IBM SPSS 
Statistics 20.0 software was used for the calculations.
scale, in comparison to the day before and an increase in stool frequency for two 
consecutive days, or a single day with an increase of ≥ 3 stools, or any day with 
passage of > 6 stools/day, and a positive C. difficile toxin stool test (Vidas, BioMérieux, 
Marcy l’Etoile, France) and culture. Among cultured strains, those strains belonging 
to PCR-ribotype 027 were identified as described earlier [15]. Serum samples were 
taken from these patients on the day they started on the whey protein concentrate 
(i.e., after 10 days of antibiotic therapy), and a second time 18 to 21 days later. 
Enzyme-linked immunosorbent assay (ELISA) for the determination 
of serum anti-TcdA and anti-TcdB IgA and IgG
Wells of flat-bottom 96-well high-binding plates (Greiner Bio-One, Frickenhausen, 
Germany) were incubated with 100 μL per well of toxin in a 100 mM carbonate buffer 
(pH9.6) overnight at 4 ºC. For the IgA antitoxin assays the wells were coated with 1.5 
μg/mL of TdA [Mucovax, Leiden, Netherlands] or 1.0 μg/ml of TcdB [kindly provided 
by dr. H. Feng, Tufts University Cummings School of Veterinary Medicine, Grafton, 
MA] and for the IgG assays wells were coated with  1.0 μg/mL of TcdA or TcdB. The 
plates were then washed 3 times with phosphate-buffered saline (PBS; pH 7.4) as 
well as  between every two incubation steps. Next, the plates were incubated with 
200 μL of blocking buffer (2% wt/v gelatine in PBS containing 0.05% v/v Tween-20) for 
1 hour at 37 ºC. Thereafter, serial dilutions of serum samples diluted in 0.2% wt/v 
gelatine in PBS with 0.05% v/v Tween-20 were transferred to the plate (100 μL/well) 
and incubated for 90 minutes at 37 ºC. All serum samples were tested in duplicate. 
The dilution buffer was used as a negative control. Subsequently, the plates were 
incubated with 100 μL of 4,000 x diluted polyclonal rabbit anti-human IgA antibodies 
conjugated with horseradish peroxidase (HRP) or 6,000 x diluted HRP-conjugated 
polyclonal rabbit anti-human IgG antibodies (DakoCytomation, Glostrup, Denmark) 
for 90 minutes at 37 ºC. Lastly, the plates were incubated with 2.5 mg/mL of filtered 
2,2’-azoni-bis(3-ethylbenzothiazoline-6-sulphonic acid) [ABTS] (Roche, Basel, 
Switzerland) in substrate buffer [47.2% of 100 mM citric acid and 52.8% of 
100 mM Na2HPO4; pH 4.2] (100 μL/well) and 0.015% v/v H2O2 for 30 minutes at 37 ºC. 
The absorbance was measured at 405 nm. For standardization, serum samples with 
high level of anti-TcdA immunoglobulins (IgA or IgG) were pooled, assigned an 
arbitrary value of 10,000 units (U) per mL, and used in all assays as standard.
ELISA for the determination of serum IgG directed against  
other antigens
The following non-toxin antigens were prepared from PCR ribotypes 001 and 027 as 
previously described: an EDTA extract representing the entire cell surface layer, a 
guanidine hydrochloride extracted S-layer proteins,  an aqueous phenol extracted 
lipoteichoic acid (LTA) analogue (only from ribotype 001) [16] and whole flagella 
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Results
Of 120 CDI patients whose data were present in the database, 16 (13.3%) suffered a 
toxin-confirmed recurrence. Table 2 shows patient characteristics. Advanced age 
and severe comorbidity were predictors of recurrence. However, immunocompromised 
state was not. Treatment with vancomycin was non-significantly associated with 
subsequent recurrence, probably reflecting more severe CDI for which treatment with 
vancomycin was preferred over metronidazole. 
Table 1  Comparison of the flow cytometric and light microscopical assessment 
of the toxic effect of TcdB on 3T3 cells.
In short,  semi-confluent monolayers of 3T3 cells were exposed for 1 hour at 37 oC 
to various amounts of TcdB that had been pre-incubated with eight-fold diluted 
patient serum for 1 hour at ambient temperature (B-E), or as positive control to 50 
ng/ml TcdB  (A) and as negative control to medium alone (F). After washing and 
subsequent culturing overnight at 37 oC, the cytopathic effect (CPE) of the toxin 
was estimated by visual inspection or, after mechanical detachment of the cells 
from the wells, quantitated by flow cytometry, ie the median fluorescence intensity 
(MFI) of the forward scatter.  We assumed that the mean of the MFI values for the 
positive control and the negative control (in this example: 409 arbitrary units [AU]) 
represents a cell population showing 50% CPE. The serum-preincubated TcdB 
concentration that resulted in a cell population with 50% CPE (in this example 
extrapolated to a TcdB concentration of 4.4 ng/L) is divided by the corresponding, 
pooled reference serum preincubated , TcdB concentration to yield a standardized 
measure of the TcdB-neutralizing capacity. 
Treatment MFI Light microscopy
TcdB 50 ng/mL 310 AU All cells showing CPE
TcdB 8.3 ng/mL with patient’s serum 332 AU More cells showing CPE than 
 unaffected cells
TcdB 5.6 ng/mL with patient’s serum 366 AU Cells showing CPE mixed with 
 unaffected cells
TcdB 3.7 ng/mL with patient’s serum 436 AU Cells showing CPE mixed with 
 unaffected cells
TcdB 2.5 ng/mL with patient’s serum 481 AU More unaffected cells than  
cells showing CPE
Medium alone 508 AU No cells showing CPE
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 Table 3 shows IgA and IgG anti-TcdA and anti-TcdB antibody levels and TcdB-
neutralizing levels in sera from patients with and those without recurrence. Low serum 
levels of IgA anti-TcdA  and IgG anti-TcdB three weeks after completing 10 days of 
antibiotic treatment for CDI were most clearly associated with recurrence, as well as 
a decrease in serum IgG anti-TcdA during this time period. Some of these associations 
reached statistical significance. Interestingly, serum levels of anti-toxin A/B antibodies 
decreased in many patients during the three weeks after antibiotic treatment. 
 Low serum TcdB-neutralizing capacity was not a predictor of recurrence, 
although none of the patients with a higher serum neutralizing capacity than the 
reference serum suffered a recurrence. There was no correlation between anti-TcdB 
IgA level in serum and its capacity to neutralize TcdB (day 0: r = 0.155, P = 0.185; 
day 18: r = 0.185, P = 0.129) and only a weak correlation between anti-TcdB IgG level 
in serum and its capacity to neutralize TcdB (day 0: r = 0.253, P = 0.036; day 18: 
r = 0.309, P = 0.011).
 Serum levels of IgG directed against any of the non-toxin cell-surface antigens 
after antibiotic treatment did not differ between patients with subsequent recurrence 
and those without subsequent recurrence (data not shown).
 Antibody levels and neutralizing capacity were dichotomized using the median 
of the entire population of patients as a cut-off. Odds ratios for the association with 
recurrence were calculated (Table 4). To investigate possible confounding, the odds 
ratios for these dichotomized antibody levels were corrected for age over 73 and the 
presence of severe comorbidity. Serum levels of IgA anti-TcdB directly after antibiotic 
treatment and IgG directed against both toxins three weeks later and a decrease in 
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Discussion
The main findings of this study in patients with CDI are that advanced age, comorbidity 
and low serum levels of antibodies directed against TcdA and TcdB were associated 
with recurrence, whereas serum levels of antibodies directed against cell surface 
antigens were not.
 The strong points of this study pertain to the study protocol and analytic methods. 
First, the data derive from a prospective study in which patient characteristics and 
sera were collected according to a standardized protocol. Second,  blood was 
collected at two time points, which allowed for the analysis of the dynamics of 
antibody levels. Third,  standardized  ELISAs for antibodies against toxins A and B 
and an objective assay for toxin-neutralization capacity of sera were developed. 
Clostridial toxin neutralization assays are commonly based on microscopic 
assessment of cypathic effect (CPE) on cells. In these assays, a cell population 
showing 50% CPE is used to compare the rate of toxin neutralization. Because there 
are grades of CPE (e.g., loss of length and number of cell processes, gradual 
rounding of cells), the proportion of cells showing CPE may vary per visual field and 
certain unaffected cells that are not fully attached to the surface may appear to show 
CPE, we felt that assessing 50% CPE microscopically is subjective.  Unfortunately, 
the relatively small number of patients with recurrence and the fact that all patients 
were treated with a whey protein concentrate containing antibodies against C. difficile 
and its toxins may have compromised statistical power to detect differences between 
CDI patients with recurrence and those without recurrence. Another limitation of the 
present study pertains to quantitation of the anti-toxin antibody levels in sera instead 
of fecal samples.  Currently, it is not known to what extent serum antibody levels 
reflect mucosal immunity, which is probably the relevant part of the immune system 
given that CDI is not an invasive infection. Finally, the analysis of toxin-neutralizing 
capacity of the sera was limited to TcdB, as this toxin was considered the most 
important one in the pathogenesis of CDI according to scientific consensus at the 
time of experimentation.
 Several studies have found associations between humoral immunity and the 
clinical course of CDI. For instance, it has been reported that serum IgG directed 
against TcdA, and less convincingly, IgG directed against TcdB and other antigens 
[5] as well as all classes of antibodies directed against whole cell C. difficile [8] are 
associated with disease instead of carriage. Warny [11] found low serum IgG and 
fecal sIgA directed against TcdA to be associated with a longer duration of illness and 
a higher risk of recurrence. Others reported that  low levels of IgM directed against 
various antigens and low levels of IgG directed against TcdA, but not TcdB or other 
antigens predict recurrence [6]. Aronsson [2] identified low serum IgG directed 
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against TcdA. Leav [7] found IgG directed against the receptor-binding domain of 
TcdB and to a lesser extent that of TcdA, but not against whole toxins, and Drudy [3] 
reported IgM directed against surface-layer proteins to predict recurrence. By 
contrast, Johnson [4] and Sánchez-Hurtado [9] found that humoral immune 
responses did not influence the clinical course of CDI. Recently, Solomon [10] 
reported no correlation between serum IgG anti-TcdA and IgG anti-TcdB and 
recurrence, but did find a relationship between low levels of these antibodies and 
30-day all-cause mortality, most of which was at least partly attributed to CDI.
 Several findings raise the possibility that serum anti-toxin antibody levels are not 
causally related with recurrences. In this study, for example,  the serum antitoxin 
antibody levels in most of the patients with and without recurrence decreased during 
the first three weeks after completion of the antibiotic course. In addition, immuno-
compromised state was not associated with recurrence. Furthermore, in contrast to 
serum antibodies directed against toxins,  the TcdB-neutralizing capacity of sera did 
not predict recurrence. It could be that low serum antibody levels are caused by fecal 
protein loss from a severely inflamed colonic mucosa. The severity of colonic 
inflammation may itself be associated with the risk of recurrence. The fact that several 
studies have found hypo-albuminemia to predict recurrence [18] and our study found 
patients with subsequent recurrence to recover less from hypo-albuminemia than 
patients without recurrence (data not shown) support this hypothesis. On the other 
hand, there are arguments against this hypothesis. Low levels of antibody against 
non-toxin, cell-surface antigens were not associated with recurrence. Moreover, the 
administration of parenteral monoclonal antibodies against the C-terminus of TcdA 
and TcdB has been found to prevent recurrences [19].
 In conclusion, low serum anti-TcdA and anti-TcdB antibodies are associated with 
a higher risk of recurrence. However, further studies into the humoral immune 
responses in CDI, simultaneously measuring serum and fecal antibody levels at 
several time points, as well as measuring fecal protein loss (e.g., by fecal alpha1- 
antitrypsin clearance), may help to distinguish between a causal relationship and 
confounding.
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Samenvatting
Doel. Wij probeerden recidiverende Clostridium difficile-geassocieerde diarree (CDAD) 
te voorkomen door behandeling met een 40%-wei-eiwitconcentraat van melk van 
koeien, geïmmuniseerd tegen C. difficile en zijn toxinen; dit weiconcentraat bevat 
specifiek neutraliserend secretoir IgA.
Opzet. Prospectief, niet-geblindeerd, klinisch cohortonderzoek.
Methode. In 2005-2006 kregen 100 patiënten met CDAD na een standaard anti -
biotische behandeling 2 weken weiconcentraat. Tot 60 dagen na de start van de 
toediening documenteerden wij aan de hand van zelfrapportage, bloedbepalingen 
en actieve surveillance eventuele bijwerkingen en het optreden van recidief-CDAD. 
Resultaten. Het weiconcentraat werd goed verdragen en veiligheidsproblemen deden 
zich niet voor. In 11 van in totaal 109 ziekte-episoden (10%) trad een recidief- CDAD op. 
Na de behandeling met weiconcentraat bleek een positieve fecestoxine-uitslag of 
feceskweek van C. difficile samen te gaan met een recidief-CDAD (relatief risico 
 respectievelijk: 8,2 (95%-BI: 1,04-64) en 4,7 (95%-BI: 0,5-47). Een positieve fecestoxine- 
uitslag tijdens de toediening van weiconcentraat ging samen met een vroeg CDAD- 
recidief.
Conclusie. In vergelijking met historische en contemporaine bevindingen bij controle-
groepen leek weiconcentraat het optreden van een recidief-CDAD met circa 50% 
te verminderen. Waarschijnlijk schoot de standaarddosering weiconcentraat tekort 
om in alle episoden de C. difficile-toxinen in feces te neutraliseren.
Clostridium difficile-geassocieerde diarree (CDAD) ontstaat als bij een individu dat 
besmet is met sporen van de anaerobe grampositieve bacterie C. difficile, de sporen in de 
darm ontkiemen tot de vegetatieve vorm en toxinen gaan produceren. Het enterotoxine 
A en het cytotoxine B beschadigen darmslijmvlies en veroorzaken diarree. Daarbij 
kan het gaan om een gering ongemak, maar een pseudomembraneuze colitis of 
een toxisch megacolon kan ook voorkomen.1 
 De behandeling van patiënten met CDAD richt zich op het tenietdoen van de 
gevolgen van diarree, zoals dehydratie, en op eradicatie van de toxineproducerende 
bacteriën. Bij lichte vormen van CDAD kan het beëindigen van een uitlokkende 
antibiotische behandeling voldoende zijn om de diarree te stoppen.2 3 Dit heeft als 
voordeel dat de residente flora van de darm niet verder verstoord wordt. Normaliter 
biedt darmflora bescherming tegen uitgroei van C. difficile, doordat de oppervlakte 
van de darm wordt afgeschermd en door de competitie om voedingsstoffen.
 Als de patiënt een zieke indruk maakt of koorts en frequente of bloederige diarree 
heeft, zijn antibiotica geïndiceerd.1 2 Het doel daarvan is de diarree in een kort tijds - 
bestek onder controle te brengen, dat wil zeggen voor klinische genezing te zorgen 
én de kans op het terugkeren van de diarree zo klein mogelijk te maken. Bij voorkeur 
dient een behandeling C. difficile uit de darm te elimineren; zo kan micro biologische 
genezing worden bereikt.
 Frequente recidivering van CDAD. In een recente Cochrane-review is vastgesteld 
dat standaardbehandeling met vancomycine of metronidazol bij de meeste patiënten 
(> 90%) tot een verbetering van het symptomenbeeld leidt.4 Maar bij ruim 20% van 
de patiënten treedt een recidief van CDAD op, meestal binnen 1-2 weken na het 
staken van het antibioticagebruik.1 4 De kans op een recidief-CDAD blijkt hoger na 
infectie met de nieuwe epidemische stam C. difficile ribotype 027,5 6 die ook Nederland 
is vastgesteld.7 Terugkerende CDAD vormt een belangrijk gezondheidsprobleem, 
voor de patiënt die door aanhoudende diarree uitgeput raakt en ook voor de arts, die 
tevergeefs zal zoeken naar evidence-based richtlijnen om terugkerende CDAD te 
voorkómen. Verder zijn de verpleegkosten hoog.8 9
 Immunisatie van koeien met C. difficile, enterotoxine A en cytotoxine B leidt tot 
specifiek secretoir IgA in de melk. Een 40%-concentraat van wei-eiwit van de melk van 
geïmmuniseerde koeien bevat een hoge concentratie van specifiek secretoir IgA.10 
 Wij onderzochten de toepassing van dat weiconcentraat voor passieve immuun-
therapie bij patiënten met CDAD en tevens voor de preventie van een terugkerende 
episode van diarree. 
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dagboek bij, waarin zij behalve eventuele bijwerkingen ook de consistentie van de 
feces noteerden (aangeduid als “normaal”, “semi-vast” of “waterig”) en de frequentie 
van de ontlasting; deze gegevens waren bij de laatste 80 patiënten gedocumenteerd. 
Ook werden patiënten tussendoor bezocht en aan het einde van het onderzoek 
telefonisch geïnterviewd. 
 Onderzoeksuitkomsten. Als primaire onderzoeksuitkomst gold de veiligheid van 
het weiconcentraat. In dit verband werden bijwerkingen en complicaties gedocumenteerd; 
ook bepaalden wij een breed scala aan hematologische en biochemische bloed - 
waarden vóór en na inname van het weiconcentraat. 
 Een secundaire onderzoeksuitkomst was het optreden van een nieuwe episode 
van diarree (recidief) in de 60 dagen van de follow-up. Een klinisch recidief werd 
vastgesteld als de patiënt een verandering van de consistentie van de ontlasting 
rapporteerde (bijvoorbeeld van “normaal” naar “semi-vast”) samen met een toename 
van de ontlastingsfrequentie over 2 opeenvolgende dagen of een toename van de 
ontlastingsfrequentie van 3 of meer keren op één dag; ook kon het gaan om elke dag 
dat de patiënt aangaf meer dan 6 keer ontlasting te hebben. Bij het vermoeden van 
een recidief bepaalden wij de toxinen in de feces en verrichtten wij de feceskweken 
op C. difficile (fecestoxinebepaling vond plaats met de “enzyme-linked fluorescent 
assay”, VIDAS, BioMérieux, Marcy l’Etoile, Frankrijk).12 
 Onafhankelijk van de kwaliteit van de ontlasting verrichtten wij bij alle patiënten 
na het beëindigen van de behandeling met weiconcentraat een fecestoxinebepaling 
en feceskweek, namelijk op dag 14-18. Bij een groot deel van de patiënten (n = 78) 
deden wij dat ook bij het beëindigen van de follow-upperiode op dag 60.
 Berekeningen. Vooraf werd geen formele poweranalyse verricht. De gegevens 
werden geanalyseerd met descriptieve statistische methoden; categorische variabelen 
werden vergeleken met de c2-toets.
Resultaten
Patiënten. In een periode van 2,5 jaar screenden wij 136 patiënten en namen wij er 
101 op in het onderzoek (tabel 1). Aanvankelijk werden vooral patiënten uit de Leidse 
regio geïncludeerd, maar tijdens de nationale uitbraak van CDAD in 20058 ook uit 
andere plaatsen in het land, met name uit Amersfoort, Gouda en Den Haag. Veel 
patiënten waren bij de start van het onderzoek opgenomen in een zorginstelling; 
nacontroles konden bij de meesten door een researchverpleegkundige thuis 
plaatsvinden. Van de gescreende patiënten werden 35 niet in het onderzoek 
opgenomen, omdat er geen informed consent verkregen was (n = 30), omdat de 
patiënt overleed vóór de standaard antibiotische behandeling was afgesloten (n = 3), 
of op verzoek van de behandelend arts (n = 2). 
Methoden en patiënten
Weiconcentraat gericht tegen C. difficile. Het weiconcentraat (40%) met polyklonale, 
specifieke secretoire IgA-antistoffen tegen C. difficile wordt gemaakt van de melk van 
koeien die geïmmuniseerd zijn met door formaldehyde gedode C. difficile en met 
geïnactiveerde toxinen uit een kweekfiltraat van C. difficile. Door een combinatie van 
nasale immunisatie en lokale immunisatie in de supramammaire lymfklieren van 
koeien met een stimulans gebaseerd op de toxigene C. difficile-stam VPI 10463, 
verkrijgt men een hoge concentratie van specifiek secretoir IgA in melk.10 Ondanks 
deze hoge concentratie verschilt de totale hoeveelheid immunoglobuline niet van die 
in melk van niet-geïmmuniseerde koeien. Immunisatie beïnvloedt dus niet de 
hoeveelheid immuunglobulinen in de melk, maar de specificiteit. Uit de melk wordt 
volgens standaardmethoden uit de zuivelindustrie wei-eiwit gezuiverd, dat voldoet 
aan de Nederlandse kwalificaties voor samenstelling, microbiologische veiligheid en 
houdbaarheid van wei-eiwitconcentraat en consumptiemelk.11 Het vloeibare product, 
in dit artikel verder aangeduid met ’weiconcentraat’, wordt uitgevuld in sachets met 
elk 5 g. Antistoffen in het weiconcentraat neutraliseren in vitro de cytotoxische werking 
van C. difficile-toxinen en bieden in een diermodel met hamsters bescherming tegen 
darmontsteking door C. difficile.10 
 Patiënten en cohortonderzoek. In een prospectief klinisch open-labelcohort-
onderzoek (Leids Universitair Medisch Centrum; protocolnummer: 2002.222) 
onderzochten wij het weiconcentraat. Wij includeerden patiënten met diarree en een 
positieve uitslag op de fecestoxinetest en een positieve feceskweek op C. difficile. Als 
exclusiecriterium gold een pre-existente darmaandoening, waardoor de interpretatie 
van de consistentie en de frequentie van de ontlasting problematisch zou zijn. Bij een 
specialistische diagnose “melkallergie” of “melkintolerantie” kon een patiënt evenmin 
deelnemen. Tenslotte moest de patiënt het product oraal of tenminste per maagsonde 
kunnen innemen.
 Alle deelnemers ontvingen tenminste 10 dagen standaard antibiotische therapie 
voordat gestart werd met de toediening van weiconcentraat. De keuze van de 
antibiotische behandeling (metronidazol of vancomycine) werd overgelaten aan de 
behandelend arts. Het weiconcentraatpreparaat werd opgelost in mineraalwater en 
gedurende 14 dagen in een dagelijkse dosering van 15 g, verdeeld over 3 giften, 
ingenomen, zo mogelijk 1 h vóór de maaltijd. De standaarddosering weiconcentraat 
werd gekozen naar rato van de effectieve dosis in het gevalideerde proefdiermodel, 
op basis van literatuurgegevens en op basis van het eerste pilotonderzoek bij 
patiënten.10
 Enkele dagen nadat de inname was beëindigd werd de patiënt bezocht, waarbij 
de therapietrouw werd beoordeeld door eventueel overgebleven sachets te tellen. 
Patiënten hielden tot 60 dagen nadat zij begonnen waren met de inname een 
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 Eén patiënt overleed na inclusie, maar vóór inname van het weiconcentraat. 
Zijn kenmerken staan wel in tabel 1, maar deze CDAD-episode werd bij de verdere 
berekeningen buiten beschouwing gelaten.
 Bij de overgebleven 100 patiënten werd weiconcentraat toegepast tijdens in 
totaal 109 episoden van CDAD: 65 maal kreeg de patiënt het concentraat na een 
eerste episode en 44 maal na één of meer CDAD-recidieven; 1 patiënt nam 3 maal 
een kuur weiconcentraat en 7 patiënten deden dat 2 maal (zie tabel 1). 
 Veiligheid van het weiconcentraat en therapietrouw. 8 patiënten maakten de 
kuur van 14 dagen niet af: 4 vanwege de smaak van het concentraat, 1 vanwege een 
vroeg recidief, 1 patiënt omdat die kwam te overlijden aan een onderliggende medische 
conditie die niet aan de inname van het weiconcentraat was gerelateerd, en 2 patiënten 
omdat de arts alle medicamenteuze behandelingen bij hen beëindigde op grond van 
progressie van een onderliggende aandoening. Tijdens de 60 dagen follow-up 
overleden 5 patiënten door progressie van een onderliggende aandoening. In geen 
van deze gevallen was er naar het oordeel van de behandelende artsen een relatie met 
het weiconcentraat. Afgezien van de 4 deelnemers die afzagen van verdere inname op 
grond van de smaak werd het weiconcentraat goed verdragen.
 Een uitgebreide screening van bloedparameters vóór en na het gebruik van het 
weiconcentraat en een evaluatie van de complicaties toonden geen negatieve invloed 
van het weiconcentraat. Het functioneren van de patiënten, afgemeten aan de karnofsky- 
score, en de gastro-intestinale kwaliteit-van-levenscore volgens de European Organisation 
for Research and Treatment of Cancer (EORTC)14 verbeterden significant tijdens de 
inname van het concentraat. Gedetailleerde gegevens over de veiligheid van het 
weiconcentraat en de gecontroleerde bloedparameters zijn elders gepubliceerd.11
 Op de 4 patiënten na (< 5%) die de inname staakten wegens onvrede met de 
smaak van het product bleek de innametrouw, afgemeten aan het ontbreken van 
overgebleven sachets, goed te zijn.
 Recidiverende CDAD na gebruik van het weiconcentraat. Na de 10 dagen 
standaard antibiotische therapie was de gemiddelde ontlastingsfrequentie ondanks 
een verbetering van de symptomen bij alle patiënten nog steeds verhoogd, tot 
gemiddeld 2,4 keer per dag. In de loop van 4 weken nam de ontlastingsfrequentie af 
tot circa 1,7 keer per dag, waarna deze rond deze waarde stabiliseerde (figuur). De 
ontwikkeling van de fecesconsistentie liep hierop vooruit; de meeste mensen 
noemden de feces na circa 2-3 weken “semi-vast” tot “vast”. Kortom, kort na het 
beëindigen van een 10-daagse antibiotische behandeling waren de ontlastings-
frequentie en -consistentie van veel patiënten nog niet genormaliseerd, en gemiddeld 
duurde het circa 4 weken voordat weer van een normaal ontlastingspatroon gesproken 
kon worden. 
 Bij 10 van de 100 patiënten werd aan de criteria voor een recidief-CDAD voldaan; 
1 patiënt kreeg 2 maal een recidief en gebruikte in totaal 3 maal een kuur wei-
 De meeste geïncludeerde patiënten waren 65 jaar of ouder en hadden een 
duidelijke onderliggende medische aandoening; bijna de helft had een “chronic 
health”-score van 5 volgens het “Acute physiology, age, chronic health evaluation”-
(APACHE)-scoringssysteem (zie tabel 1).13 
Tabel 1  Kenmerken van 101 patiënten met Clostridium difficile-geassocieerde 
diarree (CDAD; 109 ziekte-episoden)*, die gedurende 2 weken 
behandeld werden met een weiconcentraat van immune koeien voor 
het voorkómen van een CDAD-recidief na standaard antibiotische 
therapie met vancomycine of metronidazol
kenmerk
♂:♀ 50:51
mediane leeftijd in jaren (interkwartielafstand)
mediane lengte in m (interkwartielafstand)
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C. difficile; PCR-ribotype 027; n/n 24/106‡
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laboratoriumwaarden bij aanvang van de behandeling  
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*  Van de patiënten overleed er 1 na inclusie, maar vóórdat het weiconcentraat ingenomen kon worden; 
van deze patiënt zijn de kenmerken hier wel opgenomen.
†  Onderliggende aandoeningen en “chronic health”-score opgegeven volgens relevante onderdelen 
in het prognostisch “Acute physiology, age, chronic health evaluation”(APACHE)-scoringssysteem;13 
hoe hoger de score, hoe meer comorbiditeit.
‡  In 3 episoden was geen typering van de C. difficile-stam mogelijk.
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(p > 0,25). In 4 van de 24 episoden van CDAD door PCR-ribotype 027 trad een recidief op 
(17%), vergeleken met 7 van de 82 (9%) episoden veroorzaakt door een ander ribotype. 
De gemiddelde tijdsduur tot het optreden van een recidief verschilde overigens niet 
tussen infecties veroorzaakt door PCR-ribotype 027 of door andere ribotypen. 
 Recidief van CDAD gerelateerd aan fecestoxinebepaling en feceskweek. In 7 
episoden trad een recidief op tijdens of vlak na de inname van weiconcentraat (zie de 
figuur). In deze episoden was de uitslag van de fecestoxinebepaling positief. Mogelijk 
was de dosering wei-eiwit onvoldoende om de werking van de toxinen compleet te 
neutraliseren en waarschijnlijk speelde dit een rol bij het optreden van het recidief. Deze 
hypothese werd gesteund door de bevinding dat een positieve  fecestoxine-uitslag kort 
na het staken van de behandeling met weiconcentraat het optreden van een latere 
recidief-CDAD voorspelde (tabel 2). Na het voltooien van de behandeling met wei-
concentraat hadden 12 van 96 patiënten nog een positieve  fecestoxine-uitslag; van 
deze 12 kregen 2 een recidief (17%) tegenover slechts 2 van 84 patiënten (2%; relatief 
risico (RR): 8,20; 95%-BI: 1,04-64) met een negatieve fecestoxine-uitslag.
concentraat; 7 patiënten met een recidief gebruikten het weiconcentraat 2 maal, 
2 anderen zagen af van een 2e kuur. Er was dus in 11 van de 109 episoden (10%) 
sprake van een CDAD-recidief. 
 In 5 episoden trad het recidief op tijdens inname van het weiconcentraat (zie de 
figuur), in 2 episoden binnen 3 dagen na het staken van het concentraatgebruik en in 
4 tijdens de follow-up, na respectievelijk 21, 22, 30 en 40 dagen. In alle gevallen van 
recidief lag de ontlastingsfrequentie evident buiten het groepsgemiddelde (zie de 
figuur) en was zowel de uitslag van de fecestoxinebepaling als van de feceskweek 
op C. difficile positief. Dit gold ook voor patiënten die tijdens de inname van wei-
concentraat een recidief kregen.
 De keuze van de voorafgaande standaard antibiotische behandeling (vancomycine 
versus metronidazol; zie tabel 1) hing niet samen met het percentage recidieven 
Figuur   Dagelijkse gemiddelde frequentie van ontlasting bij patiënten met 
Clostridium difficile-geassocieerde diarree (CDAD) die werden behandeld 
met een weiconcentraat van tegen C. difficile geïmmuniseerde koeien. 
De behandeling duurde van dag 1-14 en is aangegeven met een balkje 
onder de horizontale as. Onder de grafiek staat de dagelijkse ontlastings-
frequentie tijdens 11 episoden die voldeden aan de definitie van 
“recidief-CDAD”; de pijlen geven het moment van het recidief aan.
Tabel 2  Risico op een recidief van Clostridium difficile-geassocieerde diarree 
(CDAD) bij patiënten die gedurende 2 weken behandeld werden met 
een weiconcentraat van immune koeien, in samenhang met de 
uitslagen van bepalingen in feces van toxinen van C. difficile en van 
bacteriekweek. Vóór de behandeling met weiconcentraat hadden de 
patiënten standaard antibiotische therapie met vancomycine of 
metronidazol gekregen*
fecestest aantal op 
dag 18-21
recidieven  
van CDAD;  
n/n (%)†
RR (95%-BI) van een 
positieve testuitslag voor 
recidief-CDAD
toxine-uitslag (n = 96)
   positief 12‡ 2/12 (17) 8,2 (1,04-64)
   negatief 84 2/84 (2)‡
kweekuitslag (n = 98)
   positief 39 3/39 (8) 4,7 (0,6-47)
   negatief 59 1/59 (2)‡
RR = relatief risico.
*  Er voldeden 7 patiënten aan de definitie van “recidief-CDAD” vóór dag 18; bij allen waren de toxine-
uitslagen en de feceskweken positief op respectievelijk dag 7, 8, 8, 8, 10, 16 en 17. 
†  Er hadden 4 patiënten een recidief-CDAD op respectievelijk dag 21, 22, 30 en 40.
‡  Eén patiënt met een negatieve toxine- en kweekuitslag op dag 18-21, maar met toch een recidief-CDAD 
op dag 40, was opgenomen in een ziekenhuis waarin zich een epidemische verheffing van CDAD door 
ribotype 027 voordeed.
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darminfecties, zoals met Helicobacter pylori,en bij diarree door enterotoxigene 
Escherichia coli, Rotavirus en Shigella flexneri.16-19 Net als in ons onderzoek werden geen 
klinisch relevante bijwerkingen van orale inname van deze concentraten gemeld. 
 Er bestaat onduidelijkheid over de aanpak van terugkerende CDAD.1 3 8 9 Bij de 
behandeling is gunstige ervaring opgedaan met specifieke schema’s van vancomycine, 
waarbij het middel na standaardbehandeling over een aantal weken afgebouwd 
(’taper’-schema) respectievelijk intermitterend gegeven wordt (’pulse’-schema).20 
Maar elke behandeling met antibiotica, vancomycine en metronidazol inbegrepen, 
hoe noodzakelijk ook, vergroot de kans op het terugkeren van CDAD, omdat 
antibiotica de residente darmflora negatief beïnvloeden en Clostridium-sporen 
resistent zijn tegen antibiotica. Komt een patiënt dan ook eenmaal in een neergaande 
spiraal van terugkerende CDAD, dan wordt de kans op een recidief steeds groter en 
deze bedraagt uiteindelijk wel 60-70%.8 9 Dit is de reden dat gezocht wordt naar 
alternatieve behandelingen, in plaats van of naast het gebruik van antibiotica (tabel 3). 
Een uitvoerige bespreking van deze alternatieven vindt men elders.3 8 9
 Geconcludeerd kan worden dat er nog onvoldoende bewijs bestaat voor de 
werk zaamheid van verschillende behandelingen, met gerapporteerde succes-
percentages die uiteenlopen van 30-100. Daarbij kan men denken aan intraveneuze 
infusie van immuunglobuline, bacteriotherapie of fecale transplantatie, toxineabsor-
berende harsen of probiotica, maar ook aan de taper- en pulsebehandeling met 
vancomycine. De hypothese achter passieve immuuntherapie van CDAD met 
weiconcentraat is dat specifieke antilichamen de toxinen van C. difficile in de darm 
kunnen neutraliseren, en de vegetatieve vorm van de bacterie kunnen beletten zich 
aan de darmoppervlakte te hechten door afscherming van adhesiefactoren. Verdere 
beschadiging van darmslijmvlies wordt daarmee voorkomen zonder de residente 
darmflora negatief te beïnvloeden. De darm zal de sporen van C. difficile uiteindelijk 
zelf klaren. Voor deze hypothese bestaat dierexperimentele onderbouwing.10 
Daarnaast onderscheidt het gebruik van weiconcentraat zich van de meeste andere 
alternatieve behandelingen, doordat het pathogeenspecifiek is. De secretoir-IgA-
antistoffen in het weiconcentraat zijn polyklonaal, zodat op meerdere plaatsen op de 
bacteriën en toxinen van C. difficile aangegrepen kan worden.11 In principe zou het 
weiconcentraat ook toegepast kunnen worden in combinatie met antimicrobiële 
therapie, of preventief bij contacten tijdens een epidemische verheffing van CDAD. 
 Het dagelijks bijhouden van frequentie en consistentie van ontlasting laat zien 
hoe belangrijk het is een strikte definitie van “recidief-CDAD” te hanteren. Het is ons 
immers duidelijk geworden dat de meeste patiënten na het voltooien van de standaard 
antibiotische behandeling nog wekenlang een hogere ontlastingsfrequentie dan 
normaal en een afwijkende fecesconsistentie hadden. Bovendien was bij een hoog 
percentage (circa 10) van de patiënten aanvankelijk nog C. difficile-fecestoxine in de 
ontlasting aantoonbaar, zonder dat er sprake was van een recidief. Ofschoon een 
 Eenzelfde verband gold voor de aanwezigheid van C. difficile in de feceskweek 
kort na het staken van de behandeling met weiconcentraat: in 3 van de 39 episoden 
(8%) met een positief kweekresultaat deed zich een recidief-CDAD voor, tegen 1 op 
59 gevallen (< 2%) met een negatieve feceskweek (RR: 4,7; 95%-BI: 0,5-47). De 12 
fecestoxinepositieve patiënten hadden ook een positieve feceskweek. Overigens, bij 
1 patiënt met een laat recidief (op dag 40) was na het staken van de behandeling met 
weiconcentraat de toxine-uitslag negatief en was C. difficile niet aantoonbaar in de 
feceskweek. Deze patiënt was steeds opgenomen geweest op een afdeling met een 
epidemische verheffing van CDAD door ribotype 027 en mogelijk werd dit recidief 
veroorzaakt door een opnieuw exogeen verkregen C. difficile ribotype 027.
 Van 78 patiënten zonder recidief waren feces, verzameld op dag 60, beschikbaar 
voor onderzoek. Bij 2 van hen bleek de fecestoxine-uitslag nog positief (2,6%; 
bevestigd in cytotoxiciteitstest) en bij 12 (15%) werd C. difficile geïsoleerd uit de 
feceskweek. Bij geen van deze 78 patiënten trad in het jaar na het onderzoek een 
recidief-CDAD op, hetgeen bleek uit telefonisch verkregen informatie.
 Tenslotte, om beter te begrijpen of het weiconcentraat in de standaarddosering 
van 15 g per dag inderdaad compleet de C. difficile-toxinen in de darm neutraliseerde, 
werd bij 18 patiënten enkele dagen na de start van de behandeling nagegaan of de 
fecestoxine-uitslag negatief geworden was. Bij 4 patiënten (22%) was die uitslag nog 
positief. Bij 1 van deze 4 patiënten trad kort daarna een recidief-CDAD op, tegen 
géén van de 14 patiënten met een negatieve fecestoxine-uitslag tijdens inname van 
het weiconcentraat (p < 0,05). 
Beschouwing
In dit prospectieve onderzoek leek de inname van het immune weiconcentraat na 
standaard antibiotische behandeling het optreden van CDAD-recidieven met circa 
de helft te kunnen verminderen. Deze conclusie berust op een vergelijking van het 
percentage recidief-CDAD in deze verkennende studie (10%) met gerapporteerde 
recidiefpercentages in de medische literatuur van 20-45 en met de Nederlandse 
gegevens over de uitbraak van 2005 met 25% recidieven.5 6 15 Hierbij merken wij op 
dat ons verkennende prospectieve onderzoek niet geblindeerd was en dat de 
bevindingen nu bevestigd moeten worden door gecontroleerd klinisch onderzoek. 
 Het weiconcentraat bevat hoge concentraties van specifiek secretoir IgA gericht 
tegen C. difficile en zijn toxinen, en de werkzaamheid zou berusten op passieve 
immuuntherapie. Het weiconcentraat werd goed verdragen en de innametrouw was 
goed, zeker gezien de oudere patiëntengroep en de vaak ernstige onderliggende 
medische aandoeningen.
 Er is in de literatuur een aantal meldingen van oraal gebruik van wei of koeien-
immunoglobulinen. Die werden ingezet bij de behandeling of preventie van maag- of 
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De toepassing van anti-CD-wei-eiwit-40%-concentraat en het klinisch onderzoek 
werden mogelijk gemaakt door niet-gerestringeerde financiële ondersteuning van 
MucoVax BV, Leiden.
Belangenconflict: geen gemeld. Financiële ondersteuning: geen gemeld.
dergelijke positieve uitslag een voorspellende waarde had voor het optreden van een 
recidief, herstelde de stoelgang bij de meeste patiënten uit deze groep spontaan. Bij 
enkele personen was de fecestoxine-uitslag zelfs bij het afsluiten van het onderzoek 
op dag 60 nog positief, zonder dat dit diarreeklachten gaf. Dit geeft aan dat 
toxinevormende C. difficile na een episode van CDAD nog lange tijd in de darm 
aanwezig kan zijn zonder klachten van een recidief te veroorzaken. Meer in het 
algemeen - en los van de huidige interventie - kan men stellen dat een positieve 
 fecestoxine-uitslag na het beëindigen van antibiotische therapie voor CDAD dan ook 
geen aanleiding dient te zijn een herstellende patiënt direct opnieuw met antibiotica 
te gaan behandelen. Ook is het de vraag of een dergelijke bepaling routinematig, 
buiten onderzoeksverband om, uitgevoerd dient te worden.
 De dosering van het weiconcentraat kwam op enigszins arbitraire gronden tot 
stand, en werd onder andere afgemeten aan de dosering gebruikt in een gevalideerd 
diermodel en aan eerste gegevens bij patiënten.15 21-23 33 Dit onderzoek toont aan dat, 
als men ervan uitgaat dat het weiconcentraat altijd werkzaam is, bij een klein deel van 
de patiënten met CDAD een dagelijkse inname van 15 g van weiconcentraat te gering 
was om C. difficile-toxinen in de feces volledig te neutraliseren. De kans op het 
optreden van een recidief-CDAD was groter als de fecestoxinebepaling tijdens de 
inname van weiconcentraat nog een positieve uitslag had. Hetzelfde gold als kort na 
het staken van het weiconcentraatgebruik de uitslag weer positief werd. Het is 
daarom aannemelijk dat de effectiviteit van de aanpak vergroot wordt door in zulke 
gevallen de dosering weiconcentraat te verhogen. Dit is mogelijk door enkele dagen 
na de start van het gebruik van weiconcentraat of kort na het staken hiervan, een 
 fecestoxinebepaling te verrichten. Als die positief uitvalt, kan de dosering van het 
weiconcentraat worden verhoogd of de inname worden hervat. Voor deze toepassing 
is nu een 80%-concentraat van het wei-eiwit ontwikkeld, dat bovendien lactosearm 
is. Inmiddels hebben wij bij enkele CDAD-patiënten ervaring opgedaan met zo’n op 
de persoon afgestemde aanpak. Hierbij bleek dat na verhoging van de dosering 
wei-eiwit de fecestoxine-uitslag inderdaad alsnog negatief wordt. Binnenkort zal een 
prospectief klinisch onderzoek starten om de effectiviteit van een geïndividualiseerde 
aanpak in een grotere patiëntengroep te bevestigen.
Conclusie
Onze eerste ervaringen met een weiconcentraat van koeien geïmmuniseerd tegen 
C. difficile en zijn toxinen tonen dat het preparaat veilig gebruikt kan worden bij 
patiënten met CDAD voor de preventie van terugkerende episoden van diarree. De 
dosering moet nader onderzocht worden. De gunstige bevindingen van ons 
verkennende, ongeblindeerde, prospectieve onderzoek dienen nu bevestigd te 
worden in gecontroleerde studies.
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Abstract
Recurrence of Clostridium difficile-associated diarrhoea prevented by the administration 
of a whey concentrate from specifically immunised cows; prospective study
Objective. To try to prevent recurrences of Clostridium difficile-associated diarrhoea 
(CDAD) by treatment with a specific neutralising secretory IgA-enriched whey-protein 
concentrate (40%) made from the milk of cows immunised with C. difficile and its 
toxins. 
Design. Prospective, non-blinded, clinical cohort study.
Method. In 2005-2006, 100 consecutive patients with CDAD received the whey 
concentrate for 2 weeks after completion of standard antibiotic therapy. For a period 
of 60 days after the start of the administration, the safety and preliminary efficacy of 
the whey concentrate were evaluated by means of a diary, blood determinations, 
active surveillance for adverse events, and the recurrence of CDAD. 
Results. The whey concentrate was well tolerated and no safety issues were raised. 
Eleven out of 109 episodes (10%) were followed by a recurrence. After completion of 
the whey concentrate therapy, a positive test for faecal toxins or culture of C. difficile 
was predictive for the recurrence of CDAD (relative risk: 8.2 (95% CI: 1.04-64), and 4.7 
(95% CI: 0.5-47), respectively). A positive faeces toxin during administration of the 
whey concentrate was also associated with an early recurrence of CDAD.
Conclusion. Compared to historical and contemporary findings in control groups, 
the whey concentrate appeared to reduce the recurrence of CDAD by about 50%. 
However, the standard dose of the whey concentrate was probably not sufficient to 
fully neutralise the C. difficile toxins in faeces in all episodes.
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Abstract
Clostridium difficile infection (CDI) is a potentially fatal illness with an increasing 
incidence worldwide. Despite extensive ongoing research into CDI treatment, 
management of CDI still poses important problems, such as a high propensity to 
relapse and refractoriness to treatment, especially when there is an ileus and oral 
drugs cannot be adminstered. This guideline evaluates the available literature, 
discusses criteria for disease severity and provides recommendations for CDI 
treatment, indicating level of evidence and strength of recommendation.
Keywords: Clostridium difficile, treatment, guideline
Summary of definitions and recommendations
Definitions
Episode of CDI =
1. a clinical picture compatible with CDI and microbiological evidence of toxin-
producing Clostridium difficile in stool without evidence of another cause of 
diarrhoea or
2. pseudomembranous colitis (as diagnosed during endoscopy, after colectomy or 
on autopsy)
Clinical pictures compatible with CDI:
1. diarrhoea =
 a.   loose stools, i.e. taking the shape of the receptacle or corresponding to Bristol 
stool chart types 5 to 7 and
 b.   a stool frequency perceived as too high by the patient
2. ileus =
 a.   signs of severely disturbed bowel passage such as vomiting and absence of 
stool and
 b.   radiological signs of bowel distension
3. toxic megacolon =
 e.  radiological signs of distension of the colon and
 f.  signs of a severe systemic inflammatory response
Signs of severe colitis:
-	 fever (core body temperature > 38.5 ºC)
-	 rigors (uncontrollable shaking and a feeling of cold followed by a rise in body 
temperature)
-	 hemodynamic instability including signs of septic shock
-	 signs of peritonitis, including decreased bowel sounds, abdominal tenderness, 
rebound tenderness and guarding
-	 signs of ileus, including vomiting and absent passage of stool
-	 marked leukocytosis (leukocyte count > 15 · 109/l)
-	 marked left shift (band neutrophils > 20% of leukocytes)
-	 rise in serum creatinine (>50% above the baseline)
-	 elevated serum lactate
-	 pseudomembranous colitis (endoscopy)
-	 distension of large intestine (imaging)
-	 colonic wall thickening including low-attenuation mural thickening (imaging)
-	 pericolonic fat stranding (imaging)
-	 ascites not explained by other causes (imaging)
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antibiotic therapy; this includes the clinical diagnoses of toxic megacolon and 
severe ileus. Colectomy should preferably be performed before colitis is very 
severe. Serum lactate may, inter alia, serve as a marker for severity (operate 
before lactate exceeds 5.0 mmol/l).
6. Treatment for a second recurrence of CDI and later recurrences:
 If oral therapy is possible:
 -  vancomycin 125 mg qid orally for at least 10 days (B-II)
 -   consider a taper (for example, decreasing daily dose with 125 mg every 3 
days)/pulse (for example, a dose of 125 mg every 3 days for 3 weeks) strategy 
(B-II)
If oral therapy is impossible:
 -   metronidazole 500 mg tid intravenously for 10 – 14 days (A-III) + retention 
enema of vancomycin 500 mg in 100 ml of normal saline every 4 – 12 h (C-III)
  and/or vancomycin 500 mg qid by nasogastric tube (C-III)
7. In all the above-mentioned cases, oral vancomycin may be replaced by 
teicoplanin 100 mg bid, if available.
Introduction
Clostridium difficile infection (CDI) may arise when a patient’s bowel is colonized 
by C. difficile after ingestion of spores, the spores subsequently germinate and the 
vegetative bacteria start producing toxins. Colonization is inhibited by the normal 
intestinal flora, which is hypothesized to compete with C. difficile for nutrients and 
space on the mucosal surface. Therefore, the use of antibiotics is the most important 
risk factor for CDI. The vegetative state of the bacterium is resistant to a varying but 
broad range of antibiotics and the spores are highly resistant to antibiotics and can 
withstand many forms of chemical attack, e.g. most high-level disinfectants. The most 
important problem in treating CDI is the high recurrence rate. Various factors, such as 
the need to continue treatment with the inciting antibiotic, have been associated with 
this (see under ‘Prognostic criteria and criteria for disease severity’). The antibiotics 
needed to kill the vegetative bacteria do not kill the spores and might even contribute 
to recurrence by disrupting the normal gut flora even further. Individuals who suffer 
a recurrence may enter a repetitive cycle of recurrences, leading to exhaustion and 
protein-losing enteropathy. A second problem in treating CDI is the fact that in severe 
forms of CDI antibiotics may fail resulting in progressive colitis with high morbidity 
and mortality. Several factors may play a role in this, such as a time lag for antibiotics 
to reach adequate intracolonic levels [1] and possibly the fact that a systemic 
inflammatory response due to severely damaged colonic mucosa may persist some 
time after removal of the etiological agent.
Severe CDI =
an episode of CDI with one or more signs of severe colitis.
CDI without signs of severe colitis in patients with high age (≥ 65), serious comorbidity, 
ICU admission, or immunodeficiency may be regarded as severe.
CDI treatment response =
1. stool frequency as perceived by the patient decreases or stool consistency 
improves after three days and
2. no new signs of severe colitis develop
CDI treatment failure =
absence of CDI treatment response
CDI recurrence =
1. stool frequency as perceived by the patient increases for two consecutive days 
and stools become looser or new signs of severe colitis develop and
2. microbiological evidence of toxin-producing C. difficile in stool without evidence 
of another cause of diarrhoea after an initial CDI treatment response
Recommendations (implementation category between brackets)
1. Antiperistaltic agents and opiates should be avoided. (B-II)
2. In general, strive to use antibiotics covering a spectrum no broader than 
necessary and narrow the antibiotic spectrum of treatment after results of 
cultures and/or susceptibility tests become known. (B-III)
3. Mild CDI (stool frequency < 4 times daily; no signs of severe colitis), clearly 
induced by the use of antibiotics, may be treated by stopping the inducing 
antibiotic. Observe patients closely for any signs of clinical deterioration and 
place on therapy immediately if this occurs. (B-III)
4. Treatment for an initial episode and a first recurrence of CDI:
 If oral therapy is possible:
 -  non-severe: metronidazole 500 mg tid orally for 10 days (A-I)
 -  severe: vancomycin 125 mg qid orally for 10 days (A-I)
If oral therapy is impossible:
 -  non-severe: metronidazole 500 mg tid intravenously for 10 days (A-III)
 -   severe: metronidazole 500 mg tid intravenously for 10 days (A-III) + intracolonic 
vancomycin 500 mg in 100 ml of normal saline every 4 – 12 h (C-III) and/or 
vancomycin 500 mg qid by nasogastric tube (C-III)
5. Colectomy should be performed to treat CDI in any of the following situations:
 -  perforation of the colon
 -  systemic inflammation and deteriorating clinical condition not responding to 
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5 to 7 [2], plus a stool frequency perceived as too high by the patient. Faecal 
incontinence may be a part of the disease. Ileus in the context of CDI is defined as 
signs of severely disturbed bowel passage such as vomiting and absence of stool, 
combined with radiological signs of bowel distension. Toxic megacolon is defined 
as radiological signs of distension of the colon combined with signs of a severe 
systemic inflammatory response. We refer to the ESCMID guideline on diagnosis of 
CDI, which is currently being prepared, for information on microbiological evidence 
for CDI. The above-mentioned criteria are largely in line with the recommendations 
by the American Ad Hoc C. difficile surveillance working group [3] and the European 
Study Group for C. difficile [4].
Prognostic criteria and criteria for disease severity
Outcome measures of CDI comprise complications, mortality and recurrences. It 
is difficult to set a rigid set of criteria for the assessment of prognosis and severity 
of CDI. First, surprisingly little research has been done on clinical predictors of 
outcome. Second, prognostic markers have not been validated in prognostic studies. 
Third, prognosis depends on disease severity and other prognostic factors, such 
as age, comorbidity, admission to an intensive care unit and antiperistaltic and 
immunosuppressive medication. It is unknown what the weight of these prognostic 
factors is in comparison to assessed disease severity. 
 Possible features of severe colitis that have been linked to a higher chance of 
recurrence are faecal incontinence [5], the endoscopic finding of pseudomembranous 
colitis [6] and longer cumulative duration of previous episodes of CDI [7]. Leukocytosis 
 Since treatment of CDI can be complicated by these many problems, the CDI 
Guidance Document Executive Committee decided that there was a need for this 
evidence-based guideline.
Objective
The objective of this guideline was to evaluate the available evidence concerning 
treatment of CDI and formulate recommendations for treatment.
Update methodology
Studies on CDI treatment were found with a computerized literature search of PUBMED 
using the terms “Clostridium difficile AND (treatment OR trial)”. All randomized 
and non-randomized trials investigating the effect of an intervention on the clinical 
outcome (resolution or recurrence of diarrhoea; incidence of complications) of CDI 
published in any language were included. Studies investigating carriage or other 
purely microbiological parameters were not considered sufficient evidence for 
treatment strategies. The resulting literature from 1978 was reviewed and analyzed. 
Furthermore, systematic reviews from the Cochrane Library and the guideline by the 
Infectious Diseases Society of America (IDSA) were evaluated. Recommendations 
were based on a systematic assessment of the quality of evidence. For indicating 
the quality of evidence and weight of recommendations the system according to The 
Canadian Task Force on the Periodic Health Examination was used (table 1).
 Three draft versions of the guideline were written by three authors (MB, EK, JvD) 
and criticized by the Executive Committee and advisors. A consensus was reached, 
resulting in the final version.
Definitions
Criteria for the diagnosis of CDI
Pseudomembranous colitis, which is an endoscopic diagnosis, is caused by C. 
difficile in the vast majority of cases and therefore may suffice for the diagnosis of 
CDI in the absence of an obvious other cause. In the rest of the cases, a combination 
of symptoms and signs plus microbiological evidence of toxin-producing C. difficile 
in stool and absence of another cause is necessary. Compatible clinical pictures 
are diarrhoea, ileus and toxic megacolon. Diarrhoea is defined as loose stools, i.e. 
taking the shape of the receptacle or corresponding to Bristol stool chart types 
Table 1  Strength of recommendation and quality of evidence according to The 
Canadian Task Force on the Periodic Health Examination
Strength of recommendation:
A:  good evidence to support a recommendation
B:  moderate evidence to support a recommendation
C:  poor evidence to support a recommendation
Quality of evidence:
I:  evidence from ≥ 1 properly randomized, controlled trial
II:  evidence from ≥ 1 well-designed clinical trial, without randomization; from cohort 
or case-controlled analytic studies (preferably from ≥ centre); from multiple time-
series; or from dramatic results from uncontrolled experiments
III:  evidence from opinions of respected authorities, based on clinical experience, 
descriptive studies, or reports of expert committees
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Admixture of blood with stools is rare in CDI and the correlation with severity of 
disease is uncertain.
Laboratory investigations:
- marked leukocytosis (leukocyte count > 15 · 109/l)
- marked left shift (band neutrophils > 20% of leukocytes)
-  rise in serum creatinine (>50% above the baseline)
-  elevated serum lactate
Colonoscopy or sigmoidoscopy:
- pseudomembranous colitis
There is insufficient knowledge on the correlation of endoscopic findings compatible 
with CDI, such as oedema, erythema, friability and ulceration, and the severity of 
disease.
Imaging:
- distension of large intestine
- colonic wall thickening including low-attenuation mural thickening
- pericolonic fat stranding
- ascites not explained by other causes
The correlation of haustral or mucosal thickening, including thumbprinting, pseudo-
polyps and plaques, with severity of disease is unclear.
Prognostic markers other than disease severity
- high age (≥ 65)
-  serious comorbidity and ICU admission
-  immunodeficiency
Criteria for response, failure and recurrence in the treatment of CDI
Treatment response is present when either stool frequency decreases or stool 
consistency improves and parameters of disease severity (clinical, laboratory, 
radiological) improve and no new signs of severe disease develop. In all other cases, 
there is treatment failure. It is only reasonable to evaluate treatment response after at 
least three days, assuming that the patient is not worsening on treatment. Treatment 
with metronidazole, in particular, may only result in a clinical response after three 
to five days [1,16]. After clinical response, it may take weeks for stool consistency 
and frequency to become entirely normal [17]. Recurrence is present when after 
an initial response stool frequency increases for two consecutive days and stools 
become looser or new signs of severe disease develop and microbiological evidence 
of toxin-producing C. difficile in stool is present without evidence of another cause. 
(leukocyte count > 20 · 109/l) has been associated with a high mortality rate in CDI 
[8], a complicated course [9], refractoriness to therapy [6] and risk of recurrence [9]. 
Hypoalbuminaemia (< 25 g/l) has also been associated with a high mortality rate 
in CDI [8] and refractoriness to therapy [6,10,11]. However, since it may be seen as 
a result of malnutrition or protein-losing enteropathy in longstanding disease, as a 
negative acute phase protein in acute disease, and as a marker for comorbidity (e.g. 
liver cirrhosis, nephrotic syndrome, wasting) this feature may be too heterogeneous 
to be a reliable marker for severe disease.
 Factors associated with unfavourable outcome that are no direct markers of 
severe colitis include high age, comorbidity, a decreased antibody response, gastric 
acid suppressants and need to prolong inciting antibiotic therapy. High age has been 
associated with a complicated course [12] and recurrence [9,12]. Comorbidity has 
been associated with a high mortality rate [8] and a higher chance of recurrence 
[13]. A decreased humoral immune response against Clostridial toxins TcdA and 
TcdB has been associated with a higher chance of recurrence and longer duration 
of symptoms [14,15], although other studies did not find this association. Use of H2-
antagonists has been associated with a higher chance of recurrence [5] and use of 
proton pump inhibitors has been associated with refractoriness to therapy [16]. Also 
the need to continue the inciting antibiotic has been associated with refractoriness to 
therapy [16]. However, it is unclear whether the use of gastric acid suppressants and 
the need to continue antibiotics have a causal relationship with unfavourable outcome 
or whether they are markers of more severe comorbidity. Obviously, admission to an 
ICU is an unfavourable prognostic feature [6,11].
Markers of severe colitis
Markers that could reasonably be assumed to correlate positively with severity of 
colitis are mentioned below, although we must stress that the prognostic value 
of these markers is uncertain. Obviously, markers should not be attributable to a 
concomitant disease, if they are to be regarded as a marker of severe CDI. Ideally, 
markers should be obtainable at the earliest time in the disease course to be a 
predictor of outcome.
Physical examination:
- fever (core body temperature > 38.5 ºC)
- rigours (uncontrollable shaking and a feeling of cold followed by a rise in body
 temperature)
- haemodynamic instability including signs of distributive (vasodilatory; septic) shock
- signs of peritonitis, including decreased bowel sounds, abdominal tenderness, 
rebound tenderness and guarding
- signs of ileus, including vomiting and absent passage of stool
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metronidazole according to disease severity, the diagnosis of severe CDI was based 
on age, body temperature, albumin level and leukocyte count. Vancomycin proved 
to be superior over metronidazole in cases of severe CDI. Two trials investigating the 
efficacy of the toxin-binding polymer, tolevamer [34,35], also showed superiority of 
oral vancomycin over metronidazole in severe cases. A recent Cochrane systematic 
review [70] has examined the available literature on antibiotic treatment options of CDI 
and concluded that teicoplanin is the most effective antibiotic treatment for moderate 
to severe CDI and vancomycin has no superiority over metronidazole. However, this 
review did not include the above-mentioned recent studies. It seems likely that the 
effectiveness of teicoplanin and vancomycin is in the same range.
 Oral metronidazole is also very effective in inducing a response and has the 
advantage of low cost and the fact that it may contribute less to the emergence of 
vancomycin-resistant enterococci.
 If metronidazole is indeed less effective than glycopeptides, this may be explained 
by the low levels metronidazole reaches in the colon, since it is absorbed in the 
small intestine and then excreted again in the bile and in the inflamed colon, 
whereas glycopeptides are not absorbed. Different doses of oral vancomycin have 
been used, but only one small randomized trial [22] has compared high versus low 
dose vancomycin and found no statistically significant difference. Since low doses 
of oral vancomycin result in high concentrations in stool, there is no need to treat 
with high doses, except in an attempt to reach sufficient concentrations in the colon 
when administering vancomycin by nasogastric tube in a patient with ileus. Given 
the poor faecal concentrations of metronidazole achieved following a 500 mg 
8-hourly dose, lower doses (e.g. 250 mg 6-8 hourly) should be less effective. Several 
studies , however, have used lower doses, usually with good results [6,7,19,27, 
28,34,35]. Even a modest increase in the MIC of metronidazole for C. difficile might 
result in insufficient faecal antibiotic concentrations to inhibit (vegetative) bacteria. 
Metronidazole resistance is to be regarded as exceedingly rare. However, the 
emergence of reduced susceptibility to metronidazole has recently been reported 
in UK C. difficile strains [1,71,72]. No reduced susceptibility to vancomycin was 
observed. The exact mechanism of reduced susceptibility to metronidazole remains 
to be determined. Notably, there is also evidence that inactivation of metronidazole 
occurs in the presence of gut contents, possibly due to metabolism by enterococci 
[73].
 Oral bacitracin and fusidic acid seem to be less effective than vancomycin and 
metronidazole, respectively, although this has not convincingly been demonstrated. 
Currently, there is insufficient evidence to advocate the use of the rifamycin derivative 
rifaximin, to which resistance has been noted, and the antiprotozoal/ anthelminthic 
nitazoxanide, which has been shown to be statistically similar to metronidazole in 
a small prospective randomized trial [28], but whose non-inferiority to vancomycin 
It is impossible to distinguish recurrence due to relapse (renewed symptoms from 
already present CDI) from recurrence due to reinfection in daily practice.
Overview of medical treatment options 
available for CDI
There is an increasing body of evidence on treatment of CDI, both initial (tables 2 
[6, 18-32], 3 [17, 33-36] and 4 [9,11,13,15,37-48]) and recurrent episodes (tables 5 
[33,49-52] and 6 [7,53-68]). Tables 2, 3 and 5 report the evidence from randomized 
trials with comments on methodology. It is difficult to compare these studies because 
of differences in diagnostic criteria, exclusion of co-pathogens, severity of CDI, co-
morbidity, inciting antibiotics and concomitant use of antibiotics. Moreover, these 
studies usually have endpoints of clinical cure or microbiological cure. However, 
the definition of clinical cure and recurrence is highly variable. Patients seldom have 
normal stools directly after treatment of CDI. With respect to microbiological cure, 
the significance of persistently or recurrently positive stool toxin tests or cultures 
is not clear. Furthermore, it is not possible to distinguish relapse from reinfection. 
Lastly, the number of participants of most trials is small. In conclusion, we need more 
randomized controlled trials on CDI treatment.
 It is important to realize that several experimental treatment options are not widely 
available, such as toxin-binding resins and polymers and specific immunotherapy.
Stopping the inciting antibiotic without antibiotic treatment
It is unknown what the rate of spontaneous resolution is in patients with mild CDI. In 
one study [40], spontaneous recovery rate in hospitalized patients with diarrhoea and 
a positive toxin assay who did not undergo endoscopy or had no pseudomembranous 
colitis on colonoscopy was 33%. More antibiotics after stopping the inciting antibiotic 
might increase the chance of subsequent recurrence, since gut flora will be exposed 
to a second antibiotic with a different spectrum (i.e. metronidazole). It may therefore 
be prudent to only stop the inciting antibiotic in the case of mild CDI, while closely 
monitoring the patient.
Oral antibiotics
There is only one placebo-controlled trial investigating the effectiveness of antibiotics 
for CDI and it had very few participants. Several antibiotics have been compared 
to each other. Oral administration of the glycopeptides vancomycin and teicoplanin 
appears most effective in inducing both clinical cure and microbiological cure, 
especially in severe CDI. The difficulty is how to define severe CDI. In one prospective, 
randomized, and blinded study [6], which evaluated the efficacy of vancomycin versus 
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could not be shown in another trial due to lack of power [31]. As yet, there is also 
insufficient evidence for routine use of fidaxomicin (OPT-80), an inhibitor of RNA 
polymerase of gram-positive bacteria although preliminary results of a recently 
presented  study are very promising[32].
Duration of antibiotic therapy
The duration of antibiotics has been ten days in most studies. Occasionally, shorter 
duration (e.g. seven days) has been studied. We feel that there is insufficient evidence 
for a shorter duration of therapy with any antibiotic to consider shorter regimens a 
treatment option.
 There is no definitive evidence that taper or pulse regimens with vancomycin 
are effective in reducing the incidence of relapses. This strategy is mainly based on 
favourable experience and the theoretical rationale that spores can still germinate 
long after the clinical symptoms have resolved. McFarland et al. [7] retrospectively 
compared a standard course of antibiotics, vancomycin taper strategies (gradually 
decreasing the daily dose of vancomycin with 125 to 750 mg per day from varying 
starting doses) and vancomycin pulse strategies (125 to 500 mg of vancomycin 
every 2 to 3 days during a period of usually 3 weeks). They found the recurrence 
rate to be lowest in pulse regimens (14%), followed by taper regimens (31%) and 
the standard regimen of vancomycin (54%; average for all dose groups). No other 
studies investigating taper or pulse regimens have been published. Further studies 
are needed.
Probiotics
Probiotics may be of value when added to antibiotics, but the studies that have 
investigated this suffer from major drawbacks such as small numbers, non-randomized 
allocation of antibiotics to which the probiotics were added and lack of homogeneity 
between study groups. This is also the conclusion reached by a recent Cochrane 
systematic review [74]. Therefore, there is insufficient evidence to recommend the 
addition of probiotics to antibiotics. In addition, several reports of invasive disease have 
been reported resulting from the use of probiotics such as Saccharomyces boulardii 
in debilitated or immunocompromised patients [75, 76]. Moreover, probiotics were 
associated with increased mortality, partly due to nonocclusive mesenterial ischemia, 
in a randomized controlled trial in acute pancreatitis [77].
Treatment when oral administration is not possible
The only parenteral antibiotic therapy for CDI, supported by case series, is 
metronidazole [78]. Furthermore, several case reports regarding the use of 
intravenous immunoglobulin have been published but the data do not provide 
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CDI is judged to be severe when one or more of the markers of severe colitis mentioned 
under ‘definitions’ is present. It is unclear whether moderate disease in a patient with other 
unfavourable prognostic factors, such as high age and comorbidity, should be regarded as 
severe. This is left to the judgment of the treating physician. There is no evidence that various 
genotypes of C. difficile should be treated differently if disease severity does not differ.
When oral therapy is impossible, we recommend the following antibiotics, according 
to disease severity (implementation category between brackets):
- non-severe: metronidazole 500 mg tid intravenously for 10 days (A-III)
- severe: metronidazole 500 mg tid intravenously for 10 days +  (A-III)
  intracolonic vancomycin 500 mg in 100 ml of (C-III)
  normal saline every 4 – 12 h
  and/or vancomycin 500 mg qid by nasogastric tube (C-III)
Recommendations for surgical treatment of CDI
Colectomy should be performed to treat CDI in any of the following situations:
- perforation of the colon
- systemic inflammation and deteriorating clinical condition not responding to anti biotic 
therapy; this includes the clinical diagnoses of toxic megacolon and severe ileus.
Since mortality from colectomy in patients with advanced disease is high, it is 
recommended to operate in a less severe stage. No definite recommendations on the 
timing of colectomy can be given. Serum lactate may, inter alia, serve as a marker for 
severity, where one should attempt to operate before the threshold of 5.0 mmol/l [80].
Recommendations for medical treatment of recurrent CDI
Observational data [12] suggest that the incidence of a second recurrence after 
treatment of a first recurrence with oral metronidazole or vancomycin is similar. 
Therefore, we recommend treating a first recurrence of CDI as a first episode, unless 
disease has progressed from non-severe to severe.
 We recommend treatment of recurrent CDI with the following antibiotics 
(implementation category between brackets):
First recurrence:
See Recommendations for medical treatment of initial CDI.
Second recurrence and subsequent recurrences:
If oral therapy is possible:
- vancomycin 125 mg qid* orally for at least 10 days (B-II)
 consider a taper/ pulse strategy (B-II)
* Oral vancomycin may be replaced by teicoplanin 100 mg bid, if available.
with ileus due to CDI. There are some anecdotal reports on delivery of vancomycin 
to the gut by other means than orally, mainly through intracolonic delivery. Questions 
regarding the efficacy, optimal dosing and duration of treatment with intracolonic 
vancomycin are unanswered. The introduction of faecal collector drainage systems 
has facilitated the use of glycopeptide retention enemas in ICUs, but they are very 
expensive. Tigecycline appeared useful as salvage therapy as reported in a recent 
case series of patients with severe CDI complicated by ileus, but these promising 
findings require confirmation in prospective clinical trials [46]. Faecal transplantation 
has been performed through instillation with a colonoscope or enemas, but there is 
insufficient evidence to recommend this. 
 There are no prospective studies assessing which CDI patients benefit from 
surgical intervention. One study found that colectomy was most successful in a 
relatively early stage of the disease, i.e. before lactate exceeds 5.0 mmol/l [80].
Recommendations for the treatment of CDI 
Recommendations for medical treatment of initial CDI
In the case of mild CDI (stool frequency < 4 times daily; no signs of severe colitis), 
clearly induced by the use of antibiotics, it is acceptable to stop the inducing antibiotic 
and observe the clinical response, but patients must be followed very closely for 
any signs of clinical deterioration and placed on therapy immediately if this occurs. 
Theoretic rationale, anecdotic evidence and one case-control study suggest that 
antiperistaltic and opiate agents should be avoided, especially in the acute setting 
[81]. There is no evidence that switching to ‘low-risk’ antibiotics when the antibiotic 
treatment that triggered the episode of CDI cannot be stopped or its spectrum be 
narrowed, is effective. It seems rational, however, to always strive to use antibiotics 
covering a spectrum no broader than necessary. When the inciting antibiotic cannot 
be stopped, antibiotic treatment for CDI should be initiated. Furthermore, there is no 
proof that stopping gastric acid suppressants is effective, either.
 In all other cases than mild CDI medical treatment for CDI should be started. 
Antibiotics may be started while awaiting diagnostics when there is sufficient clinical 
suspicion. We recommend treatment of an initial episode of CDI with the following 
antibiotics, according to disease severity (implementation category between brackets), 
when oral therapy is possible:
- non-severe:  metronidazole 500 mg tid orally for 10 days  (A-I)
- severe:  vancomycin 125 mg qid* orally for 10 days  (A-I).
* Oral vancomycin may be replaced by teicoplanin 100 mg bid, if available.
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Abstract
In 2009 the first European Society of Clinical Microbiology and Infection (ESCMID) 
treatment guidance document for Clostridium difficile infection (CDI) was published. 
The guideline has been applied widely in clinical practice. In this document an update 
and review on the comparative effectiveness of the currently available treatment 
modalities of CDI is given, thereby providing evidence-based recommendations on 
this issue. A computerized literature search was carried out to investigate randomized 
and non-randomized trials investigating the effect of an intervention on the clinical 
outcome of CDI. The Grades of Recommendation Assessment, Development and 
Evaluation (GRADE) system was used to grade the strength of our recommendations 
and the quality of the evidence. The ESCMID and an international team of experts 
from 11 European countries supported the process. To improve clinical guidance in 
the treatment of CDI, recommendations are specified for various patient groups, e.g. 
initial non-severe disease, severe CDI, first recurrence or risk for recurrent disease, 
multiple recurrences and treatment of CDI when oral administration is not possible. 
Treatment options that are reviewed include: antibiotics, toxin-binding resins and 
polymers, immunotherapy, probiotics, and faecal or bacterial intestinal transplantation. 
Except for very mild CDI that is clearly induced by antibiotic usage antibiotic treatment is 
advised. The main antibiotics that are recommended are metronidazole, vancomycin 
and fidaxomicin. Faecal transplantation is strongly recommended for multiple recurrent 
CDI. In case of perforation of the colon and/or systemic inflammation and deteriorating 
clinical condition despite antibiotic therapy, total abdominal colectomy or diverting 
loop ileostomy combined with colonic lavage is recommended.
Introduction
The previous European Society of Clinical Microbiology and Infection (ESCMID) 
guidance document, which has been applied widely in clinical practice, dates from 
2009 [1]. Meanwhile, new treatments for Clostridium difficile infection (CDI) have 
been developed and limitations of the currently recommended treatment options of 
CDI are considered. As the current ESCMID treatment guidance document is already 
implemented in clinical practice, an update of this widely applied guidance document 
is essential to further improve uniformity of national hospital infection treatment 
policies for CDI in Europe. In particular, after the recent development of new alternative 
drugs for the treatment of CDI (e.g. fidaxomicin) in the USA and Europe, there has 
been an increasing need for an update on the comparative effectiveness of the 
currently available antibiotic agents in the treatment of CDI, thereby providing 
evidence-based recommendations on this issue.
The objectives of this document are to:
1. Provide an overview of currently available CDI treatment options
2. Develop an evidence-based update of treatment recommendations
Update methodology
Studies on CDI treatment were found with a computerized literature search of 
PUBMED and Google Scholar using the terms ‘Clostridium difficile AND (treatment 
OR trial)’. All randomized and non-randomized trials investigating the effect of an 
intervention on the clinical outcome (resolution or recurrence of diarrhoea; incidence of 
complications) of CDI published in any language were included. Studies investigating 
carriage or other purely microbiological parameters were not considered sufficient 
evidence for treatment strategies. The resulting literature from 1978 was reviewed and 
analysed. Furthermore, systematic reviews from the most recent Cochrane analysis 
[2] and the up-dated guidelines of the Infectious Diseases Society of America, the 
Australasian Society for Infectious Diseases, the American College of Gastroenterology, 
and the Health Protection Agency/Public Health England guidance document 
(http://www.hpa.org.uk) were evaluated [3–5]. Recommendations were based on a 
systematic assessment of the quality of evidence. The Grades of Recommendation 
Assessment, Development and Evaluation (GRADE) system was used to grade the 
strength of our recommendations and the quality of the evidence [6,7].
 Draft versions of the guideline were written by the executive committee (consisting of: 
S. Debast, M. Bauer and E. Kuijper) and criticized by the Executive Committee and 
advisors. After this, consensus was reached, resulting in the final version. The methods 
to evaluate the quality of evidence and to reach group consensus recommendations 
were based on the method described by Ullmann et al. [8].
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algorithms were evaluated to optimize the laboratory diagnosis of CDI [14]. The 
investigators concluded that two-stage algorithms improve diagnosis of CDI. Two 
commonly recommended methods in the laboratory diagnosis of CDI are the use of GDH 
detection in stools as a means of screening for CDI, confirmed by NAAT such as PCR 
to detect toxigenic strains of C. difficile [4,12]. Furthermore, patients with a positive 
stool toxin had C. difficile disease with an increased risk of mortality compared with 
patients with only a positive toxigenic culture, thereby implying that stool toxin testing 
should be included in a testing algorithm to optimize C. difficile diagnostic testing 
[15]. Diarrhoea is defined as loose stools, i.e. taking the shape of the receptacle or 
corresponding to Bristol stool chart types 5– 7, plus a stool frequency of three stools 
in 24 or fewer consecutive hours or more frequently than is normal for the individual 
(definition World Health Organization, http://www.who.int/topics/diarrhoea) [1,3,16–18].
 Clinical pictures compatible with CDI are summarized in Table 3.
 Definition of the strength of recommendation is given in Table 1. The quality of the 
published evidence is defined in Table 2a. Grouping quality of evidence into 
three levels only may lead to diverse types of published evidence being assigned 
specifically to a level II. To increase transparency in the evaluation of the evidence an 
index (Table 2b) to the level II recommendations was added where appropriate.
 The guideline followed the Appraisal of Guidelines Research and Evaluation 
Collaboration (AGREE) self-assessment tool [9].
Definitions
Diagnosis
The diagnosis of CDI is based on (1) a combination of signs and symptoms, confirmed 
by microbiological evidence of C. difficile toxin and toxin-producing C. difficile in stools, 
in the absence of another cause, or (ii) colonoscopic or histopathological findings 
demonstrating pseudomembranous colitis [1,3,10–12]. There are many different 
approaches that can be used in the laboratory diagnosis of CDI; however, the best 
standard laboratory test for diagnosis has not been established. Diagnostic tests for 
CDI include: (i) detection of C. difficile products: cell culture cytoxicity assay (CCA), 
glutamate dehydrogenase (GDH) and Toxins A and/or B, (ii) toxigenic culture of C. 
difficile, and (iii) nucleic acid amplification tests (NAAT): 16S RNA, toxin genes, GDH 
genes. Preferably a two- or three-stage algorithm is performed to diagnose CDI, in which 
a positive first test is confirmed with one or two confirmatory tests or a reference method 
[3,4,12,13]. Faeces samples could be investigated with an enzyme immunoassay 
detecting GDH, an enzyme immunoassay detecting toxins A and B, or NAAT detecting 
Toxin B (TcdB). Samples with a negative test result can be reported as negative. 
Faeces samples with a positive first test result should be re-tested with a method to detect 
free faeces toxins, or with a method to detect GDH or toxin genes, dependent on the 
assay applied as first screening test. If free faeces toxins are absent but C. difficle 
TcdB gene or GDH are present, CDI cannot be differentiated from asymptomatic 
colonization. Recently, a large study was presented in which several diagnostic 
Tabel 1  Definition of the Strength of Recommendation Grade (SoR) ESCMID 
Strength Definition
A Strongly supports a recommendation for use
B Moderately supports a recommendation for use
C Marginally supports a recommendation for use
D Supports a recommendation against use
Tabel 2a   Definition of the Quality of Evidence (QoE) Level ESCMID.  
Adapted from ref [8]. 
Quality of  
Evidence Level
Definition
I Evidence from at least 1 properly designed randomized, controlled trial
II Evidence from at least 1 well-designed clinical trial, without 
randomization; from cohort or case-controlled analytic studies 
(preferably from >1centre); from multiple time series; or from dramatic 
results of uncontrolled experiments
III Evidence from opinions of respected authorities, based on clinical 
experience, descriptive case studies, or reports of expert committees
Tabel 2b   Definition of the Quality of Evidence (QoE) Index ESCMID.  
Adapted from ref [8].
Quality of  
Evidence Index
Definition
r Meta-analysis or systematic review of randomized controlled trials
t Transferred evidence i.e. results from different patients‘ cohorts, or 
similar immune-status situation 
h Comparator group is a historical control
u Uncontrolled trial
a Abstract published at an international meeting
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course of disease, with significant systemic toxin effects and shock, resulting in need 
for ICU admission, colectomy or death [1,4,29].
 Clostridium difficile infection without signs of severe colitis in patients with greater 
age (≥65 years), serious comorbidity, Intensive Care Unit (ICU) admission, or immuno-
deficiency may also be considered at increased risk of severe CDI [30,31].
 An overview of characteristics in patients with CDI that are assumed to correlate 
with the severity of colitis is given in Table 4 [32–39]. We must stress that the prognostic 
value of these markers is uncertain.
Definition of Clostridium difficile infection. An episode of CDI is defined as: A clinical 
picture compatible with CDI and microbiological evidence of free toxins and the 
presence of C. difficile in stool without reasonable evidence of another cause of 
diarrhoea. or Pseudomembranous colitis as diagnosed during endoscopy, after 
colectomy or on autopsy [3,11,19].
Treatment response
Definition of treatment response. Treatment response is present when either stool 
frequency decreases or stool consistency improves and parameters of disease severity 
(clinical, laboratory, radiological) improve and no new signs of severe disease develop. 
In all other cases, treatment is considered a failure. Treatment response should be 
observed daily and evaluated after at least 3 days, assuming that the patient is not 
worsening on treatment. Treatment with metronidazole, in particular, may result in a 
clinical response only after 3–5 days [21–23]. After clinical response, it may take weeks 
for stool consistency and frequency to become entirely normal [23,24].
Recurrences
Definition of recurrent Clostridium difficile infection. Recurrence is present when CDI 
re-occurs within 8 weeks after the onset of a previous episode, provided the symptoms 
from the previous episode resolved after completion of initial treatment [4,11].
 It is not feasible to distinguish recurrence due to relapse (renewed symptoms 
from already present CDI) from recurrence due to reinfection in daily practice 
[20,25–28].
Severity of disease
Definition of severe Clostridium difficile infection. Severe CDI is defined as an episode 
of CDI with (one or more specific signs and symptoms of) severe colitis or a complicated 
Tabel 3  Clinical pictures compatible with Clostridium difficile infection (CDI). 
Adapted from refs [1,3,11,19,20]
Sign/symptom Definition
Diarrhoea Loose stools, i.e. taking the shape of the receptacle or corresponding 
to Bristol stool chart types 5 to 7 and a stool frequency perceived as too 
high by the patient
Ileus Signs of severely disturbed bowel passage such as vomiting and 
absence of stool and radiological signs of bowel distension
Toxic 
megacolon
Radiological signs of distension of the colon and signs of a severe 
systemic inflammatory response Tabel 4  Clinical signs and symptoms that could reasonably be assumed to 
correlate positively with severity of colitis or a complicated course of 




- Fever (core body temperature > 38.5 ºC)
- Rigours (uncontrollable shaking and a feeling of cold followed by a 
rise in body temperature)
- Haemodynamic instability including signs of distributive (vasodilatory; 
septic) shock
- Signs of peritonitis, including decreased bowel sounds, abdominal 
tenderness, rebound tenderness and guarding
- Signs of ileus, including vomiting and absent passage of stool




- Marked leucocytosis (leukocyte count > 15 · 109/l)
- Marked left shift (band neutrophils > 20% of leukocytes)
- Rise in serum creatinine (>50% above the baseline)
- Elevated serum lactate




There is insufficient knowledge on the correlation of endoscopic findings compatible with CDI, 
such as oedema, erythema, friability and ulceration, and the severity of disease.
Imaging - Distension of large intestine
- Colonic wall thickening including low-attenuation mural thickening
- Pericolonic fat stranding
- Ascites not explained by other causes
The correlation of haustral or mucosal thickening, including thumbprinting, pseudopolyps and 
plaques, with severity of disease is unclear.
Other - High age (≥ 65)
- Serious comorbidity and/or immunodeficiency 
- ICU admission
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patients at almost all ages. Some studies on the other hand suggested that PCR 
ribotype 027 strains might only be associated with worse outcome in settings where 
027 strains are epidemic, and not in an endemic situation [38,48]. However, these 
findings are questioned by others [49]. Recently, a large study by Walker et al. clearly 
showed that strain types varied in the overall impact on mortality and biomarkers 
(predominantly those associated with inflammatory pathways) [50]. Besides C. 
difficile PCR ribotype 027, other strains are also associated with outbreaks and severe 
C. difficile infection, e.g. PCR ribotype 078 [51]. Despite increased virulence of 
specific strain types, the value of the PCR ribotype as a prediction marker for disease 
severity may be limited, as the ribotype involved in an infection is commonly not 
known upon diagnosis. However, in an epidemic situation the PCR ribotype may be 
taken into account in deciding on the choice of empirical treatment regimens [21,39].
 The level of host immune response to C. difficile exposure has been shown to be 
an important determinant of the severity and duration of clinical manifestations 
[52–57]. Anti-toxin antibody levels have been demonstrated to be higher in healthy 
adult controls compared with healthy children, and levels were found to fall with 
increasing age. In addition, anti-toxin antibodies increased after resolution of 
diarrhoea, which coincided with decreased incidence of CDI recurrence [57]. Inability 
to mount an adequate humoral immune response (e.g. during use of rituximab) may 
therefore be an important additional prediction marker for severe and/or recurrent 
CDI [25,57–62]. Unfortunately, in most cases this information is not available at 
presentation/diagnosis; also, as the strength of evidence for immunodeficiency as an 
independent predictor for severe and/ or recurrent CDI is still limited, we did not 
include this risk factor as a separate prediction marker.
 The results from individual studies, reviews and meta-analyses on prognostic 
markers for CDI were evaluated to reach a group consensus on a selection of markers 
that may be useful in clinical practice to distinguish patients with increased risk for 
severe or life-threatening CDI and recurrences. For detailed recommendations we 
refer to Tables 5 and 6.
Recommendations. Clostridium difficile infection is judged to be severe when one or 
more of the clinical markers of severe colitis mentioned in Table 4 is present, and/or 
when one or more unfavourable prognostic factors (Table 5) is present:
1. Marked leucocytosis (leucocyte count >15 9 109/L)
2. Decreased blood albumin (<30 g/L)
3. Rise in serum creatinine level (≥133 lM or ≥1.5 times the premorbid level)
Clostridium difficile infection without signs of severe colitis in older patients (≥65 
years), serious comorbidity, ICU admission, or immunodeficiency may also be 
regarded as increased risks of developing severe CDI.
Clinical prediction markers
Evidence. Clinical studies indicate superiority of specific treatment strategies 
depending on the severity of disease. In addition, alternative treatment options have 
been developed, that may be more effective in preventing recurrence of disease. 
Unfortunately some of the novel treatment strategies can be very expensive, and 
may only be cost-effective for a certain group of patients depending on the stage 
and severity of disease. This emphasizes the importance for better identification of 
clinical markers, preferably early in the course of disease, which might predict the 
benefit from specific treatment regimens to decrease CDI-related complications, 
mortality or recurrences. Surprisingly little prospective and validated research has 
been performed on clinical predictors of outcome [40]. Furthermore, for some 
complications of CDI, such as ICU admission or death, it is difficult to determine to 
what extent the complication can be attributed to CDI as opposed to the presenting 
acute illness(es) or comorbidities.
 A wide variety of risk factors for severe or recurrent CDI have been suggested 
in literature, which makes it difficult to set a rigid clinical prediction rule [1,25,41–46]. 
Recently, a systematic review was performed to derive and validate clinical rules to 
predict recurrences, complications and mortality [46]. Most studies were found to 
have a high risk of bias because of small sample sizes and much heterogeneity in the 
variables used, except for leucocytosis, serum albumin and age [46]. Bauer et al. 
used a database of two randomized controlled trials, which contained information 
for a large patient group (1105 patients) with CDI, to investigate the prognostic value 
of three markers for severe CDI. They found that both leucocytosis and renal failure 
are useful predictors of a complicated course of CDI, if measured on the day of 
diagnosis [45].
 A recent meta-analysis of two pivotal randomized controlled trials comparing 
fidaxomicin and vancomycin revealed previous vancomycin or metronidazole 
treatment in the 24 h before randomization, low eosinophil count (<0.1 9 109/L) and 
low albumin level to be independent predictors of persistent diarrhoea or death in the 
first 12 days [40]. Recently Miller et al. [36] analysed the same two clinical therapeutic 
trials to derive and validate a categorization system to discriminate among CDI 
patients and correlate the grouping with treatment response. They concluded that a 
combination of five clinical and laboratory variables measured at the time of CDI 
diagnosis, combined into a scoring system, were able to accurately predict treatment 
response to CDI therapy with fidaxomicin and vancomycin. These variables include: 
age, treatment with systemic antibiotics, leucocyte count, albumin and temperature 
(ATLAS).
 C. Strain type has been suggested as an additional cause of excess morbidity, 
disease severity and higher recurrence rates of CDI. In a Canadian study [47], PCR 
ribotype 027 was correlated with more severe disease and fatal outcome among 
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C. C: First recurrence or (risk of) recurrent CDI
D. D: Multiple recurrent CDI
E. Treatment of CDI when oral administration is not possible
The following treatment options are considered:
1. Oral and non-oral antibiotics
2. Toxin-binding resins and polymers
3. Immunotherapy
4. Probiotics
Faecal or bacterial intestinal transplantation
A.  Initial Clostridium difficile infection: non-severe disease
Oral antibiotic therapy for non-severe disease
Evidence. The antibiotics commonly used to treat CDI are oral metronidazole or oral 
vancomycin.
 Oral metronidazole has been shown to be effective in inducing a clinical response 
and has the advantage of low cost and is assumed to be associated with reduced 
vancomycin-resistant enterococci (VRE) selection risk. In a pooled intention-to-treat 
analysis (treating exclusions, deaths and relapses as treatment failures) of three 
randomized controlled trials comparing symptomatic cure between metronidazole 
and vancomycin [77,84,88], no statistically significant differences were found [2,75]. 
Symptomatic cure was achieved in 79% of patients who received vancomycin 
compared with 71% of patients who received metronidazole (three studies; 335 
patients; RR 0.91; 95% CI 0.81–1.03, p 0.14) [2]. However, a recently presented pooled 
analysis of data from two phase three randomized controlled trials on the use of 
tolevamer, comparing resolution of diarrhoea and abdominal pain (clinical success) 
for vancomycin versus metronidazole, showed that overall metronidazole was inferior 
to vancomycin [92]. Vancomycin significantly improved clinical success (81.1% vs 
72.7%; OR 1.681; 95% CI 1.114–2.537; p 0.0134). In addition a retrospective analysis 
of case records of hospitalized patients with CDI showed that the symptomatic 
response time was significantly (p <0.01) shorter in patients treated with vancomycin 
(3.0 days, n = 22) compared with those given metronidazole (4.6 days, n = 28) [23]. 
Oral metronidazole is usually recommended for treatment of non-severe disease, 
whereas oral vancomycin is generally preferred for treatment of severe infections 
[1,3–5].
 Decreased clinical effectiveness of metronidazole treatment for specific ribotypes 
causing CDI, e.g. PCR ribotype 027, has been described [93]. Although changes in 
antibiotic resistance and ribotype prevalence have been reported, in vitro studies 
Treatment of Clostridium difficile infection
Once CDI is diagnosed in a patient, immediate implementation of appropriate 
infection control measures is mandatory to prevent further spread within the hospital. 
These include early diagnosis of CDI, surveillance, education of staff, appropriate use 
of isolation precautions, hand hygiene, protective clothing, environmental cleaning and 
cleaning of medical equipment, good antibiotic stewardship, and specific measures 
during outbreaks. Measures for the prevention and control of CDI (‘bundle approach’) 
have been described in an ESCMID guideline by Vonberg et al. [73].
Additional treatment measures include [1,3,4,72,74]:
• Discontinuation of unnecessary antimicrobial therapy
• Adequate replacement of fluid and electrolytes
• Avoidance of anti-motility medications
• Reviewing proton pump inhibitor use
In general it is difficult to compare studies on the treatment of CDI because of the use 
of variable diagnostic criteria, patient selection and subgroup definitions, stringency 
of searches for potential enteropathogens, severity of CDI, comorbidities, exposures 
to causative or concomitant antibiotics, and follow up. Moreover, studies have 
employed different definitions of clinical and/or microbiological cure and recurrence 
[2,75]. The variability in definitions and criteria of randomized controlled trials of 
antibiotic therapy for CDI is illustrated in Table 7. In 13/17 randomized controlled trials 
of antibiotic treatment of initial CDI, recurrences and duration of follow up were 
defined. Follow up varied from 3 to 6 weeks after treatment for CDI. In 6/17 randomized 
controlled trials definitions for severity of disease were given. In most of the studies 
very severe and/or life-threatening CDI was excluded.
 A Cochrane analysis published in 2011 reviewed 15 studies on the antibiotic 
treatment for CDI in adults [2]. The risk of bias was rated high in 12 of the 15 included 
studies. The authors concluded that a specific recommendation for the antibiotic 
treatment of CDI could not be made. Nevertheless, and in spite of the observed 
limitations, it is apparent that a clear and up-to-date guideline on the treatment of 
CDI is urgently needed for clinical practice. For this purpose the strength of a 
recommendation and the quality of evidence are assigned in two separate evaluations 
in this guideline, hence allowing an assessment of the strength of a recommendation 
independent of the level of supportive evidence (Tables 1 and 2).
To improve clinical guidance in the treatment of CDI, treatment recommendations are 
specified for various patient groups:
A. Initial CDI: non-severe disease
B. Severe CDI
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after resolution of diarrhoea. It was concluded that the frequency of VRE contamination 
of skin or the environment was similar between patients treated with metronidazole (n 
= 17) and those given vancomycin (n = 17), although the study clearly had only 
limited power to examine this issue [102]. In a large retrospective analysis, increased 
vancomycin use during an outbreak of CDI was not associated with an increase in 
VRE colonization during a follow-up period of 2 years after the outbreak period [103]. 
The authors concluded that restriction of vancomycin use during CDI outbreaks 
because of the fear of increasing VRE colonization might not be warranted. However, 
the interpretation of the data was complicated by an outbreak of VRE (VanA) cases 
that was observed after approximately 20 months of increasing preferential use of 
vancomycin. As the rate of VanA cases subsequently decreased very quickly, the 
investigators concluded that this temporary increase reflected a localized clonal 
outbreak unrelated to the CDI therapy at that time [103].
 Although vancomycin and metronidazole are effective in the treatment of CDI, 
they are both broader-spectrum agents that cause significant disruption of the 
commensal colonic microbiota. A disruption in the commensal microbiota may 
predispose to recurrent CDI and intestinal colonization by health- care-associated 
pathogens such as VRE and Candida species. Fidaxomicin appears to cause less 
disruption of the anaerobic colonization microbiota, and has activity against many 
VRE strains [104] so it is suggested that the risk of colonization with and transmission 
of VRE associated with fidaxomicin treatment may be lower compared with 
vancomycin therapy. A recent study concluded that fidaxomicin was indeed less 
likely than vancomycin to promote acquisition of VRE and Candida species during 
CDI treatment. However, selection of pre-existing subpopulations of VRE with 
elevated fidaxomicin MICs was more common during fidaxomicin therapy [105].
 Similar cure rates have been demonstrated for oral vancomycin and oral 
teicoplanin [82,84]. For bacteriological cure, oral teicoplanin may even be more 
effective than vancomycin [2,82]. Both glycopeptides are active in vitro against C. 
difficile isolates [106]. Since 2013 teicoplanin does have a licensed indication for CDI 
and is available for oral administration. Teicoplanin is not available in the USA. For the 
purpose of this treatment guideline only oral vancomycin is included in the treatment 
recommendations.
Tables 8 and 9 report the evidence for oral treatment of initial CDI from randomized 
trials and observational studies with comments on methodology.
 Although oral metronidazole absorption is very high and potentially can lead to 
more systemic side-effects, adverse effects of oral metronidazole are commonly mild 
to moderate in severity. The most common adverse reactions reported involve the 
gastrointestinal tract [107]. Rarely, particularly in association with long duration 
therapy, metronidazole has been linked to more severe safety issues, e.g. peripheral 
and optic neuropathy [108] and interactions with warfarins [109].
indicate that MICs of metronidazole and vancomycin for endemic C. difficile have 
remained relatively low over the years. Brazier et al. concluded that the MICs of 
metronidazole and vancomycin were not indicative of clinical failure, but MICs for 
epidemic ribotypes (027, 106 and 001) were several dilutions higher [94]. Indeed 
there is increasing evidence of the emergence of reduced susceptibility to 
metronidazole in some C. difficile strains, with evidence for clonal spread [95]. 
Notably, MIC methodology is crucial to the detection of reduced susceptibility to 
metronidazole; E-tests in particular underestimate the MIC [95,96]. There is also 
evidence of inferior microbiological efficacy of metronidazole in comparison with 
vancomycin [21,22]. Although poor gut concentrations of metronidazole alongside 
reduced susceptibility to metronidazole could explain reduced treatment efficacy, 
treatment failures have not been associated with decreased susceptibility [95,97,98]. 
A case–control study found no significant differences in clinical outcome for 
CDI cases from which strains with reduced susceptibility to metronidazole were 
recovered versus matched (metronidazole-susceptible) controls [99]. Response to 
metronidazole was generally poor (slow and prone to recurrence) and the frail elderly 
patients had a 21% 30-day mortality. However, much larger study groups are needed 
to determine the clinical significance of CD isolates with reduced susceptibility to 
metronidazole [99].
 Orally administered vancomycin is poorly absorbed from the gastrointestinal 
tract, and therefore luminal drug levels are high and orders of magnitude are greater 
than the susceptibility breakpoint concentration for all strains of C. difficile tested so 
far, thereby resulting in a more rapid suppression of C. difficile to undetectable levels 
during therapy and faster resolution of diarrhoea [22,23]. Metronidazole, on the other 
hand, is well absorbed from the gastrointestinal tract. Mean antibiotic concentrations 
reported in faeces of patients receiving oral metronidazole range from <0.25 to 9.5 
mg/L, and drug concentrations in faeces decrease to undetectable levels as mucosal 
inflammation improves and diarrhoea resolves [100]. Increased MIC for metronidazole 
could therefore have implications on clinical cure or recurrences in CDI. Although 
there are no published reports in which treatment failure has been linked to 
antimicrobial metronidazole resistance in C. difficile, the pharmacokinetic properties 
of vancomycin are considered superior to those of metronidazole in severe C. difficile 
disease [88].
 There is concern that use of vancomycin may be more likely to promote 
colonization and transmission of VRE by selection pressure. However, both oral 
metronidazole and oral vancomycin have been associated with the promotion of 
persistent overgrowth of VRE in stool samples obtained from colonized patients 
during CDI treatment, thereby increasing the risk of transmission [101]. In a small 
study of VRE-colonized patients with CDI, who experienced frequent faecal 
incontinence, skin and environmental VRE contamination was common during and 
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Tabel 8  Randomized controlled trials of oral antibiotic treatment of initial 
Clostridium difficile infection (CDI). Initial cure rate, and sustained 
response rates as a percentage of all patients and relapse rate  
as a percentage of initially cured patients.
Trial Treatment Number  
of patients





[76] vancomycin  
125 mg qid, 5 days
9 78 0 78
placebo 7 14 - -
No clear case definition. No description of allocation of treatment. Only data of patients with toxin-positive 
stool shown. Unclear length of follow-up and incidence or relapse in placebo group. p < 0.02 for comparison 
of cure rates.
[77] vancomycin 
500 mg qid, 10 days
32 100 19 81
metronidazole 250 mg qid, 
10 days
32 97 6 91
Only data of patients with toxin-positive stools or pseudomembranous colitis shown. Per-protocol analysis. 
Follow-up 21 days. Differences not statistically significant.
[78] vancomycin 
125 mg qid, 7 days
21 86 33 58
bacitracin 20000 U qid,  
7 days
21 76 42 44
Double-blind. 25% drop-out during follow-up of bacitracin group. Follow-up 5 weeks. Differences not 
statistically significant.
[79] vancomycin 
500 mg qid, 10 days
15 100 20 80
bacitracin 
25000 U qid, 10 days
15 80 42 46
Double-blind. Patients had leukocytosis, fever or abdominal pain. 29% drop-out in vancomycin group, 12% 
in bacitracin group. Per-protocol analysis. Unclear definition of failure (‘worsening during treatment’). Failing 
patients crossed over to alternate drug. Interruption of study drug in vancomycin group for a mean of 2.8 
days and in bacitracin group for a mean of 1.8 days. Unclear length of follow-up. Differences not statistically 
significant.
[80] vancomycin 
125 mg qid, mean 10.6 days
24 100 21 79
vancomycin 
500 mg qid, mean 10.1 days
22 100 18 82
Variable duration of therapy. 18% dropout rate. Per-protocol analysis. Unclear length of follow-up. Differences 
not statistically significant.
[81] vancomycin 
500 mg bid, 10 days
10 100 - -
rifaximin 
200 mg tid, 10 days
10 90 - -
Article in Italian. Patients had diarrhoea, abdominal pain and fever. No description of allocation of treatment. 
Unclear definition of cure. Differences not statistically significant.
Tabel 8  Continued.
Trial Treatment Number  
of patients






500 mg qid, 10 days
20 100 20 80
teicoplanin 
100 mg bid, 10 days
26 96 8 88
No description of allocation of treatment. Per-protocol analysis. Unclear length of follow-up (‘at least 1 month’). 
Differences not statistically significant.
[83] teicoplanin 
100 mg qid, 3 days, followed 
by 100  mg bid, 4 days
24 96 35 62
teicoplanin 
100 mg bid, 7 days
23 70 50 35
Double-blind. Outcome of ‘improvement, but not cure’ (2 loose stools per day or 1 loose stool per day with 
fever or cramps) was counted as failure. 3 patients with improvement in bid group; 1 in qid group. Follow-up  
5 weeks. p = 0.08 for comparison of cure rates.
[84] vancomycin 
500 mg tid, 10 days
31 94 17 78
metronidazole  
500 mg tid, 10 days
31 94 17 78
teicoplanin 
400 mg bid, 10 days
28 96 7 89
fusidic acid 
500 mg tid, 10 days
29 93 30 65
Follow-up 30 days. Only statistically significant difference was relapse rate of fusidic acid versus teicoplanin 
(p = 0.042).
[85] metronidazole  
400 mg tid, 7 days
55 93 30 65
fusidic acid 
250 mg tid, 7 days
59 83 30 58
Double-blind. 13% drop-out during treatment; 15% further drop-out during follow-up. Per-protocol analysis. 
Follow-up 35 days. Differences not statistically significant.
[86] metronidazole  
250 mg qid, 10 days
34 82 30 57
nitazoxanide 
500 mg bid, 7 days
40 90 26 67
nitazoxanide 
500 mg bid, 10 days
36 89 16 75
No definition of relapse. Double-blind. 23% drop-out during treatment. Per-protocol analysis. Follow-up 31 days. 
Differences not statistically significant.
[87] metronidazole  
500 mg tid, 10 days
20 65 38 40
metronidazole
500 mg tid + rifampicin  
300 mg bid, 10 days
19 63 42 37
Intention-to-treat analysis. Follow-up 40 days. Differences not statistically significant.
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Tabel 8  Continued.
Trial Treatment Number  
of patients






125 mg qid, 10 days
71 97 7 90
metronidazole  
250 mg qid, 10 days 
79 84 14 72
Double-blind. 13% drop-out during treatment. Per-protocol analysis. Follow-up 21 days. p = 0.006 for 
comparison of cure rates. p = 0.27 for comparison of relapse rates. The original protocol was stratified in a 
group with mild and a group with severe disease (based on age, fever, albumin level and leukocyte count), 
which resulted in a larger difference between cure rates in the group with severe disease and a statistically 
non-significant difference between cure rates in the group with mild disease. Intention-to-treat analysis with 
dropouts regarded as failures resulted in a statistically significant difference between overall cure rates (initial 
cure minus relapse; 57 out of 90 versus 64 out of 82; risk  ratio 0.91). Other comparisons were not significant 
anymore in the intention-to-treat analysis.
[89] fidaxomicin 
50 mg bid, 10 days
14 71 8 65
fidaxomicin 
100 mg bid, 10 days
15 80 0 80
fidaxomicin 
200 mg bid, 10 days
16 94 6 88
Open-label.  Patients with signs of highly severe CDI (> 12 bowel movements per day, vomiting, severe 
abdominal tenderness, ileus, WBC > 30, toxic megacolon) were excluded. Cure = complete resolution of 
diarrhoea. Follow-up 6 weeks after end of treatment.
[90] vancomycin 
125 mg qid, 10 days
27 74 7 69
nitazoxanide 
500 mg bid, 10 days
22 77 5 73
CDI = stool EIA for toxin A or B positive AND (temperature > 38.3 ºC OR abdominal pain OR leukocytosis). 
Patients with > 1 episode in preceding 6 months were excluded. 12% dropout rate during treatment. Double-
blind, placebo-controlled. Modified intention-to-treat analysis. Industry-sponsored. Cure = complete resolution 
of symptoms during 3 days after completion of therapy. Per-protocol analysis: 87 vs. 94% cure. Follow-up 31 
days after start of treatment. No differences in severity subgroups. Differences not statistically significant.
[70] vancomycin 
125 mg  qid, 10 days
309 86 25 65
fidaxomicin  
200 mg bid, 10 days
287 88 15 75
Placebo-controlled. Industry-sponsored. Very severe CDI and more than one previous episode excluded. 
Designed as non-inferiority trial. 4 weeks follow-up for recurrences after completion of study drug. Cure = < 
4 times daily passage of unformed stools AND no necessity for additional treatment. Fidaxomicin was not 
associated with fewer recurrences in CDI due to PCR ribotype 027 as opposed to  non-027. Modified intention-
to-treat (patients who received at least one dose of the study drug) and per-protocol analyses were similar.
[91] vancomycin 
125 mg  qid, 10 days
257 87 27 64
fidaxomicin  
200 mg bid, 10 days
252 88 13 77
Methods identical to the trial by Louie [32]. Contrary to that trial, this trial did show fewer recurrences in both 
PCR ribotype 027 and non-027 patients, although the difference was not significant for the former subgroup.
Tabel 9  Observational studies of oral antibiotic treatment of initial Clostridium 
difficile infection (CDI). Initial cure rate and sustained response as a 
percentage of all patients and relapse rate as a percentage of initially 
cured patients








[113] vancomycin 79 96 14 83
[114] vancomycin 16 100 13 87
[115] metronidazole 13 100 15 85
[116] vancomycin 189 97 24 74
[106] vancomycin  
500 mg qid, 10 days
23 100 13 87
teicoplanin  
200 mg bid, 10 days
22 100 0 100
[117] metronidazole 632 98 6 92
vancomycin 122 99 10 89
[57] metronidazole 44 ? 50 -
[118] metronidazole 99 62 ? -
[119] metronidazole 207 78 28 56
[68] metronidazole 1123 84 29 60
vancomycin 112 ? 28 -
[120] fidaxomicin  
varying dose
45 91 5 86
[121] nitazoxanide  
500 mg bid, 10 days
35 74 27 54
Patients first failed metronidazole.
[101] metronidazole* 34 >90 12 >79
*Ten patients switched to vancomycin.
vancomcyin 18 >90 11 >80
[122] tigecycline varying 
duration
4 100 0 100
Severe CDI. Follow-up at least 3 months.
[123] rifaximin 400 mg tid 8 100 10 90
2 weeks follow-up.
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 Oral vancomycin has been shown to be poorly absorbed in most patients, 
usually producing minimal or subtherapeutic serum concentrations. However, bowel 
inflammation may enhance absorption of oral vancomycin, particularly in those with 
renal failure, thereby increasing the risk for systemic side-effects [110]. A recently 
performed safety analysis of fidaxomicin in comparison with oral vancomycin 
revealed no differences in serious adverse events between these agents [111]. 
Fidaxomicin is minimally absorbed. While no specific concerns related to hypersen-
sitivity reactions were identified during the drug development, hypersensitivity 
reactions associated with fidaxomicin use have been reported to the FDA in the 
post-marketing phase. The fidaxomicin labeling was revised to include information 
about the possibility of hypersensitivity reactions [112].
 To evaluate the clinical outcomes of the main antimicrobial agents used in the 
treatment of CDI, we compared dosages, cure rate, recurrence rate, stated time to 
response and adverse events of treatment with vancomycin, metronidazole and 
fidaxomicin. Only randomized controlled trials of antibiotic treatment of initial CDI 
were included. Results are summarized in Table 10.
Recommendations. In case of non-severe CDI (no signs of severe colitis) in 
non-epidemic situations and with CDI clearly induced by the use of antibiotics, it may 
be acceptable to stop the inducing antibiotic and observe the clinical response for 
48 h, but patients must be followed very closely for any signs of clinical deterioration 
and placed on therapy immediately if this occurs. Metronidazole is recommended 
as oral antibiotic treatment of initial CDI in mild/moderate disease. For detailed 
 recommendations on oral antibiotic treatment of initial non-severe CDI refer to Table 11.
Alternative treatment regimens treatment for non-severe disease
Evidence. Tables 12 and 13 report the evidence from randomized trials and 
observational studies on the non-antibiotic treatment of initial CDI, with comments on 
methodology. The majority of these alternative treatment strategies are combined 
with antibiotic treatment. Currently there are no randomized controlled trials on the 
use of human intravenous gammaglobulins (IVIG). Passive immunizations with IVIG 
have been reported to be successful in small case series, but the grade of evidence 
and strength of recommendation of IVIG are too weak to allow recommendations on 
the use of IVIG in CDI [4,130]. Hypogammaglobulinaemia, e.g. following solid organ 
transplants, may predispose to CDI. For this subgroup of patients, IVIG may be 
beneficial, but more studies are needed before this can be recommended definitively [4]. 
A recent systematic review on the use of probiotics suggests that probiotics are 
associated with a reduction in antibiotic-associated diarrhoea [131]. A recent meta- 
analysis on probiotic prophylaxis for CDI, concluded that moderate-quality evidence 
suggests a beneficial effect of probiotic prophylaxis in CDI without an increase in 
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that there was insufficient evidence to recommend probiotics, in general, as an 
adjunct to antibiotics in the treatment of C. difficile diarrhoea [133]. Although no cases 
of translocation of microorganisms have been reported in clinical trials with probiotics 
for antibiotic-associated diarrhoea or CDI, probiotics should be used with caution. 
Several studies of invasive disease have been reported, resulting from the use of 
probiotics such as Saccharomyces boulardii in debilitated or immuno compromised 
patients [134,135]. Moreover, probiotics were associated with increased mortality, partly 
due to non-occlusive mesenteric ischaemia, in a randomized controlled trial in acute 
pancreatitis [136].
Recommendations. There is insufficient evidence to support administration of 
probiotics, toxin-binding resins and polymers, or monoclonal antibodies. For detailed 
recommendations refer to Table 14.
B: Severe Clostridium difficile Infection
Oral antibiotic therapy
Evidence. In 6/17 randomized controlled trials, severity of disease was defined. 
Definitions varied among the studies. Only in 4/6 of these trials were treatment results 
specified for severity of disease (Table 15).
 Recommendations. Based on its pharmacokinetic properties vancomycin is 
considered superior to metronidazole in severe C. difficile disease [22,88]. The use of 
high doses of vancomycin (500 mg orally four times daily) was included in the 
Infectious Diseases Society of America/Society for Healthcare
 Epidemiology of America treatment guidelines [3] for management of severe 
complicated CDI as defined by the treating physician. However, there is insufficient 
evidence to the use of doses >125 mg four times daily in the absence of ileus [80].
 Fidaxomicin was not inferior to vancomycin for initial cure of CDI, but there are no 
data available on the efficacy of this drug in severe life-threatening disease [70,91]. 
For detailed recommendations on oral antibiotic treatment of severe CDI refer to 
Table 16.
Surgery for complicated Clostridium difficile infection
Evidence. Patients with fulminant CDI who fail to respond and who progress to 
systemic toxicity, peritonitis, or toxic colonic dilatation and bowel perforation require 
surgical intervention [4]. Mortality rates of emergency surgery in complicated CDI 
remain high, ranging from 19% to 71% depending on the clinical condition of the 
patient at the time of surgery [138]. However, recently as systematic review of the 
existing literature was performed to assess the effect on mortality of colectomy for the 
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C:  First Recurrence or (Risk of) recurrent  
Clostridium difficile infection
Oral antibiotic therapy
Evidence. In 3/17 randomized controlled trials of antibiotic treatment of initial CDI, 
results were specified for CDI before the study (Table 17).
Recommendations. The incidence of a second recurrence after treatment of a first 
recurrence with oral metronidazole or vancomycin is similar. Fewer secondary 
recurrences with oral fidaxomicin as compared with vancomycin after treatment of a 
first recurrence are reported [70,91,144]. However, the evidence on fidaxomicin for 
this specific subgroup of CDI patients is limited to two phase III studies and based on 
a retrospective subset analysis of data and a limited number of patients (number of 
patients in the modified intention-to-treat analysis: fidaxomicin n = 79 and vancomycin 
n = 80) [144]. There are no prospective randomized controlled trials performed with 
metronidazole, vancomycin or fidaxomicin in this specific patient group. In addition, 
fidaxomicin was not associated with fewer recurrences in CDI due to PCR ribotype 
027 as opposed to non-027 in one of the randomized controlled trials [70]. Therefore, 
based on the evidence currently available, the Strength of Recommendation for 
treating a first recurrence of CDI with oral vancomycin or oral fidaxomicin is considered 
equal (B-I), unless disease has progressed from non-severe to severe.
 For detailed recommendations on oral antibiotic treatment of mild/moderate 
initial CDI with risk for recurrent CDI or a first recurrence refer to Table 18.
D: Multiple recurrent Clostridium difficile infection
Antibiotic and non-antibiotic treatment strategies
Evidence. Tables 19 and 20 report the evidence from randomized trials and 
observational studies with comments on methodology.
Recommendations. In non-severe second (or later) recurrences of CDI oral 
vancomycin or fidaxomicin is recommended. Vancomycin and fidaxomicin are 
equally effective in resolving CDI symptoms, but fidaxomicin has been shown to be 
associated with a lower likelihood of CDI recurrence after a first recurrence [104,144]. 
However, there are no prospective randomized controlled trials investigating the 
efficacy of fidaxomicin in patients with multiple recurrences of CDI. Vancomycin is 
preferably administered using a tapered and/or pulsed regimen.
 Recently the first randomized controlled trial on faecal enteric instillation has 
been published: faecal transplantation following antibiotic treatment with an oral 
glycopeptide is reported to be highly effective in treating multiple recurrent CDI [145]. 
For detailed recommendations on treatment regimens of multiple recurrent CDI refer 
to Tables 21 and 22.
a lower mortality than continued medical treatment when this is no longer improving 
the patient [139]. Several studies suggest that earlier colectomy (time from presentation 
to surgery) is associated with improved survival [140]. Independent risk factors for 
mortality in patients who underwent colectomy that have been found among multiple 
studies include: the development of shock (need for vasopressors), increased serum 
lactate (≥5 mM), mental status changes, end organ failure, renal failure and the 
need for preoperative intubation and ventilation [29,35,138,141,142]. The more negative 
prognostic signs a patient has, the earlier surgical consultation and operative 
management should be considered. The established operative management of 
severe, complicated CDI has been subtotal colectomy with end-ileostomy [140]. 
However, recently an alternative surgical treatment with creation of a diverting loop 
ileostomy, followed by colonic lavage, has been shown to reduce morbidity and 
mortality, while preserving the colon. The surgical approach involves the laparoscopic 
creation of a diverting loop ileostomy. The colon is then lavaged in an ante-grade 
fashion through the ileostomy with a high volume of polyethylene glycol 3350 or 
balanced electrolyte solution and the effluent is collected via a rectal drainage tube. 
A catheter is placed in the efferent limb of the ileostomy to deliver vancomycin flushes 
in an antegrade fashion in the postoperative period. In addition, patients receive 
intravenous metronidazole for 10 days [143]. A multicentre randomized controlled trial 
is currently being conducted to provide level I evidence for possible implementation of 
this new treatment into standard practice [http://clinicaltrials.gov/show/ NCT01441271].
Recommendations. Total abdominal colectomy should be performed to treat CDI in 
case of
• Perforation of the colon
• Systemic inflammation and deteriorating clinical condition despite maximal antibiotic 
therapy; this includes the clinical diagnoses of toxic megacolon, acute abdomen and 
severe ileus. Colectomy should preferably be performed before colitis becomes very 
severe. Serum lactate may, inter alia, serve as a marker for severity (operate 
before lactate exceeds 5.0 mM).
A future alternative to colectomy may be diverting loop ileostomy and colonic lavage, 
combined with antibiotic treatment (intracolonic antegrade vancomycin and intravenous 
metronidazole).
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E:  Treatment of Clostridium difficile infection when 
oral administration is not possible
Evidence. Metronidazole remains the only parenteral antibiotic therapy supported by 
case series [192]. Intravenous metronidazole (500 mg intravenous three times daily) 
may be added to oral vancomycin, if the patient has ileus or significant abdominal 
distension [4,44]. However, there are no randomized controlled trials available to 
guide this recommendation.
 It is still unknown how to best treat patients with ileus due to CDI. There are some 
anecdotal reports on delivery of vancomycin to the gut by means other than orally, 
mainly through intracolonic delivery. Questions regarding the efficacy, optimal dosing 
and duration of treatment with intracolonic vancomycin remain unanswered [193,194]. 
Prospective clinical trials with other antibiotics, like tigecycline, have not yet been 
performed to support general use [122,195].
Recommendations. When oral treatment is not possible, parenteral metronidazole 
is recommended, preferably combined with intracolonic or nasogastric administration 
of vancomycin. Parenteral tigecycline as salvage therapy is only recommended with 
marginal strength. For detailed recommendations refer to Table 23.
Summary of definitions
Episode of CDI. A clinical picture compatible with CDI and microbiological evidence 
of free toxins and the presence of C. difficile in stool, without reasonable evidence of 
another cause of diarrhoea.
or
Pseudomembranous colitis diagnosed during endoscopy, after colectomy or on 
autopsy.
Clinical pictures compatible with CDI.
Diarrhoea: loose stools, i.e. taking the shape of the receptacle or corresponding to 
Bristol stool chart types 5–7, plus a stool frequency of three stools in 24 or fewer 
consecutive hours, or more frequently than is normal for the individual.
 Ileus: signs of severely disturbed bowel function such as vomiting and absence 
of stool with radiological signs of bowel distension.
 Toxic megacolon: radiological signs of distension of the colon (>6 cm in transverse 
width of colon) and signs of a severe systemic inflammatory response.
Severe CDI. Severe or life-threatening CDI is defined as an episode of CDI with (one 
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B: Severe Clostridium difficile infection
Oral antibiotic treatment
Vancomycin orally 125 mg four times daily for 10 days (A-I)
Fidaxomicin orally 200 mg twice daily for 10 days (B-I)
Notes:
• It can be considered to increase the vancomycin dosage to 500 mg four times 
daily for 10 days (B-III)
• There is no evidence that supports the use of fidaxomicin in life-threatening CDI 
(D-III)
The use of oral metronidazole in severe CDI or life-threatening disease is strongly 
discouraged (D-I).
Surgical treatment
Total abdominal colectomy with ileostomy should be per- formed in case of:
• Perforation of the colon
• Systemic inflammation and deteriorating clinical condition not responding to 
antibiotic therapy; including toxic mega- colon, an acute abdomen and severe 
ileus.
Surgical treatment should preferably be performed before colitis becomes very 
severe. Serum lactate may, inter alia, serve as a marker for severity (operate before 
lactate exceeds 5.0 mM).
 A future alternative to colectomy may be diverting loop ileostomy and colonic 
lavage, combined with antibiotic treat- ment (intracolonic antegrade vancomycin and 
intravenous metronidazole).
C:  First recurrence or (risk of) recurrent  
Clostridium difficile infection
Oral antibiotic treatment
Fidaxomicin orally 200 mg twice daily for 10 days (B-I) Vancomycin orally 125 mg four 
times daily for 10 days (B-I) Metronidazole orally 500 mg three times daily for 10 days 
(C-I)
Note: Fidaxomicin was not associated with fewer recurrences in CDI due to PCR 
ribotype 027 as opposed to non-027 ribotypes.
disease, with significant systemic toxin effects and shock, resulting in need for ICU 
admission, colectomy or death.
 One or more of the following unfavourable prognostic factors can be present 
without evidence of another cause:
• Marked leucocytosis (leucocyte count >15 9 10 /L)
• Decreased blood albumin (<30 g/L)
• Rise in serum creatinine level (≥133 lM or ≥1.5 times the premorbid level)
Recurrent CDI. Recurrence is present when CDI re-occurs
<8 weeks after the onset of a previous episode, provided the symptoms from the 
previous episode resolved after completion of initial treatment.
Treatment response. Treatment response is present when after therapy either stool 
frequency decreases or stool consistency improves and parameters of disease severity 
(clinical, laboratory, radiological) improve and no new signs of severe disease develop.
 Treatment response should be observed daily and evaluated after at least 3 
days, assuming that the patient is not worsening on treatment. Treatment with 
metronidazole, in particular, may result in a clinical response only after 3–5 days. 
After clinical response, it may take weeks for stool consistency and frequency to 
become entirely normal.
Summary of treatment recommendations
Strength of Evidence (SoE: I to III) and Strength of Recommendation (SoR: A to D) are 
shown in brackets. For grading definitions we refer to Tables 1 and 2.
A: Initial Clostridium difficile infection: non-severe disease
Non-antibiotic treatment
In non-epidemic situations and with (non-severe) CDI clearly induced by the use of 
antibiotics, it may be acceptable to stop the inducing antibiotic and observe the 
clinical response for 48 h, but patients must be followed very closely for any signs of 
clinical deterioration and placed on therapy immediately if this occurs. (C-II).
Oral antibiotic treatment
Metronidazole orally 500 mg three times daily for 10 days (A-I)
Vancomycin orally 125 mg four times daily for 10 days (B-I) Fidaxomicin orally 200 mg 
twice daily for 10 days (B-I)
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D: Multiple recurrent Clostridium difficile infection
Oral antibiotic treatment
Fidaxomicin orally 200 mg twice daily for 10 days (B-II) Vancomycin orally 125 mg 
four times daily for 10 days followed by pulse strategy (B-II)
or
Vancomycin orally 125 mg four times daily for 10 days followed by taper strategy (B-II)
Non-antibiotic treatment in combination with oral antibiotic treatment
For multiple recurrent CDI unresponsive to repeated antibiotic treatment, faecal 
transplantation in combination with oral antibiotic treatment is strongly recommended 
(A-I).
E:  Treatment of Clostridium difficile infection when 
oral administration is not possible
Antibiotic treatment
Non-severe CDI: intravenous metronidazole 500 mg three times daily for 10 days 
(A-II).
 Severe CDI: intravenous metronidazole 500 mg three times daily for 10 days 
(A-II) combined with vancomycin retention enema 500 mg in 100 mL normal saline 
four times daily intracolonic, or combined with vancomycin 500 mg four times daily 
by oral/nasogastric tube for 10 days (B-III).
 A schematic overview of currently available therapeutic regimens for CDI, 
including the quality of evidence (QoE: I to III) and strength of recommendations 
(SoR: A to D) are shown in Fig. 1.
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Summary and general discussion
Clostridium difficile, originally named after the difficulty in isolating and characterizing 
it [1], has proved to be a difficult pathogen indeed, because it has posed us for a 
number of problems, even more so during the past decade. The importance of 
various possible sources and transmission routes and the role of asymptomatic 
carriers are unclear as yet, as are the driving forces behind the emergence and 
spread of new strains. Some of these strains seem capable of spreading more 
efficiently, which may in part overlap with a higher virulence. Higher virulence may 
offer an evolutionary advantage to the bacterium if it results in more cases of refractory 
disease or recurrences, with ongoing shedding of large amounts of the bacterium 
and inherent infectiousness. Furthermore, it is currently difficult to identify those 
patients with a high risk of recurrence and modify management strategies accordingly. 
The studies described in the preceding chapters aimed to contribute to solving these 
problems. 
In the following paragraphs, the chapters will summarized in numerical order, with a 
discussion after the summary of each chapter. Chapters 1,2, 3 and 4 concern the 
epidemiology of C. difficile strains. Chapters 5 and 6 concern the prediction of an 
unfavorable outcome of CDI, particularly recurrence. Chapters 7, 8 and 9 concern the 
treatment of CDI.
Although C. difficile is a ubiquitous microorganism, which may be found in the 
environment, animals and food, its prevalence is thought to be so much higher in 
healthcare facilities that for a long time, acquisition of CDI was thought to occur 
almost exclusively during or shortly after admission to such facilities. The high 
incidence of CDI in healthcare facilities as compared to the community presumably 
results from the high density of individuals prone to CDI, typically elderly patients with 
comorbidity, who may serve as a reservoir in which C. difficile can multiply. However, 
it is increasingly realized that CDI may be acquired outside of healthcare facilities. 
Chapters 1 and 2 concern community-onset CDI. In chapter 2, we describe a study 
that investigated how often one of the large clostridial toxins was found in feces 
collected from diarrheic patients and submitted to regional diagnostic microbiologi-
cal laboratories by general practitioners. These feces were submitted for various mi-
crobiological diagnostics, most often parasitological testing according to the Dutch 
general practitioners’ guidelines. We demonstrated toxin in the feces of 1.5% of 
patients. The study was not designed for optimal recovery of the bacterium itself from 
the feces, but in a large majority of cases, culture was positive as well. Many different 
strains were encountered, but not – strikingly – the epidemic PCR ribotype 027, in 
spite of the fact that hospital outbreaks with this strain had occurred in these regions 
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Swedish study [14]. A hospital-based study in The Netherlands [15], conducted in 
2005, found 20% of 81 CDI cases to be community-onset without hospitalization in 
the preceding four weeks. After the implementation of a state-wide surveillance 
system in Connecticut in 2006, 60% of 400 evaluable community-onset CDI cases 
reported that year by acute-care hospitals met the definition of community-acquisi-
tion, i.e. no admissions to healthcare facilities in the previous three months [16]. 
Because of the above-mentioned methodological problems, it is difficult to calculate 
incidence rates from these figures. A study based on the United Kingdom General 
Practice Research Database [17] evaluated the incidence of community-acquired 
CDI (not hospitalized the previous year), using the number of inhabitants registered 
with general practitioners providing data for this database as a denominator. From 
1994 to 2004, the incidence rose from 0 to 18 per 100,000 persons per year. However, 
the fundamental problem of selection bias remains. When do GPs decide to perform 
diagnostics for a case of diarrhea and when do they specifically test for CDI? Two 
studies tried to address the latter problem by testing stool samples submitted by 
general practitioners irrespective of the requested diagnostic test. The first study [18] 
showed 9.2% of 703 stool samples from individual patients to be toxin EIA-positive; 
53% of these patients had not been hospitalized in the previous four weeks. In the 
second study [19], stool samples submitted by GPs to two microbiological labs were 
randomly selected for testing with cytotoxicity assay. Of 2000 samples, 2.1% were 
cytotoxin-positive and 45% of the corresponding patients had been hospitalized in 
the previous six months. The findings of this last study were remarkably similar to 
those of our study. 
 Few other studies into community-associated CDI used typing strategies. 
Contrary to our findings, the Swedish studies [13, 14] found similar distributions of 
PCR ribotypes among nosocomial and community-acquired cases. Farm animals 
are obvious candidates for a reservoir, since C. difficile may be a commensal and 
pathogen in animals and farm animals are often exposed to antibiotics. Spores might 
be spread either by direct contact with animals and their stools or by consumption of 
contaminated meat. Several studies have demonstrated the presence of C. difficile in 
animal faeces and meat. Evidence for farm animals as a reservoir may come from 
epidemiological associations and typing studies. Wilcox et al. [19] found the incidence 
of community-onset CDI to be slightly higher in the urban area that was investigated 
than in the semi-rural area, whereas in our study, the proportion of positive stool 
samples was highest in the more rural part. In both an earlier Australian study [6] and 
our study, there were no patients who reported contact with farm animals. However, 
in the more rural part of the Netherlands, four out of 10 infections in which PCR 
ribotyping could be performed were caused by PCR ribotype 078, whereas this 
ribotype was found in neither of the other regions. This ribotype is frequently found in 
farm animals and has been associated with community-associated CDI in another 
[2]. Some of the other PCR ribotypes may be considered highly endemic in hospitals 
or emerging, notably PCR riboptype 078 which was found in four patients, but other 
strains were rare and not linked to hospitals. The latter finding was supported by the 
finding that a large number of cases could not be linked to healthcare facilities. 
Enzyme immunoassays were used to demonstrate the toxin, which had the 
disadvantage of suboptimal sensitivity, but the advantage of a higher chance that 
these findings represented CDI and not asymptomatic carriage. This was especially 
important, since other enteropathogens were not systematically ruled out. Another 
weakness of this study was selection bias introduced because only feces submitted 
by general practitioners for testing were investigated. The general practitioners’ 
guideline recommends testing when diarrhea is severe or long-lasting. This may 
mean that mild community-onset CDI cases were missed. These cases are probably 
mostly self-limited if they are incited by antibiotics that are subsequently stopped [3]. 
 Several studies have shown a varying proportion of CDI cases to be community- 
acquired, but the definitions of community acquisition differ. Some studies [4-8] did 
not systematically examine previous admissions to healthcare facilities. Other studies 
include a certain period that the patient has not been admitted to a healthcare facility 
in the definition. The Ad Hoc C. difficile Surveillance Working Group [9, 10] advocated 
a division of CDI into healthcare-associated and community-associated CDI. The 
latter is defined as CDI with onset in the community (or in a healthcare facility within 
48 hours after admission) in a patient who has not been discharged from a healthcare 
facility in the previous 12 weeks.  If the patient was discharged between four and 12 
weeks ago, such a case should be classified as being of indeterminate association. 
A further difficulty concerning studies on community-acquired CDI is patient selection. 
The studied patient population may strongly influence the proportion of communi-
ty-acquired CDI and the extrapolated incidence in the community. Estimation of 
incidences may also be hampered by uncertainty of the size of the population from 
which stool samples were collected, e.g. a hospital’s catchment area. Lastly, C. 
difficile cannot always be assumed to be the cause of the diarrhea, since other en-
teropathogens are usually not ruled out systematically and asymptomatic carriage is 
a possibility. In 1995, Karlström et al. [11] found 28% of 1888 CDI cases, defined as 
unique patients with toxin-positive stool samples, from 13 of Sweden’s 31 microbio-
logical laboratories, to be community-acquired, defined as community-onset without 
hospitalization in the preceding four weeks. In the same year, a study in an Irish 
tertiary hospital [12] showed 11% of 73 subsequent new CDI cases (diarrhea with 
positive stool cytotoxicity test) to be community-acquired, which was defined as 
occurring on or within 72 hours of admission without hospitalization in the previous 
60 days. In 1999, a Swedish study [13] found 22% of 267 cases of first episodes of 
CDI to be community-acquired, i.e. without hospitalization in the previous 60 days. A 
year later a similar proportion of community-acquired CDI was found in another 
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was unclear whether this observation is still valid in our era of emerging epidemic C. 
difficile strains. Furthermore, no typing studies have ever been performed and no risk 
factors for C. difficile carriage in CF carriage have been investigated. Interestingly, a 
number of cases of severe colitis due to C. difficile without diarrhea have been 
described in CF patients in recent years [29-31]. In our sample of CF patients from 
one of the CF centers in The Netherlands, we found a high rate of carriage of C. 
difficile, but strikingly, predominantly non-toxigenic strains. Carriage was associated 
with younger age and more-severe CF. PCR ribotypes were multiple and mostly 
non-epidemic. 
 The studies from the 1980s found similarly high rates of C. difficile carriage, but 
only one study found a similarly low proportion of non-toxigenic strains (27%). In two 
of these studies, carriage was strongly associated with antibiotics. In our study, 
antibiotics were associated with carriage, but the association was not statistically 
significant. The majority of CF patients were taking maintenance antibiotics and even 
more had recently received antibiotic therapy, which probably limited statistical power 
to detect an association. 
 Carriage of non-toxigenic C. difficile strains probably protects against colonization 
with toxigenic strains and CDI [32, 33]. These strains circulate in the community [34], 
but carriage was much rarer among the control group of non-CF patients admitted to 
an internal medicine ward. A study aiming to colonize healthy volunteers with 
non-toxigenic C. difficile found that it was only possible to establish enduring 
colonization after administration of antibiotics and repeated doses of non-toxigenic 
C. difficile [35]. This may mean that non-toxigenic strains are able to colonize CF 
patients more efficiently than they do non-CF patients and thus protect CF patients 
against CDI. This might be related to a different composition of colonic mucus or 
microbiome [36]. It may also mean that toxigenic strains have no selective advantage 
over non-toxigenic strains with respect to colonizing the intestines of CF patients, 
because the toxins have less effect in CF patients. This latter theory is supported by 
two of the earlier studies that did find a high proportion of asymptomatic carriage of 
toxigenic strains in CF patients. If CF patients are protected against large clostridial 
toxins, could this, too, be related to the composition of their mucus? Or could CFTR 
be involved in cell entry or cell intoxication by the toxins? A more speculative 
hypothesis is that due to a presumed higher pH in endosomes of CF patients than 
that of non-CF patients [37], the conformational change TcdB needs to make in order 
to cleave itself is inhibited. Elevating the pH of cell organelles protects cells against 
the effect of large clostridial toxins in vitro [38, 39], a finding that we have replicated 
with 3T3 cells and chloroquine (unpublished data). The fact that CF patients are 
protected against secretory diarrhea (e.g., caused by Vibrio cholerae or enterotoxi-
genic E. coli) by their defective CFTR [40] seems insufficient to explain their low 
incidence of CDI, as secretion plays only a minor role in the pathophysiology of CDI, 
Dutch study [20]. Multilocus variable number tandem repeat analysis of PCR-ribotype 
078 isolates in this study revealed four clonal complexes to which both porcine and 
human strains belonged.
 Infants, who have been shown to be frequent asymptomatic carriers [21-23], 
have also been suggested as a community reservoir for C. difficile. Interestingly, 
Wilcox et al [19] showed contact with infants up to two years of age to be significantly 
associated with community-onset CDI, when cases were compared to age-matched 
controls with community-onset diarrhea due to other causes (crude OR 8.2).
 Although many patients with community-acquired CDI fulfill the classical risk 
profile, some appear to be younger with less comorbidity and, strikingly, without 
recent antibiotic use. Dial et al. [24] found that, of 836 patients of 65 years or older 
without admission to a healthcare facility in the previous 90 days who were hospitalized 
with CDI as the primary diagnosis, 46% had not used antibiotics in the previous 90 
days. Nevertheless, antibiotic use was still a major risk factor when these patients 
were compared to patients admitted with other diagnoses (RR 10.6, 95%CI 8.9 – 
12.8). Other studies, including ours, found similar proportions of patients without prior 
antibiotic use. This is a striking difference with studies into nosocomial CDI, which 
usually show that a large majority of patients have used antibiotics.
 From the existing literature and our findings (and partly also those described in 
chapter 3), we conclude that numerous different strains of C. difficile circulate in the 
community and intermittingly colonize humans, which may lead to disease under the 
right circumstances. These circumstances are discussed later in this discussion. 
New strains are probably introduced into healthcare facilities by asymptomatic 
carriers admitted from the community, as evidenced by a typing study that could not 
link several nosocomial CDI cases to other cases in the same hospital [25]. It seems 
likely that humans and animals both act as reservoirs. In order to understand more 
about the spread of C. difficile strains we need large cohorts both inside and outside 
of the hospital with regular surveillance for C. difficile carriage and typing of cultured 
strains.
In Chapter 3, we report a study into asymptomatic carriage by patients with cystic 
fibrosis (CF). CF, caused by loss-of-function mutations in the gene that encodes the 
chloride channel, CFTR, leads to a higher viscosity of airway secretions. This in turn 
leads to stasis, microbial colonization of the airways with chronic inflammation, and 
bronchiectasis. Depending on the severity of CF, these patients regularly experience 
respiratory tract infections and therefore are frequently treated with antibiotics and 
often admitted to hospital. This should make them prone to CDI, but they are thought 
to seldom develop CDI. Asymptomatic carriage of C. difficile has frequently been 
observed in CF patients who were taking antibiotics [26-28]. No studies on CDI in CF 
patients have been published since these studies from the early 1980s. Therefore, it 
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not dependent on antibiotic consumption in one study [44]. One may further speculate 
that circulation of C. difficile is somehow increased by low temperatures. The spores 
can survive high temperatures and prolonged desiccation [47, 48], but it is still 
possible that they survive longer and in greater numbers in a cold environment. 
Alternatively, prolonged survival of vegetative bacteria plays a role or more efficient 
transmission, e.g. because of crowding of humans or animals.
 Third, PCR ribotypes 015 and 018 were associated with complications of CDI, 
mainly mortality for which CDI was judged to be at least partially responsible. It must 
be stressed that attributability of mortality to CDI is often somewhat subjective - 
unless patients die of a perforated colon or a toxic megacolon - and mortality due to 
comorbidities is high in CDI patients. Attributability was therefore left to the judgment 
of the treating physician, so the associations must be regarded with some caution. 
PCR ribotype 056 was also associated with a complicated course, but the odds ratio 
had a wide confidence interval and was only statistically significant after correction 
for potential confounders. Although this was not indicated by the local hospitals, it is 
conceivable that some of the cases due to these PCR ribotypes were part of an 
outbreak, in which mortality due to a specific strain may be higher than in an endemic 
setting. Especially PCR ribotype 018 was conspicuously present in the Italian 
hospitals, suggesting rapid spread due to an outbreak.  The predominance of PCR 
ribotype 018 in Italian hospitals was later confirmed by others [49]. Not surprisingly, 
recurrences were mainly associated with previous recurrences.
 In conclusion, predominating C. difficile strains in hospitals change over time. 
What makes a strain outcompete other strains is not entirely clear as yet. The 
explanation may lie in more efficient transmission due to increased sporulation 
frequency and spore resistance, differences in germination conditions, lower 
infectious dose, larger volumes of diarrhea, longer shedding, or differences in 
antibiotic or disinfectant resistance. Strains may acquire virulence factors and other 
properties leading to their emergence, as is illustrated by differences between 
historical and epidemic PCR ribotype 027 [50]. In addition, some strains may be better 
adapted to patients with certain deficiencies. Coordinated international surveillance may 
shed more light on the dynamics of the circulation of C. difficile strains.
Chapters 5 and 6 describe studies into predictors of the course of CDI, especially a 
recurrent course. Gaining more insight in the epidemiology of complications and 
recurrences is important because of two reasons. First, we need predictors of the 
clinical course of CDI, especially because the prognosis may influence management, 
such as choice of treatment modality or of alternatives within a specific treatment 
modality, such as fidaxomicin and vancomycin. These predictors may include 
 epidemiological, clinical, biochemical, radiological and microbiological parameters. 
Second, such association studies may help to elucidate the pathogenesis of CDI. 
compared  to inflammation. Studies to elucidate the mechanism by which CF might 
protect against CDI could focus on characterizing the microbiome of CF patients, 
investigating the interaction between colonic mucus from CF patients and C. dificile 
spores, vegetative stages and toxins, studying the effect of clostridial toxins on CFTR 
knockout cell lines or animals, and studying the prophylactic and therapeutic effect 
of CFTR inhibitors in CDI in animal models and, if effective and safe, in human CDI.
After the emergence of epidemic PCR ribotype 027 in North America, the UK and The 
Netherlands, this strain was expected to gain a strong foothold in the rest of Europe. 
To investigate the distribution of C. difficile strains across Europe and morbidity and 
mortality associated with them, we conducted a study in a selection of European 
hospitals, described in Chapter 4. We found the incidence of CDI to vary widely 
across European hospitals. Evidently, the small sample size and non-random 
selection of hospitals do not warrant generalization of the findings to the level of 
whole countries. However, some findings were striking and led to a number of 
cautious conclusions. First, PCR ribotype 027 had not become highly prevalent in the 
hospitals that were studied, and PCR ribotype 078, conspicuously absent in an earlier 
European survey [41], had become the third most prevalent strain, although the 
earlier study’s different methodology and smaller sample size should be taken into 
account. 
 Second, a strikingly high incidence was found in many hospitals in countries 
bordering the Baltic Sea and North Sea. In Scandinavian countries, consumption of 
antibiotics per capita is not high, even in the winter months, when respiratory tract 
infections may lead to more antibiotic use [42]. A lower threshold for testing for CDI 
might be suggested as an explanation for a higher incidence of CDI, and certainly 
differences in testing rates were found to correlate with CDI incidence. However, if this 
difference in testing should account for all of the differences between the various 
hospitals, this would mean that many cases of hospital-acquired diarrhea were not 
tested for CDI, contrary to study protocol. Moreover, it would mean that many CDI 
cases were not noticed, suggesting that these cases were all self-limiting, which is 
unlikely in hospital-associated CDI. Therefore, the differences in testing rates could 
also have arisen because there simply were fewer cases of diarrhea due to CDI. If the 
differences in CDI incidences are true, then they might be explained by differences in 
patient characteristics between countries, such as severity of comorbidity. The 
threshold to admit patients to hospital may be higher in countries with well-functioning 
state-sponsored home care. More speculatively, there may be an association 
between high CDI incidence and cold or temperate climates. This is especially 
interesting because the first outbreaks due to PCR ribotype 027 were described in 
Canada and the northern United States [43]. Also, a seasonal variation of CDI with 
peaks in late winter - early spring has been described [44-46]. Seasonal variation was 
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drawn that recurrences are not entirely explained by an inadequate humoral immune 
response. Serious comorbidity was associated with recurrence, but not a specific 
comorbidity. A possible explanation is that serious comorbidity is associated with 
changes in the intestinal microbiome, predisposing to recurrences of CDI. Studies 
that investigate age, comorbidity, antibiotic consumption (measured carefully in 
defined daily doses, preferably over an extended period), immune response (using 
the best correlate of mucosal immune response) and microbiome have never been 
performed. These studies might clarify which of these parameters is associated most 
strongly with recurrence. The result may have implications for etiological theories of 
CDI, but also directly for management. The intestinal microbiome may very well be 
the strongest predictor of recurrence. If so, finding a set of characteristics of the 
microbiome that can be measured relatively simply in clinical practice would be a 
worthwhile objective of future studies.
Since antibodies may play a role in the pathogenesis of CDI, the administration of 
antibodies against C. difficile may be an effective strategy to influence the course of 
the disease. Preferably, these antibodies should be administered enterally, since 
parenterally administered antibodies may not reach the intestinal lumen, where C. 
difficile resides and produces its toxins. Chapter 7 reports on a cohort study in which 
participants who had just recovered from CDI after antibiotic treatment were given an 
experimental product, derived from milk from cows immunized with toxoid and killed 
whole-cell C. difficile, in order to prevent recurrences. Some of the participants were 
infected with PCR ribotype 027. Compared to historical controls, participants had a 
lower recurrence rate, but this is of course no definite proof that the product works. 
Nonetheless, it seems plausible that passive immunotherapy in the intestinal lumen 
may be effective by neutralizing toxins and hindering mucosal attachment and 
cell-cell interactions by the pathogen. Intravenously administered monoclonal 
antibodies directed against large clostridial toxins were shown to prevent recurrences 
in one randomized trial [57]. The next step in studying the effectiveness of the milk 
product should be a randomized placebo-controlled trial. An additional finding of our 
study was that persistence or reappearance of clostridial toxin in feces after initially 
successful treatment is associated with relapse. Fecal toxin might be a useful 
parameter to guide dosage of the experimental product.
 For a full overview of all currently available treatment options for CDI, the reader 
is referred to Chapters 8 and 9, which are the first CDI treatment guidance document 
issued by the European Society of Clinical Microbiology and Infectious Diseases, 
and a recent update. Currently, the biggest challenge is to find a treatment modality 
that is as effective in preventing recurrences as fecal transplant, but less cumbersome. 
Possibly, a mix of bacterial strains may be found as the core component of fecal 
transplant. This should have the same effect as fecal transplant, but without the 
 The study described in Chapter 5 investigates the association between one 
clinical marker (temperature) and two biomarkers (blood leukocyte count and serum 
creatinine level) with failure of initial therapy for CDI, persistence of diarrhea and 
recurrence after initially successful therapy for CDI. The data were derived from two 
large clinical trials that compared fidaxomicin to vancomycin for the treatment of CDI 
[51, 52]. Failure of initial therapy was partially based on the treating physician’s 
judgment of whether additional therapy was necessary, and therefore less objective 
than persistence of diarrhea, which was based on the number of unformed bowel 
movements per day. Failure of therapy was associated with fever, leukocytosis and 
renal failure, whereas only renal failure was associated with a lower probability of 
resolution of diarrhea and longer duration of diarrhea. An explanation may be that the 
treating physician felt a need to start additional therapy for CDI more often when there 
was fever or leukocytosis. Also, recurrence was only associated with renal failure and 
not with fever or leukocytosis. The prognostic value of renal failure as a predictor of 
unfavorable outcome of CDI has been shown previously [53, 54]. Acute renal failure 
is a common complication of CDI, which is interesting because the volume of diarrhea 
is not typically large nor is the systemic inflammatory response typically so strong 
that septic shock with organ hypoperfusion develops. Could there be a direct effect 
of CDI on renal function? Toxemia has been demonstrated in two children with fatal 
CDI [55] and in animal models [56]. However, toxemia does not appear to be a 
common occurrence in human disease. 
 In this study, we have also shown that leukocyte counts and serum creatinine 
levels fluctuate around the time of diagnosis of CDI. Follow-up of these parameters 
after diagnosis of CDI may therefore be important if values are around the upper limit 
of normal.
 In the study described in Chapter 6, serum levels of antibodies directed against 
the large clostridial toxins and other antigens, measured directly after 10 days of 
antibiotic therapy and three weeks later, were investigated in relation with recurrences 
during a 60 day follow-up. Also, the relation between recurrences and the neutralizing 
effect of serum on TcdB was studied. Low serum levels of antibodies against TcdA and 
TcdB were associated with recurrence, whereas antibodies against other antigens were 
not, nor was serum neutralizing effect a strong predictor. The main drawback of the 
study was the fact that sera were taken from patients receiving passive immunotherapy 
for CDI, and the small number of participants, both of which may have limited the power 
to detect an association between antibody levels and recurrence. Strikingly, antibody 
levels often decreased during the three weeks between the two blood samples, which 
is strange for an immune response directly after an infection and raises the question 
whether fecal protein loss may have played a role.
 Since there was significant overlap in antibody levels between patients who went 
on to suffer a recurrence and those with a single episode, the conclusion may be 
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potential for transmission of pathogens, and could be less expensive because there 
would be no need for screening donors.
The studies described in this thesis aimed to contribute to finding the answers to 
questions regarding the epidemiology of C. difficile strains and the prediction and 
treatment of CDI with a high risk of recurrence and complications. We feel that we 
have made a modest contribution by investigating the distribution of C. difficile strains 
in Dutch general practices, among CF patients and in European hospitals. 
Furthermore, we hope to have shed more light on the etiology and prediction of 
recurrences and how to minimize the risk of recurrence.
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Inleiding
Ontstaan van ziekte en ziekteverschijnselen
Clostridium difficile is een bacterie die voorkomt in de bodem en in water, maar ook 
in het maagdarmkanaal van allerlei zoogdieren. De bacterie heeft als kenmerkende 
eigenschap dat ze in ongunstige omstandigheden over kan gaan in een sporevorm. 
Deze sporen kunnen jaren overleven onder ongunstige omstandigheden en weer 
ontkiemen als de omstandigheden gunstiger zijn. Ook de darm van de mens kan 
gekoloniseerd raken met deze bacterie. De sporen worden ingeslikt en ontkiemen 
onder invloed van gal in de darm. Als het aantal en de verscheidenheid van de 
bacteriën in de darm zijn afgenomen, wat vooral onder invloed van antibiotica 
gebeurt, krijgt C. difficile de kans zich te vestigen op het darmslijmvlies. C. difficile 
veroorzaakt ziekte door de toxines TcdA en TcdB te maken, die het darmslijmvlies 
aantasten. Er ontstaat een ontstekingsreactie waarbij pusvormende witte bloedcellen 
migreren naar het aangedane gebied in de darm. In het bloed is dit zichtbaar als een 
verhoging van het aantal witte bloedcellen (leukocytose). Aan het darmslijmvlies is dit 
met het blote oog te zien als plakken pus op het oppervlak, de zogenaamde pseudo-
membranen. De patiënt krijgt diarree en in ernstige gevallen een zeer zieke darm, die 
doorlaatbaar is voor afbraakproducten van bacteriën met koorts tot gevolg. In uiterste 
gevallen moet de zieke darm operatief worden verwijderd. De ziekte is te behandelen 
met een aantal antibiotica, waarvan metronidazol en vancomycine (de vorm die oraal 
moet worden ingenomen) en sinds kort fidaxomicine het meest gebruikt worden. 
Deze antibiotica leiden tot een geleidelijke verbetering van de klachten, maar helaas 
is de sporevorm niet gevoelig voor antibiotica. Na de behandeling kunnen de sporen 
weer ontkiemen en opnieuw klachten geven, mede omdat de darmbacteriën verder 
zijn aangetast door deze laatste antibiotica. Zo kan de ziekte steeds weer terugkomen, 
soms vele keren achter elkaar. Dit leidt tot ernstige verzwakking van de patiënt en 
eiwitgebrek, omdat deze zieke darm  eiwit lekt. 
Diagnose
De diagnose is te stellen door de toxines of de toxineproducerende C. difficile-stam 
in de ontlasting aan te tonen. Niet alle methoden zijn even goed zijn in het aantonen 
van de infectie en het is niet altijd mogelijk onderscheid te maken tussen infectie en 
kolonisatie, waarbij C. difficile wel aanwezig is, maar de klachten veroorzaakt worden 
door iets anders.
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antistoffen tegen de toxines TcdA en TcdB bleek de kans op recidieven na antibiotische 
behandeling te verminderen. De wijze van analyse van de studie was alleen 
twijfelachtig, omdat de studie in eerste instantie was opgezet om aan te tonen dat de 
ziekte minder ernstig zou verlopen na toevoeging van deze antistoffen, maar de 
onderzoekers er later voor kozen te kijken naar recidieven bij die patiënten die 
diarreevrij waren geworden. Op die manier is er een selectie aangebracht die in het 
voordeel van de antistoffen kan werken, omdat patiënten die ondanks de antistoffen 
diarree hielden, niet werden meegenomen in de analyse. Naast immunotherapie is 
behandeling met micro-organismen geprobeerd. Bekend zijn de probiotica, de 
‘goede’ bacteriën en gisten die tegenwoordig aan allerlei zuivelproducten worden 
toegevoegd. Deze hebben niet overtuigend aangetoond dat ze de uitkomst van C. 
difficile-infectie kunnen beïnvloeden. Een behandeling waarvoor het bewijs wel heel 
sterk is, is het toedienen van een heel ecosysteem van micro-organismen in de vorm 
van feces van een gezonde donor, de zogenaamde fecestransplantatie. Deze lijkt 
ook effectief bij patiënten die meerdere recidieven hebben gehad, een patiënten-
categorie waarvoor tot nu toe geen enkele andere behandelwijze bewezen effectief 
is. Tot slot wordt onderzocht of toediening van C. difficile-stammen die géén toxines 
maken, van nut kan zijn om C. difficile-infectie te voorkomen of behandelen door 
competitie met de toxineproducerende stammen aan te gaan.
Onbeantwoorde vragen
Er blijven veel onbeantwoorde vragen in het onderzoeksveld van C. difficile-infectie. 
Zo is het bijvoorbeeld niet duidelijk waar nieuwe stammen vandaan komen die zich 
vervolgens verspreiden en wat hun opkomst uitlokt en stimuleert. Verder is het niet 
goed te voorspellen welke patiënten na behandeling een recidief zullen krijgen. Dit is 
belangrijk, omdat de keuze van therapie kan afhangen van de inschatting of er een 
grote kans is op een recidief. Tot slot is er nog geen therapie die de kans op recidieven 
tot nul reduceert. De onderzoeken beschreven in dit proefschrift richten zich op 
diverse aspecten van C. difficile-infectie die gecompliceerd wordt door een ernstig 
zieke darm of door recidieven. Allereerst gaat het om de verspreiding van C. difficile- 
stammen die met zo’n ernstig of recidiverend beloop geassocieerd zijn, vervolgens 
over het voorspellen van zo’n beloop en tot slot over hoe behandeling de kans op 
zo’n beloop zou kunnen minimaliseren.
Hoofdstuk 1
Hierin worden twee gevallen van C. difficile-infectie die optraden buiten het ziekenhuis 
beschreven. Het eerste geval lijkt ook echt opgelopen buiten het ziekenhuis door een 
patiënte die niet aan het klassieke risicoprofiel voldoet, het tweede blijkt waarschijnlijk 
wel opgelopen in het ziekenhuis. Naar aanleiding van deze gevallen wordt een 
overzicht gegeven van de wetenschappelijke literatuur over C. difficile-infectie 
Verspreiding
De bacterie werd tot voor kort gezien als een typische ziekenhuisbacterie, omdat 
patiënten tijdens hun ziekenhuisopname een C. difficile-infectie kunnen krijgen. De 
verklaring daarvoor kan zijn dat de meest vatbare patiënten, ouderen met chronische 
ziekten die behandeld worden of zijn met antibiotica, in het ziekenhuis geconcentreerd 
zijn. De bacterie kan daar efficiënt worden overgedragen via voorwerpen en de 
handen van ziekenhuispersoneel, zich vermenigvuldigen en in sporevorm overleven. 
Daarbij komt nog dat de sporen niet gedood worden door veel gebruikte desinfectie-
middelen, zoals alcohol. Vanaf de ingang van het nieuwe millennium werden 
zieken huizen in Canada, gevolgd door de VS, het Verenigd Koninkrijk, Nederland en 
veel andere Europese landen, getroffen door uitbraken van C. difficile-infectie met 
een hoge sterfte en veel recidieven. Deze uitbraken bleken veroorzaakt door een 
specifieke C. difficile-stam, volgens de meest gangbare typeringsmethode 
aangeduid als PCR-ribotype 027. Door deze ontwikkeling ontstond er opnieuw 
aandacht voor C. difficile-infectie en heeft het onderzoek ernaar een grote vlucht 
genomen. Inmiddels worden gemiddeld zo’n 15 wetenschappelijke artikelen per 
week gepubliceerd over het onderwerp. Het idee dat C. difficile-infectie voornamelijk 
in het ziekenhuis wordt opgelopen, wordt tegenwoordig in twijfel getrokken. Dit komt 
onder meer omdat typeringsstudies vaak geen verband tussen verschillende 
gevallen in het ziekenhuis kunnen leggen, tenzij er sprake is van een duidelijke ziek-
enhuisuitbraak. 
Behandeling
Er is nog geen behandeling voor C. difficile-infectie die de kans op recidieven tot nul 
reduceert. Antibiotica hebben het inherente nadeel dat ze de darmbacteriën ook 
aantasten en daarmee de kans op een recidief vergroten. Ook na behandeling met 
het nieuwe middel fidaxomicine, dat relatief selectief C. difficile doodt, treden 
recidieven op. Er is daarom gezocht naar niet-antibiotische behandelingen. Toxine-
bindende harsen bleken onvoldoende werkzaam. Er is nog geen vaccin beschikbaar 
tegen C. difficile-infectie, hoewel er studies met een experimenteel vaccin worden 
uitgevoerd. Een andere optie is het toedienen van antistoffen, die de toxines van de 
bacterie onschadelijk maken of op andere wijze het functioneren van de bacterie 
hinderen. Men onderscheidt verschillende vormen van deze zogenaamde passieve 
immunotherapie. Ten eerste is er een gradatie in de selectiviteit van de antistoffen. Er 
zijn ongeselecteerde antistoffen van bloedbankdonoren (antistoffen tegen C. difficile- 
toxinen komen in de algemene bevolking voor). Meer selectief zijn mengsels van 
antistoffen afkomstig van dieren die gevaccineerd zijn tegen C. difficile en/of de 
toxinen. Het meest specifiek zijn zogenaamde monoclonale antistoffen, die in een 
laboratorium geproduceerd worden. Ten tweede kan de toedieningsweg verschillen: 
intraveneus of oraal. Een combinatie van twee intraveneus toegediende monoclonale 
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Ongeveer de helft van hen (55 patiënten) leverde ontlasting in. We vonden dat 47% 
van de patiënten drager was van C. difficile. Geen van deze patiënten had diarree. 
Opvallenderwijs bleek 77% van de gekweekte stammen geen toxine te produceren. 
Dit is een veel hoger percentage dan we aantroffen bij een controlegroep van 
patiënten opgenomen op een afdeling Interne Geneeskunde van het Ziekenhuis 
Bronovo in Den Haag. Dragerschap bij cystic fibrosis-patiënten was verrassenderwi-
js geassocieerd met een lagere leeftijd en - niet zo verrassend - met ernstiger cystic 
fibrosis. Er werden veel verschillende, deels zeldzame stammen gevonden, wat 
suggereert dat de patiënten de stammen niet van elkaar hadden gekregen en 
evenmin in het ziekenhuis hadden opgelopen. Ook deze bevinding sluit aan bij de 
conclusie van het vorige hoofdstuk dat er veel verschillende C. difficile-stammen 
buiten het ziekenhuis circuleren. Verder is het de vraag waarom er zoveel niet-toxine-
producerende stammen worden gevonden bij patiënten met cystic fibrosis. Mogelijk 
circuleren deze stammen ook in de gemeenschap, maar kunnen ze de darmen van 
mensen zonder cystic fibrosis moeilijk koloniseren. De andere samenstelling van het 
darmslijm en/of de darmbacteriën bij cystic fibrosis-patiënten leidt er misschien toe, 
dat niet-toxineproducerende stammen hun darmen wel kunnen koloniseren. Ook 
hebben toxineproducerende stammen misschien geen voordeel ten opzichte van 
niet-toxineproducerende stammen bij de kolonisatie van de darm van cystic fibrosis- 
patiënten. Hiervoor zijn meerdere hypothesen te bedenken. De toxines dringen 
mogelijk moeilijk door de darmslijmlaag van cystic fibrosis-patiënten, of de toxines 
kunnen minder schade berokkenen, doordat het eiwit dat afwijkend is bij cystic 
fibrosis- patiënten een rol speelt bij de werking van de toxines. Dit laatste zou ook 
kunnen verklaren waarom cystic fibrosis-patiënten zo weinig klachten van toxine-
producerende C. difficile-stammen hebben. Kolonisatie met niet-toxineproduceren-
de C. difficile-stammen zou de cystic fibrosis-patiënten ook kunnen beschermen 
tegen ziekte door hun toxineproducerende verwanten. Zoals eerder vermeld wordt er 
zelfs onderzoek gedaan met niet-toxineproducerende stammen voor preventie en 
behandeling van C. difficile-infectie. Hierbij is een opvallende eerste bevinding dat 
kolonisatie met niet-toxineproducerende C. difficile alleen bereikt kan worden bij 
gezonde vrijwilligers als ze eerst 5 dagen met vancomycine behandeld worden en 
dan 14 dagen niet-toxineproducerende C. difficile toegediend krijgen.
Hoofdstuk 4
Om beter in kaart te brengen welke C. difficile-stammen in Europese ziekenhuizen 
voorkomen na de opkomst van de epidemische stam PCR-ribotype 027, en of infecties 
door deze stammen leiden tot complicaties en recidieven, hebben we een netwerk 
opgezet van 106 laboratoria, verbonden aan Europese ziekenhuizen. Het vóór komen 
van C. difficile-infectie in de ziekenhuizen bleek sterk te variëren. De ziekte kwam het 
meest voor in ziekenhuizen in noordelijke landen, waar het antibioticumgebruik in het 
opgelopen buiten het ziekenhuis. Daaruit blijkt dat er grote verschillen in definitie van 
buiten het ziekenhuis opgelopen C. difficile-infectie zijn, maar dat er vaker patiënten 
worden beschreven zonder de gebruikelijke risicofactoren recent antibioticum-
gebruik, hoge leeftijd, chronische ziekte en frequent contact met zorginstellingen. 
Hoofdstuk 2
Dit hoofdstuk beschrijft een studie waarbij patiënten die zich meldden in de huisarts-
praktijk met diarree, werden getest op C. difficile-infectie, ongeacht de vraagstelling 
van de huisarts. Er werd bij 1,5% van de patiënten C. difficile-toxine gevonden. 
Drieëntwintig procent van deze patiënten was niet opgenomen geweest in een 
zorginstelling in het jaar daarvoor en had evenmin antibiotica gebruikt in het afgelopen 
halve jaar. Opvallend was dat de epidemische stam PCR-ribotype 027 niet werd 
aangetroffen, ondanks het feit dat in de drie regio’s waar de studie werd uitgevoerd, 
Haarlem, Utrecht en Zwolle, ziekenhuisuitbraken waren geweest met deze stam. 
Ook werden verschillende zeldzame en niet eerder getypeerde stammen gevonden, 
die meestal niet gevonden worden in ziekenhuizen. Een zwakte van de studie was 
dat andere verwekkers van diarree niet stelselmatig werden uitgesloten, er werd 
alleen gekeken naar de ziekteverwekkers waarvoor de huisarts een test had 
aangevraagd. Onderzoek naar een andere verwekker was nooit positief als C. diffi-
cile-toxine werd aangetroffen. Onze conclusie was dat buiten het ziekenhuis veel 
verschillende C. difficile-stammen circuleren. Deze stammen koloniseren de menselijke 
darm onder bepaalde omstandigheden, zoals na aantasting van de darmbacteriën 
door antibiotica, en veroorzaken eventueel ziekte. Waarschijnlijk gaat een deel van 
deze ziekte-episoden vanzelf voorbij zonder behandeling, zeker als de diarree 
duidelijk uitgelokt is door antibiotica en deze antibiotica vervolgens weer gestopt 
worden. 
Hoofdstuk 3
Dit hoofdstuk beschrijft een studie naar dragerschap van C. difficile  bij patiënten met 
cystic fibrosis, ook wel bekend als taaislijmziekte. Deze genetische ziekte leidt tot de 
vorming van veel dikker slijm in de luchtwegen dan bij gezonde mensen. Hierdoor 
worden bacteriën moeilijk verwijderd door de trilharen van de luchtwegen. Het gevolg 
is het herhaaldelijk optreden van bronchitis en longontsteking, waardoor de 
luchtwegen beschadigd raken. Logischerwijs worden deze patiënten vaak met 
antibiotica behandeld en komen ze regelmatig in ziekenhuizen. Je zou verwachten 
dat C. difficile-infectie veel voorkomt bij deze patiënten, maar studies uit de jaren ’80 
tonen aan dat ze vaak drager zijn van C. difficile, maar geen klachten hebben. We 
wilden deze oude waarneming bevestigen nu C. difficile-infectie frequenter voorkomt 
en er epidemische stammen zijn. We hebben hiervoor aan alle cystic fibrosis-patiënten 
van het Erasmus Medisch Centrum in Rotterdam gevraagd ontlasting in te leveren. 
248 | Nederlandse samenvatting Nederlandse samenvatting | 249
Hoofdstuk 6
Een belangrijke andere vraag bij C. difficile-infectie is hoe groot de rol van het 
immuunsysteem is bij het beloop van de infectie, met name de antistoffen. Deze 
antistoffen, die worden geproduceerd door bepaalde witte bloedcellen, zijn heel 
specifiek gericht tegen een ziekteverwekker (bacterie, virus, schimmel, eencellige of 
worm) of een toxine. Ze kunnen de ziekteverwekker markeren om het opruimen van 
de ziekteverwekker door het immuunsysteem te vergemakkelijken, de ziekteverwek-
ker hinderen in zijn functioneren, of toxines onschadelijk maken. Antistoffen worden 
niet van nature gemaakt - het afweersysteem moet namelijk ‘leren’ antistoffen te 
maken tegen de ziekteverwekkers of toxines waarmee het op dat moment 
geconfronteerd wordt. Voor de meeste infecties geldt, dat als eenmaal een antistof-
reactie op gang gekomen is, het afweersysteem vervolgens geheugen opbouwt en 
er bij een volgende confrontatie met deze ziekteverwekker sneller antistoffen worden 
aangemaakt dan bij de eerste confrontatie. Het ligt voor de hand bij C. difficile-infec-
tie te kijken naar antistoffen, omdat de ziekteverschijnselen het gevolg zijn van toxines 
en toxines bij uitstek een goed doelwit zijn voor antistoffen. 
 Voor de studie beschreven in dit hoofdstuk hebben we gebruik gemaakt van 
opgeslagen serummonsters (bloed ontdaan van cellen en stollingsfactoren) van 
patiënten met C. difficile-infectie die hadden deelgenomen aan de studie die 
beschreven staat in het volgende hoofdstuk. We wilden de associatie tussen 
antistoffen en het optreden van recidieven onderzoeken. Die associatie is interessant 
voor het oorzakelijk denken over C. difficile-infectie (Welke rol speelt de antistofreac-
tie bij het optreden van recidieven van C. difficile-infectie?) en het voorspellen van 
recidieven. Patiënten met hoge serum-concentraties van antistoffen tegen de toxines 
TcdA en TcdB bleken meestal geen recidieven te krijgen. Dit gold niet voor antistoffen 
tegen eiwitten op het oppervlak van C. difficile. Deze bevindingen ondersteunen de 
hypothese dat antistoffen een rol spelen bij het beloop van C. difficile-infectie. Ze 
vormen echter niet de hele verklaring voor het optreden van recidieven. Waarschijnlijk 
zijn andere factoren belangrijker, zoals de diversiteit en het aantal van de 
darmbacteriën. Verder was opvallend dat de concentraties antistoffen tijdens de 
infectie vaak daalden, wat merkwaardig is voor een antistofreactie tijdens en direct na 
een opgelopen infectie. Een mogelijke verklaring is dat er eiwitten, waaronder 
antistoffen, uit de zieke darm lekken naar de ontlasting en de antistoffen op die 
manier verdwijnen. Een nadeel van deze studie was het feit dat de patiënten allemaal 
een experimenteel middel namen, dat antistoffen tegen C. difficile afkomstig van 
koeien bevatte. De metingen van de menselijke antistoffen werden overigens niet 
verstoord door de aanwezigheid van de dierlijke antistoffen. Dit experimentele middel 
was bedoeld om recidieven te voorkomen. Daardoor zou de sterkte van de associatie 
tussen antistoffen en het optreden van recidieven kunnen zijn afgenomen.
algemeen laag is. Misschien zijn er veel gevallen gemist in de Zuid-Europese 
zieken huizen. Als er echt een verschil is in het optreden van C. difficile- infectie tussen 
Noord- en Zuid-Europa, zijn mogelijke verklaringen hiervoor een verschil in de ernst 
van chronische ziekten van de opgenomen patiënten (misschien is de drempel tot 
opname hoger in landen met een goed georganiseerde eerstelijnszorg) of verschil in 
de efficiëntie van overdracht (misschien draagt een kouder klimaat bij aan efficiëntere 
overdracht, bijvoorbeeld doordat sporen langer overleven of mensen dichter op 
elkaar leven). PCR-ribotype 027 bleek niet het meest voorkomende type in de 
deelnemende Europese ziekenhuizen – het kwam op de zesde plaats. De top drie 
bestond uit PCR-ribotypes 014/020, 001 en 078. Het laatste type is interessant, 
omdat het eigenschappen deelt met PCR-ribotype 027, hoewel het wat minder 
schadelijk lijkt. Het werd in een kleinere Europese studie in 2005 nog vrijwel niet 
gevonden. Ook in Nederland is dit type inmiddels een van de meest voorkomende 
types geworden. Verder blijkt het ook bij boerderijdieren veel voor te komen. Dit roept 
de vraag op of het ribotype via vlees overgedragen wordt. Er zijn echter nooit 
uitbraken herleid tot een voedselbron. 
 Verder viel op dat na drie maanden 22% van de patiënten overleden was, wat 
illustreert dat C. difficile-infectie in ziekenhuizen nog steeds een ziekte is van oudere 
mensen met chronische ziekten. De behandelde artsen schatten in, dat C. difficile 
medeverantwoordelijk was voor een derde van deze sterfgevallen en zelfs direct ver-
antwoordelijk voor 7%. Infecties door PCR-ribotypes 027, 015 en 018 hadden een 
ernstiger beloop dan de overige ribotypen.
Hoofdstuk 5
Zoals vermeld in de inleiding, is het niet goed te voorspellen hoe het beloop van een 
C. difficile-infectie zal zijn en kan het verwachte beloop wel relevant zijn voor de keuze 
van behandeling. Er is geprobeerd goede voorspellers te vinden en er zijn diverse 
bevindingen, vooral bloedbepalingen, in verband gebracht met complicaties of 
recidieven. Het nut van die bloedbepalingen in relatie tot elkaar is niet duidelijk en de 
verbanden zijn gevonden in kleine studies. We hebben de databases van twee grote 
geneesmiddelenstudies voor de behandeling van C. difficile-infectie gebruikt om drie 
voorspellers van een ongunstig beloop te onderzoeken. Dit waren lichaamstem-
peratuur, aantal witte bloedcellen in het bloed en een bloedbepaling die de nierfunctie 
weerspiegelt (creatinine). De uitkomsten waren de duur van de diarree en het 
optreden van recidieven na verdwijnen van diarree. Vooral een slechte nierfunctie bij 
diagnose bleek samen te hangen met het voortbestaan van diarree en het optreden 
van recidieven. Verder bleek in deze studie dat de waarden van witte bloedcellen en 
nierfunctie per patiënt sterk varieerden rond het stellen van de diagnose C. difficile- 
infectie. 
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Hoofdstuk 7
Dit hoofdstuk beschrijft de studie die in de vorige paragraaf genoemd werd. Patiënten 
die zojuist tenminste 10 dagen succesvol behandeld waren voor C. difficile-infectie 
met antibiotica, namen een experimenteel product in om recidieven te voorkomen. 
Dit product was gemaakt van melk van koeien die gevaccineerd waren met gedode 
C. difficile en onschadelijk gemaakte C. difficile-toxines. Hierdoor bevatte de melk 
een hoge concentratie antistoffen tegen de bacterie en de toxines. De eiwitfractie van 
de wei van deze melk was vervolgens verwerkt tot een poeder, dat opgelost moest 
worden met water en drie maal per dag ingenomen. Bij proefdieren bleek het product 
effectief te zijn. In vergelijking met bekende recidiefpercentages hadden de studie-
patiënten weinig recidieven: deze traden op bij 11 van de 109 ziekte-episoden (10%). 
Dit is echter geen bewijs dat het product werkt, want daarvoor zou een studie 
noodzakelijk zijn met een placebo-arm, waarbij het lot bepaalt of een patiënt placebo 
of het wei-eiwit krijgt en patiënt en onderzoekers tijdens de studie niet weten welk van 
beide de patiënt krijgt. Mits er voldoende patiënten in de studie zitten, is dit de beste 
garantie dat een verschil tussen beide studie-armen verklaard kan worden door het 
wei-eiwit en niet door verschillen in ziekte-ernst of andere factoren die moeilijk 
meetbaar zijn.
Hoofdstukken 8 en 9
Hierin staan de eerste en tweede richtlijn voor behandeling van C. difficile-infectie, 
die we hebben opgesteld in opdracht van de European Society for Clinical Micro - 
 biology and Infectious Diseases. We doen hierin aanbevelingen voor keuze van 
therapie op grond van de beschikbare wetenschappelijke literatuur. 
Met de studies beschreven in de voorgaande hoofdstukken hopen we de kennis over 
C. difficile-infectie enigszins vergroot te hebben. Nieuwe bevindingen waren onder 
meer dat C. difficile-infectie in de Nederlandse huisartsenpraktijk voorkomt, soms 
zonder de gebruikelijke risicofactoren. Verder blijken Nederlandse patiënten met 
cystic fibrosis vaak asymptomatisch gekoloniseerd met C. difficile-stammen, die 
overwegend geen toxine produceren. Onze studie in Europese ziekenhuizen toonde 
aan dat de epidemische stam PCR-ribotype 027 niet de meest dominante stam 
geworden is. Tot slot bleken een slechte nierfunctie en lage serumconcentraties van 
antistoffen tegen C. difficile-toxines geassocieerd met een later recidief van C. difficile- 
infectie.
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